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ABSTRACT 
Iron is ubiquitous in the human body, fulfilling many crucial roles. However, accumulating 
evidence implicates excess iron as a carcinogen. This study aimed to further investigate the 
role of iron and haem in breast carcinogenesis and the potential utility of chelators in therapy. 
We demonstrate that the transport machinery for iron and haem is dysregulated in breast 
cancer, with import being promoted and export down-regulated to allow the accumulation of 
intra-cellular iron. In vitro studies demonstrate that, in contrast to benign cells, malignant cells 
are capable of importing haem as well as ionic iron. Both iron and haem stimulate aggressive 
behaviour in malignant cells, up-regulating viability, proliferation, adhesion, migration and 
invasion. These changes are abrogated by iron chelation. In addition, the expression profile of 
iron and haem transporters is shown to favour intra-cellular accumulation even when iron is 
plentiful and import would be expected to be down-graded.  
Overall this study suggests that breast cancer may be due to an inappropriate expression 
profile of iron and haem transporters, leading to excess intra-cellular iron which drives a 
malignant cell phenotype. In addition the action of chelators to downgrade malignant 
behaviour implies a potential therapeutic role. 
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CHAPTER 1: INTRODUCTION AND BACKROUND 
1.1 Breast Cancer 
1.1.1 Epidemiology 
According to the UK National Cancer Registries1-4, in 2006 breast cancer had the highest 
incidence of all malignancies in the UK. 45 500 new cases accounted for 31% of cancer 
diagnoses in women in 2006 (the next most common being lung cancer with 11%). Based on 
figures from 2001-2005, the lifetime risk of a woman in the UK developing breast cancer was 
calculated as 1 in 9 in February 20095. 
The disease is largely one of late middle and old age. 81% of cases occur in the over 50s, 48% 
in those aged between 50 and 691-4. 
The combination of high incidence and low mortality (greater than 80% five year survival) 
also means a high prevalence of breast cancer in the UK population. Based on data up to the 
end of 2004 it was estimated that 550 000 of the UK female population at the time had at some 
point been diagnosed6. This equates to 2% of the total UK female population, or almost 12% 
of women over 65. The incidence continues to rise; since the late 1970s there has been a 63% 
increase in the incidence of breast cancer in Britain (from 75 to 122 cases per 100 000). 
Worldwide there are over 1 million new diagnoses of breast cancer made annually, comprising 
10% of all new cancers and 23% of cancers in females7. 429 900 new cases are reported 
annually in Europe, 182 460 in North America8. The highest incidence was found in the USA, 
with a rate of over 100 cases per 100 000 females, whilst the lowest was in China, with less 
than 207. 
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The advent of breast screening in the developed world saw a transient increase in the incidence 
of breast cancer as a pool of undiagnosed cases was brought to light. This occurred in the late 
1980s in the UK1-3.  
In the 1990s, the use of HRT (Hormone Replacement Therapy) to combat menopausal 
symptoms in middle-aged women contributed to increasing incidence of breast cancer9. 
However, this trend is now reversing within the 50-70 age-group, as increased awareness of 
the associated risks has decreased the uptake of HRT. 
The lower rates previously seen in Eastern Europe and the Far East are now rising to approach 
those seen in the West10-12. This has been attributed to changes in reproductive behaviour, use 
of HRT, increasing obesity and increased consumption of alcohol. 
1.1.2 Environmental Risk Factors 
1.1.2.1 Socio-Economic Status 
Increased affluence confers a higher risk of developing breast cancer13-16. This likely reflects 
altered exposure to environmental factors as a consequence of differing lifestyles, education, 
and career plans and expectations. Interestingly, after diagnosis, higher social status actually 
improves prognosis17;18. There could be a number of reasons for this phenomenon. Patients of 
higher socio-economic status tend to be more adherent to treatment, including neo-adjuvant 
and adjuvant therapies. Breast cancer discovered via screening mammography is likely to be at 
an earlier stage than those detected through imaging for symptomatic cancers, and will 
therefore carry a better prognosis. Patients in lower socio-economic groups are less likely to 
attend screening appointments, and may also delay seeking help even for clinically overt 
disease19.  
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Higher socio-economic status is often accompanied by an increased drive to learn about the 
illness and “red-flag” signs to watch for during recovery. These patients are also more willing 
to question doctors and ensure that all treatment avenues are explored. 
Although not necessarily linked to socio-economic status, a slower decrease in breast cancer 
incidence has been reported in the rural USA as compared to urban areas20. This may represent 
saturation of mammography services in remote rural areas causing a backlog of undiagnosed 
cases which are still coming to light. 
1.1.2.2 Hormone Replacement Therapy and the Oral Contraceptive Pill  
That oestrogen can be a causative factor in breast cancer was first demonstrated in 1896 when 
bilateral oopherectomy induced remission in premenopausal women21.  
Initial studies suggested a correlation between HRT and breast cancer22-24 that swiftly 
vanished after cessation of treatment. These studies were validated when the incidence of 
oestrogen receptor positive (ER+) tumours fell from 2001 onwards in response to lower HRT 
prescription rates across the globe25-29. In the USA an 11.8% fall in incidence of ER+ tumours 
in those aged 50-69 between 2001 and 2004 was related to a massive decrease in prescription 
rates of two oestrogen-rich HRT preparations. Incidence of ER- tumours was unchanged30. 
Evidence published by the American Women’s Health Initiative described a 24% increased 
risk of breast cancer in post-menopausal women receiving conjugated oestrogens and 
medroxyprogesterone acetate31. The carcinogenic potential of oestrogen-only preparations is 
demonstrably less than that of combined alternatives32, and reducing the use of oestradiol-
based preparations had no effect on cancer rates in Norway and Germany33;34. The World 
Health Organisation now adopts the view that the evidence for a causal link between 
combination HRT and breast cancer in post-menopausal women is incontrovertible35.  
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The oral contraceptive pill (OCP) is implicated as a carcinogen due to its 
oestrogen/progesterone content. The mitotic activity that such preparations induce in breast 
tissue may outweigh the protective benefits bestowed by anovulation36. Older studies simply 
relate use of the oral contraceptive to breast cancer without subgroup analysis 37;38, while 
others suggest a stronger link where OCP use has been prolonged39 or commenced at an early 
age39;40.  
1.1.2.3 Reproductive Behaviour and Endogenous Oestrogen 
Ovarian synthesis and secretion of oestrogen and progesterone begins at menarche and 
continues until the menopause. During the luteal phase of the menstrual cycle, increased 
circulating oestrogen and progesterone drive mitotic activity in the breast; it is during these 
phases of increased secretion that tumourigenic events occur41;42. Early menarche and late 
menopause prolong exposure to sex hormones and increase the risk of such events taking 
place43.  
Most women undergo menarche within an age window of just a few years so effects on 
population incidence of breast cancer are limited. It is estimated that every 2 year delay in the 
onset of menarche confers a reduction in the relative risk of contracting breast cancer of 
around 10%44. In contrast, every additional year before initiation of the menopause is 
associated with a 2.8% increase in the risk of breast cancer22. The population-wide effects are 
thus dramatic, with a woman experiencing the menopause before the age of 40 having only a 
50% chance of suffering breast cancer relative to one over 5022. These effects are no different 
between natural menopause and that surgically induced through bilateral oopherectomy22.  
The first full-term pregnancy stimulates differentiation in the breast to a phenotype suitable for 
lactation45. This phenotype is more stable than “naive” mammary tissue, and much less 
susceptible to the carcinogenic effects of sex hormones. A full-term pregnancy at a young age 
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thus reduces breast cancer risk, whereas nulliparity increases it46,47. Multiple pregnancies and 
more time spent breast-feeding also reduce breast cancer risk48.  
1.1.2.4 Obesity  
Obesity is linked to a number of cancers, including colon and breast. The metabolic syndrome 
and insulin-resistance are also implicated; indeed the oral anti-diabetic preparation metformin 
has been shown to decrease overall cancer risk49. The action of metformin is mediated by 
AMP-kinase, which inhibits cellular proliferation by limiting the supply of lipid available for 
synthesis of new cell membranes50, and also directly blocks the cell cycle through induction of 
p53. 
Obesity is also associated with increased plasma levels of leptin; an adipokine which acts as an 
appetite-suppressant, among other functions. It is thought that obese individuals fail to respond 
correctly to leptin, hence the increased circulating levels. High levels of leptin are significantly 
associated with breast cancer51. Leptin induces aromatase expression in MCF-7 breast cancer 
cells in culture52. Aromatase is a cytochrome p450 enzyme found in breast parenchyma that 
can catalyse oestrogen synthesis. Breast cancer in post-menopausal women may be due to 
local oestrogen synthesis, which would explain the increasing incidence of breast cancer with 
age, despite the lack of functioning ovaries53. Aromatase inhibitors are now widely-used in 
treatment of breast cancer worldwide. 
1.1.2.5 Alchohol 
Alchohol is a recognized risk factor for development of breast cancer54-56. Most experts agree 
that the underlying factor is oestrogen. The mechanism for this alchohol-oestrogen axis may 
be through alchohol-induced up-regulation of sex steroid synthesis57;58 or inhibition of 
oestradiol clearance59. Additionally, ethanol up-regulates oestrogen receptor (ER) 
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expression60;61, proliferation of ER-positive cells (but not ER-negative)61, and activity of the 
ER-α receptor subgroup60. Other hypotheses implicate the ethanol metabolite acetaldehyde as 
a potential carcinogen62, as well as alchohol-induced reactive oxygen species and lipid 
peroxidation63. The higher incidence of breast cancer secondary to alchohol intake is limited 
exclusively to ER+ cancers64. 
1.1.3 Genetic Risk Factors 
Having one first degree relative who has suffered breast cancer approximately doubles the 
relative risk for a given individual65. Familial relative risk increases when more relatives are 
affected65;66; and the sister of an affected monozygotic twin is more likely to contract breast 
cancer than that of a dizygotic twin67.  
Around a third of ER-negative breast cancer is thought to be due to mutations in the BRCA1 
(breast cancer 1) or BRCA2 genes, whereas roughly 10% of ER-positive breast cancer is 
caused by one of 12 recently discovered single nucleotide polymorphisms. Triple negative 
breast cancers (lacking oestrogen receptors, progesterone receptors or human epidermal 
growth factor receptor 2) are the only ones which do not demonstrate a familial 
preponderance68.   
BRCA1 was linked to breast cancer susceptibility in 199469; BRCA2 a year later70. Both are 
DNA repair genes which are also associated with increased incidence of ovarian cancer71. 
Family studies reveal that the likelihood of BRCA1/2 mutations increases both with numbers 
of breast or ovarian cancers in the family, and with lower ages at diagnosis72;73. They also 
suggest a penetrance of 50-85% for breast cancer by the age of 70 secondary to these 
mutations74;75. Both genes exhibit a range of potentially carcinogenic mutations, although the 
existence of populations displaying specific well-characterised mutations has allowed 
meaningful epidemiological research. 1% of Ashkenazi jews carry the 185delAG mutation in 
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BRCA176; this is thought to be responsible for 20% of early onset breast cancer occurring 
within that population. 1.2% feature the 6174delT mutation in BRCA2 which accounts for a 
further 8% of cases77;78. In Iceland, the 999del5 mutation in BRCA2 is found in 24% of breast 
cancers diagnosed before the age of 4079. Penetrance estimates based on data from these 
populations are lower than from family studies; 56% of affected Ashkenazi jews would 
contract breast cancer by the age of 7080, as would 38% of affected Icelandic women81. 
The ATM gene causes ataxia-telangiectasia (an autosomal-recessive condition)82 and is 
associated with a 100-fold increase in cancers of all types. These cancers are predominantly 
lymphoid in childhood and epithelial in adults83. There have been over 300 mutations 
identified in the gene, with an overall prevalence of 0.5-1% in the Western world84. 
Heterozygotic ATM mutations cause a 2-fold increase in the risk of breast cancer, with a 
penetrance of 15%82. 
CHEK2 is a cell cycle checkpoint kinase involved in mediating DNA damage-response 
pathways85. The 1100delC mutation doubles the risk of breast cancer86. It has also been 
reported to increase the risk of colorectal cancer87. 
TP53 is a tumour suppressor gene encoding a transcription factor involved in cell cycling, 
apoptosis, DNA repair and genomic stability88. Mutations in TP53 cause the Li-Fraumeni 
syndrome; a genetic predisposition to breast cancer, as well as sarcomata and brain tumours89. 
Most mutations in TP53 are point mutations which prevent sequence-specific protein-DNA 
binding and inhibit p53 activation89;90. 
CDH1 encodes E-cadherin, a glycoprotein involved in cell adhesion91. Mutations are 
implicated in familial diffuse gastric cancer; an autosomal dominant syndrome which confers 
around a 50% risk of lobular breast cancer92. 
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PTEN is a tumour suppressor gene encoding for phosphatidylinositol phosphate phosphatase. 
The protein product is involved in cellular regulation, although its exact role is unclear93. 
PTEN mutations may cause Cowden disease; an autosomal dominant syndrome pre-disposing 
patients to breast, thyroid and endometrial carcinomas and hamartomas94. 
1.1.4 Staging of Breast Cancer 
A staging protocol for breast cancer is given below95. Breast cancer is also staged using the 
TNM classification which takes into account extent of local tumour invasion, number and 
location of involved lymph nodes and the presence or absence of distant metastases. 
STAGE 0 Ductal/lobular carcinoma in situ (DCIS/LCIS) 
  No micro-invasion 
  5 year survival 92% 
 
STAGE I Invasive/ductal carcinoma of <2cm OR 
  DCIS/LCIS with micro-invasion 
  No lymph node involvement/metastases 
  5 year survival 87% 
 
STAGE II Invasive cancer of up to 5cm with up to 3 involved axillary lymph nodes OR 
  Cancer of greater than 5cm diameter with no nodes involved 
  5 year survival 75%  
 
STAGE III Cancers up to 5cm with 4 or more involved axillary nodes OR 
  Greater than 5 cm with any nodal involvement OR 
  Any cancer with involvement of the ipsi-lateral internal mammary nodes OR 
  Any skin involvement/chest wall fixation OR 
  Any inflammatory cancer 
  5 year survival 46% 
STAGE IV Any cancer with distant metastasis 
  5 year survival 13% 
1.1.5 Histological Classification and Grading of Breast Cancer 
75% of neoplastic breast lesions are either DCIS (13%), invasive ductal carcinoma (55%), or 
invasive lobular carcinoma (5%)96. Medullary carcinomas also form in mammary tissue.  
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DCIS is a non-invasive condition; the term describes an accumulation of neoplastic cells 
within a lactiferous duct with no evidence of spread beyond it. Autopsy studies97, and studies 
on DCIS missed at biopsy98;99, suggest that lifetime risk of progression to invasive ductal 
carcinoma is substantially less than 50%.  
Ductal carcinoma is further subdivided into cribriform, mucinous, tubular and papillary 
phenotypes, although the majority are unspecified. These four more differentiated forms carry 
a better prognosis. The breast may also be the site of other skin, connective tissue, vascular 
and neuroendocrine tumours. 
Breast cancers are categorized according to histological findings – lobular carcinoma exhibits 
an arrangement of cells in large indistinct lobules. Ductal carcinomas retain a modicum of 
ductal architecture, albeit with massive disorganisation.  
Breast cancers are assigned a histological grade, which is combined with stage at diagnosis to 
inform estimates of prognosis. The Bloom-Richardson scoring system rates cells according to 
3 criteria: tubular structure formation; nuclear size, shape and staining intensity; and mitotic 
rate100. Cells can score up to 3 in each of these areas. Tumours are then described as low 
(scores of 5 or less), intermediate (6-7) or high (8-9) grade. 
Histopathologists report evidence of vascular invasion when recording the details of 
specimens; this increases the risk of spread and suggests an increased likelihood of recurrence 
in the future, even in the absence of clinically detectable metastases at the time of staging. 
Histopathologicaly also provides information on receptor status of breast cancers. All breast 
cancers are now described as positive or negative for oestrogen, progesterone and human 
epithelial growth factor receptors (ER, PR and HER2). Receptor positivity or negativity guides 
the selection of the adjuvant and neo-adjuvant biological, chemo- and hormonal therapy 
regimes used as adjuncts (or alternatives) to surgical resection of the primary lesion. 
10 
 
1.2 Iron 
1.2.1 Normal Iron Homeostasis 
Iron is an element crucial to many of the basic functions of the human body. Its ubiquity is due 
to the fact that it is a divalent metal that can easily switch between its ferric (Fe3+) and ferrous 
(Fe2+) states. This capability means it is easily able to donate and accept electrons in redox 
reactions101, including those responsible for oxygen transport, DNA biosynthesis, xenobiotic 
metabolism and oxidative phosphorylation102.  
Paradoxically, it is the same chemical feature which is also responsible for the deleterious 
effects of excess body iron; as the majority of cytoplasmic iron is in the ferrous form, it readily 
donates electrons to undergo oxidation and generate free radicals. When this occurs in 
conjunction with hydrogen peroxide (H2O2) or lipid peroxides as recipients, the resulting 
Fenton reaction will produce Fe3+, OH- and the highly reactive hydroxyl (.OH) radical101. The 
reaction can compromise lipid membranes and lead to oxidative damage to DNA and other 
macromolecules103 in an environment of so-called oxidative stress104;105. 
The adult human body contains a total of 3-4g iron, of which around 70% is bound into the 
haem moieties of haemoglobin molecules in erythrocytes and their precursors106;107. To keep 
pace with erythrocyte destruction, 20-25mg103;107 of iron is required per day to manufacture 
new haemoglobin in the bone marrow. Although the Western diet contains approximately 
10mg iron per day, only 1-2mg of this is absorbed108; the remainder of the iron needed for 
haem synthesis is appropriated from the recycling of defunct red cells107. 
Given the potentially fatal consequences of both paucity and excess, optimal levels of 
circulating and stored iron are maintained by a finely balanced homeostatic mechanism. 
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Dietary iron is available as haem (mainly in red meat) and in its inorganic form. The pathways 
for absorption of each are illustrated in figures 1.1 and 1.4. 
1.2.2 Non-haem Iron Metabolism 
Briefly, inorganic iron is imported from the gut lumen via the action of DMT1 (divalent metal 
transporter 1, a transmembrane shuttle), having first been reduced to Fe2+ by Dcytb (duodenal 
cytochrome b, a ferric reductase expressed on the luminal surface of duodenal enterocytes). 
Following import, iron is subject to one of three fates: 1) Stored bound to ferritin; 2) Utilised 
in one of the many intracellular processes requiring iron; 3) Exported from the enterocyte by 
ferroportin then oxidised by hephaestin for transport. Exported iron is then bound to 
transferrin and circulates around the body to be captured by cells expressing the transferrin 
receptor (TfR). The whole system is regulated by a number of different proteins, although the 
most important is likely to be the hormone hepcidin. The process is summarised below in 
figure 1.1. Individual proteins are discussed in detail thereafter. 
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Figure 1.1 Import of Dietary Iron from the Duodenum 
Dietary ferrous iron is reduced by Dcytb to its ferric form for import via DMT1. If not utilised 
by the cell, the iron is then stored bound to ferritin, enters the labile iron pool or is cycled 
through the cell and exported by ferroportin. Ferroportin requires the action of hephaestin to 
re-oxidise the iron after export such that it can bind to transferrin for transport around the 
body. HCP1 is an importer of haem iron, discussed in due course (original diagram C Vulpe; 
University of California). 
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1.2.2.1 Duodenal Cytochrome b (Dcytb) 
Inorganic (non-haem) iron is found mainly in grains and vegetables and is absorbed by active 
transport from the gut lumen. The protein responsible for this active transport is DMT1 
(Divalent Metal Transporter 1), but it is only capable of transporting iron in its ferrous (Fe2+) 
form. Owing to the low luminal pH of the upper gastrointestinal tract, dietary inorganic iron is 
usually to be found in the ferric (Fe3+) state109and must therefore be reduced prior to 
absorption. The duodenum was found to have a ferric reductase activity in 1992110, but Dcytb 
was not formally identified as the protein responsible until 2001. It is a di-haem protein 
located in the upper villous parts of the duodenal brush border, regulated in response to 
systemic iron levels. Anaemia induces an up-regulation of expression to facilitate further 
absorption of iron109. Murine studies demonstrate increased levels of Dcytb in a 
haemochromatosis (iron overload) mouse model, along with DMT1111. However, further 
murine studies report normal iron uptake in mice lacking Cybrd1, the murine homolog of 
Dcytb112, raising the question of whether Dcytb is in fact essential for iron uptake from the gut 
or whether other import mechanisms exist. 
In terms of structure and membrane topology the protein strongly resembles the trans-
membrane electron shuttle cytochrome b561. Cytochrome b561 uses semidehydroascorbic 
acid as a substrate to accept electrons113; the binding site for this is preserved in Dcytb 
suggesting a similar mechanism for its reductase function. 
1.2.2.2 Divalent Metal Transporter 1 (DMT1) 
DMT1 (Nramp2, SCL11A2) was first described in 1997 by two separate groups114;115. Initially 
identified owing to a gene mutation in the mutant microcytic anaemia (mk) mouse114, it has 
since been shown to be a glycoprotein featuring 12 membrane-spanning domains and 
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displaying marked hydrophobicity. It functions as an ion transporter for a range of divalent 
substrates including cadmium, lead, zinc, manganese, copper and cobalt116. 
The mutation seen in one of the trans-membrane domains in the mk mouse (Gly185Arg) has 
also been identified in the anaemic Belgrade rat117, further confirming the role of DMT1 as an 
iron importer. 
DMT1 exists in 4 different isoforms owing to splice variants at either the 3’ or 5’ end. At the 
5’ end alternative splicing generates 2 initiation points for transcription at exons 1A and 1B, 
while at the 3’ end it is responsible for the inclusion or omission of an iron-response element 
(IRE)118. The 1A isoform contains an extra 29 amino acids at the 5’end. The IRE in IRE+ 
DMT1 is contained within the 3’ un-translated region (UTR). Some of the other iron transport 
proteins (ferroportin119;120, TfR105 and ferritin105) also feature IREs. These are expressed in the 
3’ UTR in DMT1 and TfR1, when the aim of interaction with iron regulatory proteins is to up-
regulate expression, and the 5’ UTR in ferritin and ferroportin when interaction is designed to 
down-regulate expression. Iron regulatory proteins are discussed in detail in section 1.2.2.8. 
All 4 DMT1 isoforms function with equal efficacy as iron transporters; the differences in 
structure allow for variation in location and regulation according to the requirements of 
different tissues121. DMT1A is predominantly found on the apical membranes of enterocytes 
throughout the intestine, primarily focussed in the duodenum. DMT1B is ubiquitously 
expressed, although it is especially prevalent in red cells and is largely cytosolic122;123. It is 
therefore likely that DMT1A functions mainly as a duodenal iron importer, whereas DMT1B 
facilitates extrusion of iron from intracellular endosomes following endocytosis of transferrin-
bound iron (discussed later)115.  
The IREs are used to regulate expression of DMT1 in response to systemic iron levels. Under 
normal circumstances intestinal expression of DMT1 is kept at a low level, but this is up-
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regulated when dietary iron is deficient and intracellular concentrations are low122;124. This up-
regulation is achieved through induction of the iron response proteins IRP1 and IRP2 which 
bind to the IREs and stabilise DMT1 mRNA, thus increasing DMT1 protein expression and 
iron uptake from the gut105. IRP1 and IRP2 are further discussed in section 1.2.2.8. 
1.2.2.3 Ferritin  
Following absorption from the duodenal lumen, iron may be utilised in enterocytes, exported 
to the circulation or stored. Ferritin is the protein to which iron binds for storage and is 
ubiquitously expressed throughout all tissue types (in multiple intracellular locations) and in 
the serum125-128. This storage facility sequesters a potentially harmful intracellular “labile iron 
pool” of ferrous iron129. Ferritin consists of 24 subunits arranged in a globular shell-like 
structure130. These subunits are either heavy (H) or light (L); the H and L subunits are encoded 
by different genes and the ratio of H to L is tissue-dependent131;132. Ferritin H is profusely 
expressed in cardiac tissue, whereas the liver and spleen exhibit a preponderance of ferritin 
L125. The H subunit deploys a ferroxidase activity to oxidise the ferrous iron imported by 
DMT1 back into its ferric (Fe3+) form for binding129. The L subunit stabilises the shell 
structure and facilitates uptake of ferric iron into it133. Each ferritin protein is capable of 
sequestering 4500 iron atoms125.  
The mechanism of action of ferritin lends it anti-oxidant properties. Induction of ferritin H by 
NF-κB via TNF-α suppresses the production of reactive oxygen species (ROS) from Fenton 
reaction chemistry, thus inhibiting apoptosis134. Murine studies have demonstrated reduced 
oxidative stress in mice in which ferritin H has been genetically upregulated135. Tissue culture 
experiments have shown that HeLa and murine erythrolukaemia cells that over-express ferritin 
accumulate less labile iron and ROS136;137; conversely use of siRNA to disrupt ferritin H in the 
same murine cells induced oxidative stress138.  
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Ferritin is also regulated by IRP1 and IRP2. The IRE of ferritin is found in the 5’ UTR of its 
mRNA139. Excess iron induces IRP1 to assemble a cubane iron-sulphur cluster (ISC), the 
binding site for which overlaps that for the H ferritin IRE. Thus, when iron levels increase and 
more storage capacity is needed to avoid high levels of labile iron, IRP1 is prevented from 
binding to the ferritin IRE. Because IRP1 is inhibitory to translation of ferritin mRNA, 
reduced IRP-IRE interaction is permissive for up-regulation of ferritin protein to buffer the 
increasing numbers of free Fe2+ ions105;140. Similarly, when cells are iron replete, IRP2 
undergoes proteasomal degradation, again allowing ferritin to be expressed at higher 
concentrations105. In murine knockout studies, IRP1 knockout mice demonstrated very little 
dysregulation in iron homeostasis, whereas IRP2 knockouts displayed abnormal ferritin 
induction and consequent abnormalities in iron handling. This suggests that IRP2 is in fact the 
primary factor in control of ferritin regulation141;142. 
Ferritin is also regulated in response to changing concentrations of haem. Friend Leukaemia 
Cells induced to differentiate by exogenous haem were observed to up-regulate ferritin 
expression via activation of NF-Y and p300143;144. NF-Y binds to a site approximately 100bp 
upstream from the initiation site for ferritin H transcription, and the haem-responsive element 
in the ferritin promoter region has been shown to overlap with the anti-oxidant response 
elements of both ferritin L and H which allow ferritin to act as an anti-oxidant in times of 
oxidative stress145;146. 
1.2.2.4 Ferroportin  
Ferroportin (IREG-1, MTP-1) was discovered by two independent groups; one identified a 
protein termed ferroportin 1 in mutant zebrafish, where gene mutations conferred a state of 
hypochromic anaemia119, the second identified iron regulatory gene-1 in hypotransferrinaemic 
(sla) mice and later cloned the protein they named metal transport protein-1120. Ferroportin is 
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now the universally accepted name for this transporter, which is the only exporter of inorganic 
iron found to date.  
Ferroportin is a 571 amino acid protein with multiple transmembrane domains. It is densely 
expressed in human liver, kidney, spleen, heart, placenta and enterocytes120;147. Expression is 
far more abundant on the basement membranes of polarized duodenal enterocytes in 
particular, consistent with a role in the export of iron from these cells120. 
The ability of ferroportin to export iron out of cells has been demonstrated by in vitro tissue 
culture experiments. Reduced cytosolic iron levels were reported following artificially induced 
over-expression of ferroportin124, while viral transfection to over-express ferroportin in a 
murine macrophage cell line led to a 70% increase in efflux of 59Fe after phagocytosis of 59Fe-
labelled erythrocytes148.  
Regulation of ferroportin is achieved via two distinct mechanisms. The first is reliant on the 
fact that ferroportin mRNA also features an IRE, in the 5’ UTR. At low iron concentrations 
the IRP-IRE interaction would act to inhibit ferroportin expression in the same manner seen 
with ferritin to increase intracellular availability120. However, the primary system for 
ferroportin regulation is through the action of the hormone hepcidin. Now regarded as a 
master-regulator of iron metabolism, hepcidin binds to and phosphorylates ferroportin, which 
is then internalized, de-phosphorylated, ubiquitinated and directed for lysosomal 
degradation149-151. Hepcidin is synthesized in the liver152; its expression is up-regulated in 
response to increasing iron levels and inflammation, and decreased by hypoxia and 
anaemia153;154. Hepcidin is discussed further in section 1.2.2.6. 
As might be expected, mutations in the gene which codes for ferroportin can lead to iron 
overload due to autosomal dominant forms of haemochromatosis unrelated to mutations in the 
HFE gene. The A77D missense mutation generates a disease phenotype characterized by early 
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iron overload in reticuloendocytic macrophages. This form of haemochromatosis comes about 
because of localisation of ferroportin to the cytosol rather than the cell membrane, depriving 
macrophages of their capability to extrude iron155;156. The N144H missense mutation results in 
the classic phenotype of hereditary haemochromatosis in which the functionality of enterocytic 
ferroportin is augmented by a lack of response to inhibitory hepcidin, thus increasing efflux of 
iron from the intestines157;158. In this variation of the disease there is a high concentration of 
serum transferrin and vastly increased liver deposits of iron158. 
1.2.2.5 Hephaestin 
Ferroportin exports iron from cells in the ferrous (Fe2+) form. However, iron is transported 
around the body bound to transferrin in its ferric state. In many cell types, including glioma 
cells, astrocytes and macrophages, the multi-copper oxidase caeruloplasmin (Cp) converts 
divalent iron into trivalent for transport159-161. The human condition acaeruloplasminaemia 
(lack of Cp) results in iron accumulation in the retina, basal ganglia, spleen, liver and 
pancreas162. Murine studies on a Cp-knockout revealed similar hepatic and splenic iron 
overload, as well as high iron levels in cells of the reticuloendothelial system160. 
Caeruloplasmin is not found in the intestine; its role there is filled by a transmembrane-bound 
homologue named hephaestin. This first came to light following studies on the sex-linked 
anaemia (Sla) mouse, members of which population exhibit a microcytic anaemia consequent 
upon impaired efflux of iron absorbed (in the normal manner) by the intestines163. The 
impairment in function is due to a 582 nucleotide deletion in the hephaestin gene which would 
code for a 194 amino acid sequence in its protein product163. Hephaestin and ferroportin 
expression are closely related, with marked co-localisation on the basement membranes of the 
duodenal enterocytes responsible for iron uptake164.  
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The mechanisms by which hephaestin expression is regulated are unclear. Hephaestin is 
known to be up-regulated by the homeobox transcription factor CDX2, whose main role is in 
regulating intestinal development and differentiation. High levels of intracellular iron induce 
CDX2, with the resulting expression of hephaestin leading to increased iron efflux and 
restoration of normal iron levels165. However, an alternative hypothesis proposes that 
hephaestin is regulated in response to systemic iron levels rather than at the cellular level; in 
this model, systemic shortages of iron trigger up-regulation of both ferroportin and hephaestin, 
with the consequent fall in intracellular iron levels causing compensatory up-regulation of 
DMT1 to increase overall body stores166.  
1.2.2.6 Hepcidin 
Hepcidin was identified in 2000-2001 when a number of groups isolated it independently of 
each other in plasma167, urine152 and liver153. Murine studies demonstrate iron overload in 
USF2 (upstream stimulatory factor 2) knockout mice, which also lack the hepcidin gene168, 
and severe anaemia in mouse models in which hepcidin is over-expressed169. Administration 
of synthetic hepcidin also induces hypoferraemia in mouse models170. Hepcidin is a 25 amino-
acid peptide synthesized in the liver as an 84 amino-acid precursor152. It has hydrophilic and 
hydrophobic elements, enabling it to function as an anti-microbial (in fact its original name 
was liver-expressed anti-microbial peptide or LEAP-1)171. It is known to be expressed in 
response to increasing systemic iron levels and inflammation153, while its expression is down-
regulated in response to hypoxia and anaemia154. 
As described earlier, hepcidin has been shown to bind to ferroportin to trigger its 
internalization and lysosomal degradation150. It is accepted that the active part of the hepcidin 
peptide in this context is the N-terminus; deletion of the 5 amino-acids positioned here 
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completely abrogates the decrease in iron levels usually seen when hepcidin is over-
expressed172.    
Hepcidin is now routinely described as the master-regulator of systemic iron levels173, with 
iron overload inducing hepatic hepcidin mRNA153. Hepcidin mRNA does not appear to 
contain the IRE seen in many of the other iron-regulatory proteins174, so an alternative method 
of regulation must be operating. The discovery of CCAAT/enhancer-binding protein (C/EBP) 
sequences in the hepcidin promoter region, as well as signal transducer and activator of 
transcription (STAT) motifs in its DNA, suggest that expression may be modulated at the 
transcriptional level175. C/EBPα in particular is implicated; iron loading doubles hepatic 
expression of C/EBPα in murine liver, and C/EBPα-deficient mice possess lower levels of 
hepcidin mRNA175. How iron can stimulate C/EBPα to initiate the hepcidin-ferroportin 
regulatory axis has yet to be elucidated. 
The gene associated with hereditary haemochromatosis (HFE) is also implicated in control of 
hepcidin expression. HFE knockout mice exhibit no up-regulation of hepcidin mRNA in 
response to increased iron loading, leading to hepatic deposition of iron and increased 
transferrin saturation176. Reconstituting hepcidin in these knockouts restored a normal 
response to iron loading and normalised the haemochromatosis phenotype177. Human studies 
comparing haemochromatosis patients to normal individuals revealed a similar picture of 
failure of hepcidin up-regulation in response to increasing serum iron levels and over-
expression of ferroportin178.  
Hemojuvelin, otherwise known as HFE2, has also been shown to up-regulate hepcidin 
expression179; mutations therein are thought to be responsible for juvenile 
haemochromatosis180. HFE2 acts through a signalling pathway involving bone morphogenetic 
proteins (BMPs). BMPs are members of the TGFβ superfamily which act through Smad 
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proteins and MAP kinases, and have been demonstrated to stimulate hepcidin production179. 
HFE2 mutations suppress BMP signalling, and Smad4 knockout mice exhibit lower levels of 
hepcidin in response to iron loading179.  
Transferrin receptor 2 (TfR2) mutations confer a similar phenotype to those seen in 
conjunction with HFE and hemojuvelin abnormalities181;182. This suggests a potential role for 
TfR2 in hepcidin regulation in addition to its role as an importer of iron from the circulation 
into hepatocytes183;184. 
Murine studies have also implicated hepcidin in the development of the anaemia of chronic 
inflammation/disease185;186. The induction of hepcidin expression by inflammation is mediated 
via the activity of IL-6185. Antibodies against IL-6 counteract the up-regulation of hepcidin 
mRNA expression in murine hepatocytes seen during inflammation153 and IL-6 knockout mice 
are incapable of generating this response185. IL-6 effects hepcidin up-regulation via activation 
of STAT3187, which subsequently interacts with one of the STAT binding sites in the hepcidin 
gene promoter region188;189.  
Leptin is also implicated in the induction of hepcidin expression. Human hepatoma (HuH7) 
cells incubated with leptin exhibit marked over-expression of hepcidin mRNA190. Obese 
individuals whose leptin levels are high display deranged iron homeostasis.  
Finally, hepcidin is also regulated in response to hypoxia, with lower oxygen tension resulting 
in down-regulation of hepcidin expression154;191. This is mediated by hypoxia-inducible factor 
(HIF-1); hypoxia causes accumulation of cytoplasmic HIF-1α which then relocates to the 
nucleus and binds to HIF-1β. The resulting complex binds to a hypoxia responsive element in 
hepcidin DNA to down-regulate transcription191. The resulting increase in iron efflux from 
cells permits increased erythropoiesis to generate increased capacity for oxygen carriage. The 
existence of this axis for hypoxia-mediated control of hepcidin expression has been proven by 
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various murine studies. Knockout mice lacking von Hippel-Lindau (a negative regulator of 
HIF-1) display increased ferroportin expression, while HIF-1α knockouts exhibit augmented 
hepcidin expression in response to hypoferraemia191. The actions and regulation of hepcidin 
are summarised diagrammatically in figure 1.2. 
  
Figure 1.2 Regulation and actions of hepcidin 
Increased iron, infection and inflammation induce hepcidin expression, which then exerts an 
inhibitory effect on iron export from cells by suppression of ferroportin activity (original 
diagram LL Dunn; Trends Cell Biol).  
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1.2.2.7 Transferrin Receptor 
The transferrin receptor (TfR) binds transferrin-bound iron for absorption into destination cells 
via receptor-mediated endocytosis. The process is summarised in figure 1.3 and described in 
detail below.  
 
Figure 1.3 TfR-Mediated Endocytosis 
The iron-transferrin complex binds to TfR and undergoes receptor-mediated endocytosis. 
Acidification of the endosome liberates Fe3+ which is reduced by Steap3. Fe2+ is exported to 
the cytoplasm by DMT1 for utilization, storage or entry into the labile iron pool (original 
diagram K Pantopoulos; Biochem J). 
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Transferrin is the protein to which ferric iron binds for transport around the body in the 
circulation192. It is synthesized and secreted by the liver193 as a hinged bi-lobar structure; the 
cleft between the two lobes can bind two iron atoms for delivery to the tissues194. Transferrin 
binds to the transferrin receptor (TfR) expressed on the cell membranes of destination tissue, 
where receptor-mediated endocytosis internalizes the complex192. In common with many such 
internalization mechanisms, the vesicle is coated in a proteinaceous coat of clathrin which 
helps to form the vesicle and package its contents195. A conformational change in transferrin is 
induced by the acid environment of the endosome to release iron115 whereupon it is reduced to 
Fe2+ by the ferric reductase Steap3196 and transported from endosome to cytoplasm by 
DMT1B115.  
TfR exists in 2 forms; TfR1 and TfR2197. TfR1 is expressed throughout the body and has a 
high affinity for the transferrin-Fe complex. TfR2 is localised to the liver and intestinal iron-
absorbing cells198 and demonstrates lower affinity197;199. TfR is expressed as a homodimer, 
each half being composed of an extracellular stalk, a transmembrane segment and a 
cytoplasmic domain. Transferrin binds across the dimer200, triggering an internalization signal 
emanating from a tyrosine near the cytoplasmic N-terminus of TfR201.  
TfR expression is regulated by iron levels and hypoxia. In common with many of the other 
iron transport proteins, TfR mRNA possesses IREs; in this case 5 of them, all located in the 3’ 
UTR202. Thus, IRP binding stabilises the mRNA permitting increased translation in times of 
iron shortage to allow increased import from the serum139.  
Hypoxia regulates TfR at the transcriptional level. TfR promoter DNA contains an HRE which 
(in contrast to the inhibitory HRE found in hepcidin mRNA) up-regulates transcription when 
hypoxia causes HIF-1α and HIF-1β to complex and bind to it203;204. In vitro studies on K562 
(hepatoma) cells and HeLa (human cervical carcinoma) cells demonstrated up-regulation of 
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TfR1 mRNA in response to hypoxia, abrogation of this response when the HIF-1 binding site 
in the HRE was mutated, and enhanced TfR1 promoter activity in the face of over-expression 
of the HIF-1α/β subunits203;205. Iron chelators have been found to increase TfR1 transcription 
in HepB3 human hepatoma cells, which response was again abrogated following mutation of 
the HRE or in the presence of dysfunctional HIF-1α206.  
1.2.2.8 Iron Regulatory Elements and the Iron Response Proteins 
As has already been mentioned, several of the proteins involved in iron handling incorporate 
iron-responsive elements (IREs) in un-translated regions of their mRNA to allow post-
transcriptional regulation of expression in response to intracellular iron levels105;118-120;202. 
These IREs can occur in either the 3’ or 5’ UTR of the mRNA and their location is of 
functional importance207. With an IRE at the 3’ end, binding of an iron response protein (IRP) 
to it stabilises the mRNA to up-regulate translation, thereby increasing expression of the 
protein end-product. Conversely, IRP-IRE interaction at the 5’ end interferes with assembly of 
the 43S pre-initiation complex to inhibit protein expression208. As can be inferred, proteins 
with 3’ IREs include TfR and DMT1, whereas ferroportin and ferritin (both L and H) feature 
IREs at the 5’ end103;105. Hence, induction of the IRE-IRP system will increase influx of iron 
from the gut or circulation, whilst liberating intracellular stores and preventing efflux. 
There are 2 IRPs, both members of the iron-sulfur cluster isomerase family209. Both are 
thought to be formed of 4 domains; 3 closely linked with the 4th attached by a flexible hinge 
mechanism105. The major difference is that IRP-2 contains a 73 amino-acid insertion in 
domain 1, encoded by a unique exon, which is rich in cysteine and proline.  
Both IRP1 and IRP2 are ubiquitously expressed105 and do not appear to differ in their relative 
capacities to influence regulation of iron transport proteins210-212. However, cell culture studies 
have demonstrated that proportional responsibility for regulation may differ between tissue 
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types. In murine J774 cells213 and RAW macrophages214;215, only IRP2 modulation was seen to 
affect TfR and ferritin expression, with no part played by IRP1. The situation was reversed in 
human RD4 (rhabdomyosarcoma)216 and H1299 (lung cancer)217 cells where expression of the 
mutant IRP1C437S led to dysregulation of the same two proteins. 
Regulation of IRP1 and IRP2 is achieved through 2 distinct mechanisms. When iron is 
plentiful, IRP1 assembles a 4Fe-4S cluster218 which prevents normal binding to IREs and 
confers upon IRP1 the activity of a cytosolic aconitase, which may play a role in redox 
control219. Iron depletion induces disassembly of the cluster220, which probably reorganises the 
cleft between domains 1-3 and the hinged domain 4, providing more space therein and 
restoring IRE-binding potential221. The iron-sulphur cluster is also induced to disassemble in 
times of oxidative stress in response to H2O2 and NO
222;223, which may implicate IRP1 in the 
inflammatory response and the anaemia of chronic disease (by increasing cellular import of 
iron and down-regulating export, leading to decreased levels of circulating iron). The 
regulation of IRP2 is markedly different – it is synthesized de novo when iron is in short 
supply224 and undergoes proteasomal degradation when iron levels increase225. The control 
mechanism was originally thought to rely on the 73 amino acid insertion described earlier. It 
was proposed that this domain functions as an iron sensor, and that the binding of iron to it 
induces oxidation of 3 cysteine residues (C168, C174 and C178), rendering IRP2 recognisable 
to the proteasome and marking it for degradation226. Recent work has demonstrated that 
mutations in these 3 residues227, or even deletion of the entire insert227;228, does not protect 
IRP2 from degradation, although an alternative method for its down-regulation in iron-replete 
cells has not yet been delineated. 
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Figure 1.4 The Role of IRP1 and IRP2 in Regulation of Intracellular Iron Levels 
High iron concentrations reduce IRP/IRE interaction to encourage intracellular sequestration 
by ferritin and efflux by ferroportin. At low iron concentrations increased IRP/IRE interaction 
blocks iron efflux, reduces binding to ferritin and encourages import from the circulation via 
TfR and DMT1. 
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1.2.3 Haem Metabolism 
Haem (iron-protoporphyrin IX) is less common in the diet than the inorganic iron previously 
discussed, being confined to red meat, but it is more efficiently absorbed. It has a key role to 
play in the function of haemoprotein enzymes such as catalase, peroxidase, cytochromes c and 
p450 (electron transfer and drug metabolism), nitric oxide synthase (signal transduction) and 
NAPDH oxidase. Disordered haem metabolism is implicated in the pathogenesis of 
haematological disorders such as porphyria and sickle-cell disease. It is also a component of 
haemoglobin, myoglobin, cytoglobin and neuroglobin and has been shown to be involved in 
regulation of transcription, translation and cellular differentiation229;230. Because free haem is 
potentially cytotoxic (much like ferrous iron, it can generate harmful reactive oxygen species), 
it is tightly controlled to maintain a low intracellular concentration. This is achieved (in non-
erythrocytes at least) through the negative feedback effect of haem on the synthetic enzyme δ-
aminolaevulinic acid synthase (ALAS), and its positive effects on expression of catabolic 
haem oxygenase-1 (HO-1)231-233. 
Although a multitude of proteins involved in the handling of inorganic iron, from the GI tract 
to the peripheral tissues, have been identified and exhaustively researched, relatively little was 
known until recently about mechanisms of haem transport into and out of cells. HCP-1 (haem 
carrier protein 1) has now been identified as a haem importer protein, and LRP1 (lipoprotein 
receptor-related protein 1) is thought to have a similar role. Haem within cells can either be 
broken down by haem-oxygenase-1 (HO-1) into free iron and biliverdin (then reduced to 
bilirubin), or trafficked through cells and exported by FLVCR (feline leukemia virus subgroup 
C receptor) or BCRP (breast cancer resistance protein, also known as ABCG2). Haem 
transport is summarised below in figure 1.4. The individual proteins involved are discussed in 
greater detail thereafter. 
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Figure 1.5 Iron and haem transport in the enterocyte 
Inorganic iron transport is shown on the left side of the above illustration, haem transport on 
the right. HCP-1 has been shown to import haem; LRP1 is likely to share this role. HO-1 is 
capable of catabolising haem to release inorganic iron which then enters the normal 
intracellular iron-handling machinery as shown. FLVCR and BCRP (ABCG2) are both 
implicated in haem export. 
30 
 
1.2.3.1 Haem Carrier Protein 1 (HCP-1) 
It is recognised that haem, as a lipophilic molecule, is capable of diffusing across cell 
membranes without the need for active transport234. Initial evidence for the existence of an 
unspecified transporter able to import haem came from studies on intestinal Caco-2, and non-
intestinal K562 (human leukaemia) and HepG2 (human hepatocellular carcinoma) cells, 
reporting energy-dependent haem uptake235;236. This work followed the demonstration of an 
intestinal brush border haem receptor in both porcine237 and human235 gut, although at the time 
it could not be characterized. While some researchers postulated that haem was degraded in 
the gut lumen prior to absorption238, electron microscopy has clearly illustrated the presence of 
haem porphyrin rings in micro-endocytic vesicles in the bases of gut microvilli and in 
tubovesicular structures in the adjacent cytoplasm of the epithelial cells239. 
HCP-1 was isolated from mouse duodenum via subtractive suppression hybridization240. It is 
primarily expressed in the duodenum, but can also be found in liver and kidney240, and is 
expressed by macrophages241. It is a 446 amino acid protein exhibiting marked hydrophobic 
tendencies, with 9 transmembrane domains240.  
Varied evidence exists to demonstrate that HCP-1 functions as a haem transporter. Xenopus 
oocytes and cultured cells both exhibit 2-3-fold increase in haem uptake secondary to HCP-1 
expression, and HCP-1 also facilitates uptake of the structurally homologous Zn-
protoporphyrin. Conversely, uptake of radio-labelled haem by duodenal cells was inhibited in 
the presence of anti-HCP-1 antibodies230. 
Regulation of HCP-1 occurs at both transcriptional and post-translational levels. HCP-1 
mRNA is up-regulated by hypoxia and hypotransferrinaemia230 through a regulatory 
mechanism that has yet to be clarified. Post-translational regulation is better understood. 
Before the discovery of HCP-1, rodent studies had already described an increase in haem 
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absorption in response to iron-deficiency242. The group responsible for identifying HCP-1 also 
determined that its location within the cell changes in response to iron load; iron-replete rats 
sequester HCP-1 in the cytoplasm, whereas it is translocated to the apical membrane when 
they are rendered iron-deficient240. 
The activity of HO-1 may also be related to HCP-1 expression. Iron deficiency induces up-
regulation of HO-1243; the resulting catabolism of haem may trigger increased membranous 
HCP-1 expression to compensate. Haem catabolism generates ferrous iron, CO and biliverdin 
(then reduced to bilirubin)230. The Fe2+ can be processed by the inorganic iron transport chain 
in the usual manner. It has been demonstrated that induction of HO-1 in Caco-2 cells using 
CdCl2 causes both expression of HCP-1 and haem absorption to be up-regulated
231.  
More recently HCP-1 has been identified as the primary folate transporter in humans, utilising 
a proton-coupled transport mechanism to import folate from the duodenal lumen. Hereditary 
folate malabsorption has been shown to be secondary to mutations in the HCP-1 gene244.  
1.2.3.2 LDL Receptor Related Protein 1 (LRP1) 
Haemopexin (Hx) is a haem scavenger which acts to prevent the toxic inflammatory and pro-
oxidant effects of free haem245-247. It functions in a way analogous to haptoglobin, which acts 
as a scavenger; binding to free haemoglobin and enabling uptake by macrophages or splenic 
monocytes via CD163-mediated endocytosis 248. It was previously known that a receptor 
capable of haemopexin-haem uptake through endocytosis existed in hepatocytes, macrophages 
and syncytiotrophoblasts249-252; this receptor was identified as low density lipoprotein 
receptor-related protein 1253 using the ligand affinity purification techniques previously 
utilised to characterize the C163 haptoglobin-haemoglobin receptor248. 
Binding studies confirmed the ability of LRP1 to bind Hx-haem, whereas the known LRP 
inhibitor RAP (receptor-associated protein) and anti-LRP IgG both blocked binding253. 
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Experiments on the COS-1 (simian kidney) cell line, which is known to express LRP1, 
demonstrated uptake of 125I-Hx-haem and again showed inhibition by RAP/anti-LRP. 
Furthermore, uptake of 125I-Hx alone was much less avid than the haem complex253. Confocal 
microscopy demonstrated co-localization of LRP1 and Hx-haem, and also divulged overlap 
with the early endosomal protein EEA1 (early endosome antigen 1). After 1 hour, the LRP1 
had relocated to the cell membrane, whereas the fluorescent Hx-haem remained cytoplasmic; 
this corresponds exactly with the pattern expected of receptor-mediated endocytosis253. Hx-
haem and haem were both shown to induce HO-1 mRNA in human LRP- and HO-1-
expressing monocytes, with haem alone stimulating the more marked response. HO-1 
induction by Hx-haem was reduced by around 50% by RAP and anti-LRP IgG (although not 
by control IgG)253. In combination, these results clearly delineate a role for LRP1 in haem 
import and also suggest a potential role in the response to inflammation via induction of HO-1. 
Expression of LRP1 is predominantly in hepatocytes and hepatic and splenic 
macrophages254;255. Unsurprisingly, the majority of exogenous Hx-haem administered by 
injection can eventually be localized to the liver256. The co-localization of LRP1 and HO-1 in 
the placenta suggests an avenue for iron delivery to the foetus following LRP1-mediated 
uptake of Hx-haem257;258. 
1.2.3.3 Feline Leukaemia Virus Subgroup C Receptor (FLVCR) 
FLVCR was first characterized as a receptor for feline leukaemic virus, subgroup C259;260. 
FeLV-C causes aplastic anaemia (red cell aplasia) in cats due to failure of maturation of burst-
forming units-erythroid (BFU-E – erythroid progenitors) into colony-forming units-erythroid 
(CFU-E), thus arresting erythropoiesis261;262. FLVCR is, like HCP-1, a member of the major 
facilitator superfamily263 and has been shown to comprise 12 hydrophilic transmembrane 
domains. It is widely expressed in haematopoietic cells, as well as in liver- and intestine-
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derived cell lines (all of which tissue types could potentially require a haem-trafficking 
function). The utility of FLVCR as an exporter of haem has been demonstrated. Initially cells 
suspected to require the ability to transport haem were shown to exhibit over-expression of 
FLVCR mRNA and protein. These included the intestinal phenotype Caco-2, hepatic HepG2 
and the haematopoietic progenitor line K562. Significantly, FLVCR expression is absent in 
the mature erythroid line HEL-R which manifests spontaneous haemoglobinization (thus 
buffering excess intracellular haem)264. Engineered over-expression of FLVCR in rat renal 
epithelial (NRK) cells significantly lowered their haem content, whereas infection of feline 
embryonic fibroblasts (FEA) with feline leukaemia virus (to block surface expression of 
FLVCR) led to higher intracellular haem levels264. Quantitative fluorescence microscopy using 
the (fluorescent) haem analogue zinc mesoporphyrin confirmed that NRK and K562 
(haematopoietic cells of erythroid phenotype) lines transfected with FLVCR display increased 
export of haem in a temperature-dependent manner264.  
FLVCR has also been shown to be integral to normal erythropoiesis. It is avidly expressed by 
K562 cells; abrogating haem export from these cells with the FeLV ligand caused inhibition of 
differentiation, and apoptosis when differentiation was induced. CFU-E cells display profuse 
expression of FLVCR, which is down-regulated as globin synthesis commences and 
haemoglobinization can occur. Because erythroid cells lack the same regulatory mechanisms 
for intracellular haem seen in other tissues (via HO-1-mediated degradation etc), FLVCR 
likely functions as a safety-release valve in CFU-E cells to prevent excess haem causing toxic 
damage as up-regulation of globin synthesis catches up with that of haem264.   
1.2.3.4 Breast Cancer Resistance Protein (BCRP) 
BCRP is a member of the ATP-binding cassette (ABC) family (it is also known as ABCG2). 
These proteins serve as exporters of myriad substrates. BCRP and others of the G subset of 
34 
 
ABC proteins are capable of exporting chemotherapeutic agents from cells, and it was in this 
context that BCRP was first discovered – conferring resistance to chemotherapy in breast 
cancer265;266. All ABC transporters possess a conserved cytosolic domain, 2 cytosolic 
nucleotide-binding domains and a minimum of 2 trans-membrane segments. ABCG2 features 
6 trans-membrane segments and its nucleotide binding domains are located near the N-
terminus of the peptide, in common with all members of the G sub-family267. 
BCRP is regulated, at least in part, by a hypoxia response element in its promoter region in a 
similar manner to TfR/IRE. Transcription is thus modulated through binding of HIF1. Akt1 
(an upstream regulator of HIF1) directs BCRP expression to the plasma membrane268. This 
localization of BCRP is in contrast to most ABC transporters, which are to be found in cellular 
organelles269. It is this distribution which allows BCRP to function as a detoxifier, exporting 
drugs, toxins and metabolites from the liver, kidney, intestine and placenta270;271. 
The ability of BCRP to function as a haem exporter was discovered coincidentally when 
ABCG2-null mice developed photo-toxicity, subsequently discovered to be secondary to 
cutaneous deposition of pheophorbide A272. This substance, a chlorophyll degradation product 
found in their diet, is analogous to protoporphyrin IX, which displayed a similar pattern of 
atypical accumulation in the skin and erythrocytes of ABCG2-/- mice. Confirmation of the role 
of BCRP as a haem exporter was obtained through a number of complimentary experiments. 
Elevated intracellular levels of protoporphyrin IX were demonstrated in ABCG2-/- erythroid 
progenitors273, whereas those over-expressing ABCG2 manifested lower concentrations274. 
ABCG2-/- progenitors were demonstrably more susceptible to hypoxia than wild-type cells, 
although inhibition of ABCG2 in these cells with fumitremorgin C or reserpine rendered them 
equally sensitive to lower oxygen tensions. Inhibiting haem synthesis in the mutant cells with 
succinyl acetone prevented intracellular accumulation of porphyrins and enhanced their 
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survival275. In combination, this evidence suggests that ABCG2/BCRP is induced by HIF1 in 
response to hypoxia to export intracellular porphyrins, thus conferring a survival advantage on 
haematopoietic cells by minimizing generation of ROS. 
1.2.4 Iron and Carcinogenesis 
 
Iron was first linked to carcinogenesis in 1959 by induction of sarcomata in rats injected 
repeatedly with an iron-dextran complex276. These results were replicated in rabbits277.  
Similar effects were subsequently demonstrated in humans receiving therapeutic intra-
muscular iron injections278. Evidence has since continued to mount that iron is fundamentally 
involved in the pathogenesis of multiple types of cancer in humans. 
Initial data supporting this theory was epidemiological. Anaemia appears to be protective 
against lung cancer in women, while total iron binding capacity is inversely proportional to 
lung cancer rate279. Transferrin binding is significantly higher and total iron binding capacity 
significantly lower in cancer patients than the normal population (all cancers)280. A Chinese 
study demonstrated that ferritin levels increase and transferrin levels decrease in cancer 
patients. Carrier status for the hereditary haemochromatosis gene (conferring an iron-
overloaded phenotyope) is also linked to cancer279-281.  
A number of potential mechanisms exist through which iron could exert a carcinogenic effect, 
discussed in detail below. 
1.2.4.1 Iron and Redox Chemistry 
A proportion of the carcinogenic effects of iron are dependent on Fenton reaction chemistry. 
The Fenton reaction describes the production of highly reactive hydroxyl radicals following 
exposure of ferrous iron to hydrogen peroxide: 
Fe(II) + H2O2 → Fe(III) + ˙OH + OH-  
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These reactive oxygen species (ROS) cause lipid peroxidation and damage to lysosomal 
membranes, mitochondria and microsomes282. Excess iron leads to increasing amounts of ROS 
via Fenton reaction chemistry. Where iron levels are increased, these carcinogenic effects of 
oxidative stress could therefore be considered to be due to iron surplus.  
A renal carcinoma model demonstrates this concept. Intra-peritoneal injections of Fe-NTA 
(ferric nitrilotriacetate) induce renal proximal tubular necrosis283 and eventual renal cell 
carcinoma284 in rats and mice. Biochemical and histological analysis confirmed 
contemporaneous lipid peroxidation in the afflicted rodents283. It has thus been argued that 
induction of oxidative stress by Fe-NTA leads to renal carcinogenesis285. 
The high incidence of lung cancer in patients exposed to asbestos has been attributed to its 
high iron content of (around 30% by weight). Asbestos compounds with higher iron content 
are more likely to be carcinogenic. Evidence suggests that this is due to ROS generated by 
Fenton reaction chemistry stimulated by iron in the asbestos fibres, although ROS production 
in macrophage lysosomes and via IL-8 induction is also implicated285.  
Iron may also exert a carcinogenic effect by inhibiting the protective mechanisms cells employ 
to defend themselves against oxidative stress. It has been shown to reduce levels of vitamin E 
and superoxide dismutases, both of which act as reductive systems in times of oxidative stress. 
However, increasing levels of other reductive substances have been observed in a number of 
cancers. Glutathione-S-transferase pi (GSTP) is expressed in colon, lung and cervical cancer 
and was shown to be induced in the renal parenchyma following Fe-NTA administration in the 
renal cell carcinoma model described above. Higher GSTP levels are associated with poor 
prognosis in colon cancer. This suggests that certain cancers may have evolved protective 
mechanisms to survive conditions of persistent oxidative stress285. 
37 
 
As well as generating ROS, iron can also cause direct damage to DNA. Ferric citrate is 
capable of mediating oxidative single- and double-stranded breaks on plasmid DNA in 
vitro286. The majority of the increased free iron in haemochromatosis patients is complexed 
with citrate287 and haemochromatosis patients are known to have a much higher incidence of 
hepatocellular carcinoma than control populations285. 
1.2.4.2 Iron and Cell Cycling 
Progression of the cell cycle through G0, G1, S, G2 and M phases is regulated by cyclins and 
cyclin-dependent kinases (CDKs). The CDKs act as catalysts for the cyclins; a heterodimer 
formed of the two comprises the regulatory unit. Cyclins A, D and E are responsible for 
progress through G1, cyclin A for the S phase and cyclin B for the M phase
288. The regulatory 
units are in turn controlled by cyclin-activating kinases (CAKs), which phosphorylate the 
cyclin-CDK complexes to activate them289. Inhibitory control of the cycle is mediated via 
CDK inhibitors (CKIs)290. 
A key factor in cell cycle control is the p53 tumour suppressor protein, expression of which is 
up-regulated in response to a variety of insults, including DNA damage, hypoxia, loss of 
survival signals, disordered cell growth and, critically, iron chelation291-294. When any one of 
these stressors stimulates p53 activation, it is able to arrest the cell or induce apoptosis295.  
Introducing iron chelators to a variety of cultured cells in vitro reduces expression of cyclins 
D1, D2, D3, A and B. This phenomenon was observed in cells derived from 
neuroepitheliomas, breast cancers, leukaemias and Kaposi’s sarcoma296-298. As the presence of 
pre-complexed chelators and Fe had no effect, this down-regulation must be due to depletion 
of available iron by unbound chelator296.  
Fe chelation reduced expression of cdk2 mRNA299 in leukaemia cells and the protein296 in 
neuroepithelioma cells. Complexes of cyclin D with cdk4, and cyclin E with cdk2, are 
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necessary for cycling through G1/S; when any of these components are scarce, cells may arrest 
at this stage296;297.  
The same cell lines demonstrate up-regulation of CKI mRNA in response to iron chelation, 
particularly p21, although paradoxically this was not mirrored at the protein level290.  
Iron chelation also induces p53 activity, though this appears to reflect increased activation of 
latent p53 rather than increased mRNA/protein expression, as both are measurably 
unchanged290;296. 
Iron has also been shown to be crucial to the functioning of the enzyme ribonucleotide 
reductase, the rate-limiting step in DNA synthesis300-302. Chelating iron decreases 
ribonucleotide reductase activity in human leukaemia K562 cells, as well as inhibiting DNA 
synthesis and cell growth. Similar effects are seen following addition of an anti-TfR antibody 
to block iron uptake by the cells. These experiments demonstrate the importance of adequate 
iron in normal ribonucleotide reducatase function and thus cell proliferation303. 
The inhibitory effect of iron chelation on the cycling of malignant cell lines in vitro indicates a 
crucial role for iron in their propagation, as well as providing a potential therapeutic avenue. 
1.2.4.3 Iron and the Immune System 
The anti-tumour effects of macrophages appear to be inhibited by iron; phagocytosed 
erythrocytes, erythrocyte lysate, haemoglobin, iron dextran and iron salts all diminish the 
tumouricidal action of macrophages, an effect not achieved by erythrocyte ghost membranes, 
latex spheres, myoglobin or dextran alone304. Excessive iron has also been shown to inhibit 
function of helper (CD4) T lymphocytes305;306, as well as increasing the numbers of active 
suppressor (CD8) T cells306. An increased CD8/CD4 ratio could impair immune surveillance 
of cancer cells307. 
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1.2.4.4 Iron and Colon Cancer 
As most dietary iron is excreted rather than absorbed, the human colon contains large amounts 
of iron. As a result a significant amount of work has been done in an effort to link iron and 
colorectal cancer (CRC). Positive associations have been demonstrated between both dietary 
iron content and body iron stores and CRC280;308 and precancerous lesions309;310; 75% of large 
studies in a comprehensive analysis indicated this to be the case311. CRC is also more likely in 
haemochromatosis patients with high intracellular iron levels312.  
Rodent studies demonstrated that excess dietary iron bestows a more unstable environment on 
cells of the colonic mucosa. Increasing dietary iron was shown to increase the number of free 
radicals in the colon, and the amount of subsequent lipid peroxidation313, as well as increased 
numbers of aberrant crypt foci, which are recognised as a pre-malignant change314. Rats fed on 
haem exhibited up-regulated proliferation of colonic epithelium compared to controls (as 
manifest by increased epithelial uptake of 3H-thymidine into colonic mucosa)315. 
When reactive oxygen species degrade lipids, one of the by-products is malondialdehyde316 – 
a reactive aldehyde that can be used as a marker for oxidative stress317. In HFE-knockout mice 
(which by definition display a haemochromatosis phenotype), increasing amounts of dietary 
iron are shown to produce increasing concentrations of colonic and mammary 
malondialdehyde, implying a more severe degree of damage to the tissues secondary to iron 
intake318.   
It has been demonstrated that expression of the proteins concerned with transporting non-haem 
iron is dysregulated in CRC cells, allowing them to sequester abnormally high levels of 
intracellular iron. Expression of Dcytb, DMT1 and TfR1 is increased to boost iron import. 
Although ferroportin expression also increases, it is localised to the intracellular compartment 
rather than the basement membrane. As hephaestin expression is decreased, the overall effect 
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is to block iron export and dramatically increase intracellular iron levels319. The changes seen 
in ferroportin expression can be partly explained by the discovery of hepcidin expression in 
34% of colorectal cancer specimens. In these cases it was associated with ferroportin 
inhibition. Urinary hepcidin levels show a positive correlation with pathological T stage of 
colorectal cancer320. High serum ferritin concentrations are linked to a predisposition for 
developing colonic adenomas321.  
The potentially carcinogenic effect of rising intracellular iron concentrations in the colonic 
epithelium has been demonstrated by artificially increasing the amount of iron contained 
within human intestinal (Caco-2) cells in culture. This led to increased oxidative stress and 
consequential damage to protein and DNA322.  
APC is a tumour suppressor gene, mutations in which are strongly implicated in colorectal 
carcinogenesis. It has been shown that iron is capable of inducing the oncogenic Wnt 
signalling pathway in cells lacking functional APC, stabilising β-catenin to cause increased 
expression of mRNA for c-myc and Nkd1, as well as increased cellular proliferation. 
Transfection of wild-type APC into the cells blocked this effect. Iron excess could therefore 
help drive the carcinogenic process in APC-deficient cells323. 
The role for iron in colorectal carcinogenesis is thus clear, with both a demonstrable 
mechanism for increasing iron levels within colorectal cancer cells, and a tangible oncogenic 
effect of iron in APC deficient colonocytes. 
1.2.4.5 Iron and Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is usually the endpoint of a pathological progression of 
parenchymal liver disease. Some form of initial, usually chronic, physiological insult to 
hepatocytes results in cellular damage and death. Fibrosis and scarring ensue, followed by 
regeneration of the damaged liver324. Repeated cycles of destruction and regeneration lead to 
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the development of cirrhosis, which confers a 200-fold increase in the risk of developing 
HCC325.  
There are myriad aetiological factors recognised in the pathogenesis of cirrhosis. The most 
common in the Western world are alchohol and hepatitis viruses B and C. However, iron is 
also implicated, primarily in patients suffering from hereditary haemochromatosis326. HCC is 
in fact the leading cause of death in haemochromatosis patients327. Classically, 
haemochromatosis was considered to arise from one of two point mutations in the HFE gene 
(juvenile haemochromatosis, discussed in relation to hepcidin in section 1.2.2.6, represents a 
different disease phenotype). Under normal circumstances, HFE will complex with TfR at the 
cell membrane of hepatocytes in order to inhibit transferrin binding and therefore iron import. 
This action relies on the ability of HFE to bind to β2-microglobulin; an ability abrogated by the 
C282Y mutation which substitutes a tyrosine residue for one of 4 invariant cysteine residues. 
These 4 residues are a shared feature with major histocompatability complex (MHC) class I 
molecules, in which they form disulphide bridges in the α2 and α3 domains328. In fact, HFE 
was initially known as HLA-H, owing to the marked similarity between the two proteins326. 
Around 90% of haemochromatosis patients are homozygous for the C282Y mutation329, which 
also localises HFE to the cytosol rather than the cell membrane where wild-type HFE is 
expressed330;331. This autosomal recessive inheritance pattern is in contrast to those described 
in relation to the ferroportin mutations discussed earlier, which also instigate a 
haemochromatosis phenotype155;156.  
A second point mutation has also been described in “classical” haemochromatosis; 
His63→Asp (H63D) is frequently observed in patients heterozygous for the C282Y mutation. 
Although the precise nature of the dysfunction prompted in HFE by this mutation is unclear, it 
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is thought to relate to changes in the way in which HFE is able to interact with other 
proteins329. 
Whichever of the HFE mutations is responsible, the consequences of haemochromatosis are 
unaltered. Increased binding affinity between transferrin and TfR results in increased cellular 
uptake of iron in all tissues, but particularly the liver, which is the primary organ involved in 
iron storage and metabolism326. Iron then mediates cellular and DNA damage to initiate the 
sequence of events culminating in development of neoplasia. 
It is worth noting that iron plays a secondary role in HCC pathogenesis through its function as 
a cofactor for viral propagation. Persistent infection with hepatitis B or C also results in a 
chronic insult to hepatocytes that may eventually lead to cirrhosis and hepatoma332. 
Also of interest is the fact that liver iron concentrations are slightly raised in HCC even when 
haemochromatosis and cirrhosis have no part in the disease process333. 
1.2.4.6 Iron and Renal Cell Carcinoma 
The link between iron and renal cell carcinoma (as well as other types of renal malignancy) is 
less well understood than that for CRC and HCC.  
Rodent studies have demonstrated the carcinogenic properties of ferric nitrilotriacetate (Fe-
NTA) on the kidney334. Oxidative damage to the renal tubules causes acute tubular necrosis; 
repeated exposure may eventually lead to RCC in a similar fashion to the development of 
HCC in cirrhotic livers. Products of lipid peroxidation, including malondialdehyde, were 
found to be elevated in treated rats335. Fe-NTA was a more potent carcinogen than its cupric 
equivalent, and NTA alone had no carcinogenic effects336. The p16 tumour suppressor gene 
suffered allelic loss after treatment with Fe-NTA, providing a second potential aetiopathogenic 
mechanism for iron-induced RCC in rats337.    
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In terms of the human disease, population studies provide the only hard evidence that iron may 
be an environmental carcinogen affecting the kidney. In one such study, involving multiple 
international centres, the relative risk of RCC was found to be 1.6 in iron and steel workers 
compared to normal individuals (95% confidence interval 1.2-2.2)338. However, no specific 
compounds have been identified and no particular genetic mutations discovered.  
1.2.4.7 Iron and Other (Non-Mammary) Cancers 
Increased incidence of both lung and stomach cancer has been reported in iron and steel 
workers339;340. It is thought that the responsible agent is the dust circulating in these 
environments, which is either ingested or inhaled. These dusts display surface redox activity in 
aqueous solution341;342 and have been shown to be increasingly reactive when a larger fraction 
of the dust is formed of bio-available iron. The redox activity of similar dusts found in coal 
and asbestos-handling facilities was found to be dependent on available free iron and was also 
proportional to ferritin induction and lipid peroxidation in cells exposed to them343-347.  
Iron seems to act as a potentiator of chemically-induced skin cancer in murine models. Using 
7,12-dimethylbenz(a)anthracene to induce murine skin cancer was more effective in 
conjunction with intramuscular iron injections348. A low iron diet led to a fall in the incidence 
of tumour formation and down-regulated the rate of conversion of papillomas to cancers349. 
 Iron supplementation has also been seen to stimulate proliferation, inflammation, nitric oxide 
synthase and tumour formation in rats with Barrett’s oesophagus350.  
1.2.4.8 Iron and Breast Cancer 
Iron has long been proposed by some groups to be a potential carcinogen responsible for the 
development of breast cancer. It has been demonstrated that iron (in common with other 
transition metals capable of propagating oxidative stress) is present in higher than expected 
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concentrations in malignant human breast tissue when compared to normal351. In opposition to 
this argument, a number of studies have failed to demonstrate any significant relationship 
between dietary intake of iron (whether haem or non-haem) and breast cancer risk352-354. 
However, it has been shown that plasma concentrations of malondialdehyde are elevated in 
breast cancer354;355, suggesting a role for oxidative stress, which is known to be induced by 
increased levels of free iron104;105. Research has also revealed increased ˙OH-DNA adducts 
and single/double strand DNA breaks in patients with invasive breast cancer, consistent with 
damage due to oxidative stress356-358. Additionally, it has been demonstrated that there is active 
Wnt signalling in breast cancer, with stabilization of β-catenin being observed in human breast 
tumours, and that induction of Wnt signalling causes murine mammary carcinogenesis359. 
It is conceivable that dysregulation in the iron transport chain could confer upon breast cancer 
cells the ability to sequester unusually large amounts of intra-cellular iron, even in the face of 
normal circulating concentrations. 
Ferritin levels in malignant breast tissue have been shown to be 6 times higher than in normal 
tissue, although the tissue samples were unmatched (taken from different individuals)360. In 
addition, ferritin concentration corresponds to the degree of proliferation of malignant breast 
epithelium and the extent of epithelial pleomorphism360.  
More recent work has demonstrated that ferritin is over-expressed in aggressive breast cancer 
cell lines of mesenchymal phenotype (such as MDA-MB-231) compared to more indolent 
lines of epithelial phenotype (MCF7, T47D) in tissue culture361. The distribution of ferritin 
within cells also changes; the more aggressive lines exhibit higher expression in the 
cytoplasmic and chromatin-bound nuclear fractions361. It has previously been demonstrated 
that heavy chain ferritin can translocate to cell nuclei to protect DNA in the face of iron-
overload362 – breast cancer lines may have evolved to utilise a similar survival strategy. 
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Increased ferritin levels have also been shown to correlate with shrinkage of the labile iron 
pool, which is thought to trigger induction of vaso-active endothelial growth factor (VEGF) 
and bestow a more aggressive phenotype363. These observations tally with clinical studies 
demonstrating a link between tissue concentrations of H-ferritin mRNA and both clinical and 
histological prognosis in breast cancer, including nodal status, the presence of metastases and 
overall clinical staging364. 
It is not unreasonable to suppose that, although an increase in the labile iron pool may act as 
an initiator or propagator of malignancy via increased oxidative stress, the more malignant 
breast cancers could potentially achieve higher rates of survival and proliferation through an 
increase in ferritin expression following phenotypic transformation.  This would mitigate the 
effects of increased iron import by buffering the larger labile iron pool, protecting cell 
structures and DNA from oxidative damage361. Similar mechanisms have already been 
reported in erythroid, leukaemic and hepatic cell lines136;137;365.  
It has been shown that ferroportin plays a role in breast cancer – in particular that ferroportin 
levels are reduced in cancer relative to normal tissue. This is true both in vitro and in human 
tissue. Cultured epithelial breast cells display expression of ferroportin, which can be 
regulated by hepcidin366. Ferroportin levels are reduced in malignant cell lines366. There is an 
inversely proportional relationship between ferroportin levels and the degree of anaplasia 
observed in human cancer specimens, where lower ferroportin levels are seen in the most 
anaplastic specimens366. Xenograft models have demonstrated that transfection of breast 
cancer cells with ferroportin significantly inhibits development of breast cancers in the mouse 
mammary fat pad after orthotopic implantation366. Gene expression profiling has revealed that 
decreased ferroportin expression is an independent predictor of poor prognosis in terms of 
disease- and metastasis-free survival366. Ferroportin down-regulation has been found to 
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promote breast cancer growth367 and this has recently been attributed to decreased expression 
of the transcription factors Nrf2 and MZF-1368. 
Transferrin receptor expression is known to be altered in breast cancer. TfR expression has 
been demonstrated to be up-regulated in breast cancer relative to normal tissue369;370. 
Immunohistochemical investigation has exposed a negative association between TfR 
expression and the degree of differentiation of breast tumours (high TfR correlated with poorly 
differentiated cancers)371 while rodent studies revealed TfR to confer on breast cancer cell 
lines an increased capability to proliferate and metastasize372. High levels of expression of TfR 
mRNA correspond to poorly differentiated tumours364 and gene expression studies 
demonstrate high TfR gene expression to be a predictor of poor prognosis in breast cancer367. 
Recent in vitro studies demonstrated increased expression of both DMT1 and TfR in human 
breast cancer cells compared to normal breast epithelium, and also showed absent ferroportin 
expression in the cancer cells373. Proliferation of 4T1 murine mammary adenocarcinoma cells 
in culture is inhibited by TfR antisense oligonucleotides, which are also shown to inhibit TfR 
mRNA expression and intracellular iron levels. The same oligonucleotides inhibited tumour 
and metastasis growth in the 4T1 murine mammary adenocarcinoma model373. 
IRP2 over-expression has recently been linked to more aggressive breast carcinomas, the 
effect being attributed to a combination of up-regulated TfR1 expression and inhibition of 
ferritin H (the overall effect being to increase the intra-cellular labile iron pool)374.  
The above evidence suggests that non-haem iron transport is significantly altered in breast 
cancer and that the expression profile of the transport proteins is modified to sequester large 
amounts of intracellular iron. Whether this is simply a mechanism to acquire the iron needed 
to meet the demands of a rapidly proliferating cell population, or a carcinogenic process is 
unclear. No evidence supports similar dysregulation in haem transport pathways. 
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1.2.5 Iron Chelators 
Given that breast cancer, in common with many other malignancies, displays a phenotype 
specifically geared towards acquisition of iron360;366;367;369;370, it is not unreasonable to suppose 
that agents designed to deprive cancer cells of iron could potentially be useful anti-tumour 
therapies. Binding Fe3+ prevents Fenton reaction chemistry and limits oxidative stress. 
Minimising the available iron for use in cell cycling and proliferation will also preferentially 
inhibit malignant cell populations with a higher turnover than normal cells. 
Chelators are compounds that are capable of binding free metal ions. Iron chelators were first 
utilised medically in the treatment of conditions such as β-thalassaemia, which involve iron 
toxicity. As the role of iron in carcinogenesis has become better understood, the potential of 
chelators to inhibit cancer progression or even cause tumours to go into remission has been 
investigated.  
Desferrioxamine (DFO) was the first chelating agent used against β-thalassaemia375. It has 
since been shown to possess potent anti-cancer activity in vitro, inhibiting proliferation and 
inducing apoptosis in malignant cell lines including cervical and ovarian cancer, and more 
recently breast cancers376-378. In tissue culture DFO has been shown to potentiate the effects of 
traditional chemotherapy agents379. However a short half life and the lack of an orally active 
preparation, along with significant side effects and limited efficacy in many trials, make 
widespread use as an anti-cancer medication unfeasible380. 
Deferiprone has a similar spectrum of activity in vitro against malignant cell lines including 
Kaposi’s sarcoma298 and (oral) squamous cell carcinoma381. It has the advantage that it is 
available as an oral preparation but in vivo studies did not report significant anti-cancer 
activity and the side effect profile again limits frequent use as a therapeutic agent380. 
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Deferasirox (ICL670A) is a chelating agent frequently used in treating iron overload. It has 
demonstrable anti-tumour effects against leukaemia and hepatoma cell lines in vivo382;383. The 
anti-hepatoma activity is more marked than the inhibition of proliferation and viability exerted 
on normal hepatocytes, implying a degree of selectivity for malignant populations382. 
Deferasirox has proven anti-tumour activity in vivo, suppressing leukaemia development in a 
murine model383.  
Although it has been demonstrated that depriving MCF-7 cells of iron in vitro causes 
apoptosis, and that the effect was replicated in a rat mammary adenocarcinoma model384, there 
has been no other meaningful investigation of the wider effects of iron chelation on breast 
carcinoma, or any comparison of the relative effects of chelation on malignant compared to 
normal breast tissue.  
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1.3 Hypothesis 
Background 
A role for iron in the development and propagation of a number of cancers, including breast, 
has now been established.  
Although there are defined oncogenic mechanisms through which iron induces carcinogenesis 
in certain organs (notably the colon), it is not yet clear whether the demonstrable changes in 
iron transport observed in breast cancer are a response to the demand for iron in rapidly 
proliferating tissue or a fundamental requirement for breast carcinogenesis.  
Furthermore, although clear in vitro and in vivo evidence describes changes in expression of 
many of the proteins involved in transporting non-haem iron in cancer compared to normal 
breast tissue, no studies compared expression in prospectively collected matched tissue pairs, 
and no evidence yet suggests a role for dysregulated haem transport in breast cancer.  
Finally, despite mounting evidence advocating iron chelation in the treatment of a number of 
cancers, there has been very little evaluation of the effects of iron chelators in breast cancer. 
Hypothesis 
The malignant progression of breast cancer is associated with modulations in expression of 
both inorganic and haem iron metabolic machinery. These modulations confer a selective 
advantage to breast cells in acquiring increased levels of inorganic and haem iron and this in 
turn stimulates development of a more aggressive phenotype. 
Suppression of cellular iron through the use of chelators will depress the aggressive behaviour 
of these cells. 
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1.4 Aims 
The aims of this study are: 
1. Examine the expression of non-haem iron transport proteins in breast carcinoma 
compared to normal breast tissue and validate these results using prospectively 
collected matched tissue pairs. 
2. Evaluate expression of haem transport proteins in breast carcinoma compared to 
normal breast tissue. 
3. Determine the effects of iron and haem on the phenotype of benign and malignant 
human mammary cells in vitro. 
4. Determine the effects of iron and haem on expression of their respective transport 
proteins in benign and malignant human mammary cells in vitro. 
5. Investigate the effects of iron chelation on cell phenotype and expression of iron 
transport proteins. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Laboratory Reagents 
General, cell culture and molecular biology reagents were obtained from: 
 
Anatomical Pathology International, Runcorn, Cheshire  
Shandon Consul-Mount 
 
BD Biosciences, Bedford, Bedfordshire 
Matrigel (basement membrane matrix) 
 
Bioline Ltd, London 
Sensimix (PCR mastermix) 
 
Dako, Ely, Cambridgeshire 
Delimiting pen; EnVisionTM Detection System; REAL antibody diluent  
 
Eurogentec, Fawley, Hampshire 
18S rRNA control kit (FAM-TAMRA); 5’-FAM, 3’-TAMRA double dye oligonucleotides; 
Reverse transcriptase core kit; qPCR optical seals; Sub-skirted, low profile 96-well qPCR 
plates 
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Fisher Scientific, Loughborough, Leics 
BCA protein assay kit (Pierce); Ethanol; Methanol; Mr Frosty cryobox (Nalgene); Xylene 
 
GE Healthcare UK Ltd, Little Chalfont, Bucks 
Amersham ECL Western blotting detection reagents; Amersham full-range rainbow molecular 
weight markers; Amersham Hyobond-P PVDF Membrane; Amersham hyperfilm ECL 
 
Invitrogen Ltd, Paisley, Renfrewshire (incorporating Gibco BRL) 
Dulbecco’s Modified Eagle’s Medium (DMEM); DMEM x2; Histostain Plus 
immunohistochemistry kit; NP40 cell lysis buffer; PenStrep (5000U/ml Penicillin, 5000µg/ml 
Streptomycin); Trypsin/EDTAx4Na  
 
Leica Microsystems (UK) Ltd, Milton Keynes 
W-Cap antigen retrieval solution 
 
Life Technologies Ltd, Inchinnan Business Park, Paisley 
Combined probe and primer PCR kits 
 
PAA Laboratories, Yeovil, Somerset 
Standard quality fetal bovine serum  
 
Roche Diagnostics Ltd, Burgess Hill, West Sussex 
BrdU cell proliferation ELISA kit (colorimetric) 
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Sigma-Aldrich Company Limited, Poole, Dorset 
Agar; Alamar blue; Ammonium Persulfate; β-mercaptoethanol; Bovine serum albumin; 
Bromophenol blue; Chloroform; Dimethyl sulphoxide; Ferric Chloride; Ferrous sulphate 
heptahydrate; Ferrozine; Fibronectin adhesion-promoting peptide; Glycine; Guanidine 
hydrochloride; Hemin; HEPES (N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid); 
Hydrochloric acid; Hydrogen peroxide; Isopropanol; Mayer’s haematoxylin 0.1% solution; 4-
Morpholinepropanesulfonic acid (MOPS); MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide); Nuclease-free water; Phosphate buffered saline tablets; 
Polyacrylamide; Propidium iodide; RNAlater stabilization solution; RNase A; Sodium acetate; 
Sodium ascorbate; Sodium chloride; Sodium citrate; Sodium deoxycholate; Sodium dodecyl 
sulphate (SDS); Sodium hydroxide; Sodium pyrophosphate; Trichloroacetic acid; Tris-HCl; 
Trizma base; N,N,N’,N’-Tetramethylethylenediamine (TEMED); Trizol reagent 
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2.1.2 Primary Antibodies 
Antigen Antibody Type Product Number 
Abcam, Cambridge Science Park, Cambridge 
β-actin Mouse monoclonal IgG1 ab8226 
BCRP Mouse monoclonal IgG2a ab3380 
Ferritin Rabbit polyclonal IgG ab65080 
Ferroportin Rabbit polyclonal IgG ab58695 
FLVCR Mouse monoclonal IgG2b ab57317 
HCP1 Rabbit polyclonal IgG ab25134 
Hepcidin Rabbit polyclonal IgG ab30760 
Hephaestin Mouse monoclonal IgG2a ab56729 
LRP1 Mouse monoclonal IgG1 ab20384 
Invitrogen (Zymed), Inchinnan Business Park, Paisley 
Transferrin Receptor 1 Mouse monoclonal IgG1 13-6800 
 
Table 2-1 Primary Antibodies 
Gifts 
Dcytb; rabbit polyclonal IgG, clone 834 (kind gift from Professor A McKie) 
DMT1; rabbit polyclonal (kind gift from Professor G Anderson) 
 
Secondary antibodies  
Amersham Biosciences, Amersham, Bucks 
Horseradish peroxidise-conjugated sheep anti-mouse IgG 
Horseradish peroxidise-conjugated donkey anti-rabbit IgG  
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Primary Antibodies 
Target Antigen Optimal Dilution 
β-actin WB: 1/1000 
BCRP IHC: 1/20 WB: 1/500 
Dcytb IHC: 1/250 WB: 1/1000 
DMT-1 IHC: 1/250 WB: 1/400 
Ferritin IHC: 1/400 WB: 1/2500 
Ferroportin IHC: 1/100 WB: 1/2000 
FLVCR IHC: 1/100 WB: 1/500 
HCP-1 IHC: 1/50 WB: 1/250 
Hepcidin IHC: 1/50 WB: 1/1000 
Hephaestin IHC: 1/100 WB: 1/200 
LRP WB: 1/500 
TfR1 IHC: 1/400 WB: 1/1000 
Secondary Antibodies 
Antibody Optimal Dilution 
Mouse IgG-HRP 1/10000 
Rabbit IgG-HRP 1/10000 
Envision Rabbit/Mouse (HRP) 1/10000 
 
Table 2-2 Primary and Secondary Antibody Concentrations 
IHC – Immunohistochemistry; WB – Western Blotting 
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2.1.3 Oligonucleotide Sequences 
Probes and primers were designed against human DNA sequences and obtained from 
Eurogentec. In addition, assays for BCRP and FLVCR mRNA utilised pre-inventoried 
TaqMan gene expression assay kits, combining probes and primers. These kits were obtained 
from Life Technologies Ltd. 
Gene Probe Forward Primer Reverse Primer 
Dcytb CCAGGGCATCGCCATCATC
GT 
CATGGTCACCGGC
TTCGT 
CAGGTCCACGGCAGT
CTGTA 
DMT1 AGGCAGCTCCACACTGTGA
ACTAAAATCATA 
CATGAGGAAGAA
GCAGCTGAAGA 
TGTTCAGGACCCAGC
ACCAT 
Ferritin AGTTGTATGCCTCCTACGTC
ATCTGTCTATGTCTTGTTAT 
GGAACATGCTGAG
AAACTGATGAA 
CATCACAGTCTGGTT
TCTTGATATCC 
Ferroportin AGGATTGACCAGTTAACCA
ACATCTTAGCCC 
AGCAAATATGAAT
GCCACAATACG 
CAAATGTCATAATCT
GGCCAACAG 
HCP1 ATGGCTTGCTTTTCCTCTCA
TTAGTCATCACA 
CTATCACGCCTCT
CATGTTCAC 
GGAGAGTTTAGCCCG
GATGAC 
Hepcidin AGCTGCAACCCCAGG CCCACAACAGACG
GGACAA 
TCTGGAACATGGGCA
TCC 
Hephaestin ACAGTGACATAGTGGCTTC
CAGCTTCTTAAAGTCTG 
GGAAGAAATGTCA
TCACGAAC 
TCCCCCTATCCGGTT
CTTG 
IRP1 ACTCCTATGGCTCCCGCCG
AGG 
CCTGCCTAACTCC
ACGAGAATT 
TGCCATGACGGCGTC
AT 
IRP2 TTTGACAAACAGAGGCCTT
ACCCC 
AGGAATAGTGCTG
CCGCTAAG 
TCGAGCTCCGTAAGA
GTTGAATT 
LRP1 TGCCATTTACTCAGCCCGTT
ACGACG 
TGGATTGACGCCA
GGTCAG 
CCCGAAGCACCTCCA
TGT 
TfR1 AAAGACAGCGCTCAAAACT
CGGTGATCATAG 
CGTGATCAACATT
TTGTTAAGATTCA 
CCACATAACCCCCAG
GATTCT 
 
Table 2-3 Probe and Primer Base Sequences 
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2.1.4 Cell Lines 
All cell lines used were human mammary lines. They were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with L-glutamine, 110mg/l sodium pyruvate and 4.5g/l glucose, 
supplemented with 10% (v/v) fetal calf serum (FCS) and 1% (v/v) Penicillin/Streptomycin 
solution (5000IU/ml Penicillin, 5000µg/ml Streptomycin). 
Cell Line Phenotype Growth Medium 
HB2 Normal epithelium385 DMEM 
MCF7 Malignant (adenocarcinoma)386 DMEM 
MDA-MB-231 Malignant (adenocarcinoma)387 DMEM 
 
Table 2-4 Cell Lines Used 
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2.1.5 Fresh Tissue  
Fresh tissue was obtained from the Queen Elizabeth Hospital and City Hospital, Birmingham 
(UK). Informed consent was obtained by a trained member of the laboratory team using forms 
approved by the ethics committee. Material was taken from mastectomy specimens only. 
Donor patients were naïve to both hormone and chemotherapy to ensure no modification of 
cancer phenotype or protein expression. Fresh specimens were taken to a consultant 
pathologist to remove samples of tumour and matched normal tissue (one normal sample from 
the extremity of each quadrant of the breast; hence wide local excision specimens were un-
usable). Only samples confirmed as normal following formal histological assessment of the 
entire specimen by the pathologist were used as matched normal tissue for analysis. At Queen 
Elizabeth hospital the samples were immediately flash frozen in liquid nitrogen and stored at -
80ºC until needed. On the City Hospital site, samples were kept at 4ºC in RNAlater solution 
(which preserves both protein and RNA) until they could be transported to the laboratory for 
storage at -80ºC (RNAlater having first been removed to avoid crystal formation). A total of 
20 samples were collected during this study, 19 of which were obtained from the City Hospital 
site using the RNAlater protocol. 
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2.2 Methods 
2.2.1 Ethical Approval 
Ethical approval for this study was sought from the Coventry Research Ethics Committee and 
granted on April 9th 2008 (REC reference number 08/H1210/11). Site specific approval was 
granted for tissue collection from Birmingham’s Queen Elizabeth and City hospitals and 
confirmed by local R+D departments within University Hospital Birmingham and Sandwell 
and West Birmingham Hospitals NHS Trusts respectively. 
2.2.2 Immunohistochemistry 
2.2.2.1 Immunohistochemistry Using W-Cap 
W-Cap is a mixture of retrieval salts and paraffin sequestering agents. It was used in 
conjunction with the Dako REAL EnVision detection system. W-Cap was pre-heated to 95ºC 
in a water bath. As it heated, formalin-fixed paraffin-embedded tissue sections were warmed 
in an incubator at 60ºC to soften the wax. Warmed slides were bathed in heated W-Cap for 1 
hour then allowed to cool to 40ºC. After a wash in warm tap water, then TBS at pH 7.6, slides 
were blotted dry and sections outlined with a Dako delimiting pen. Primary antibodies were 
diluted in Dako diluent to appropriate concentrations (determined by previous optimization – 
see table 2-1). 100µl antibody solution (more if the tissue was not adequately covered) was 
pipetted onto each section and left overnight at 4ºC in humidified chambers. Primary antibody 
was then removed and sections washed twice for 5 minutes in TBS. Samples were incubated 
with 100µl EnVision reagent (peroxidase-conjugated dextran coupled with goat anti-
rabbit/mouse immunoglobulins) for 30 minutes. Following 2 further 5 minute washes in TBS, 
100µl of 1:50 DAB+ chromogen in substrate buffer was left on the sections for 8-10 minutes 
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to visualise immuno-reactivity. Sections were washed in running water then left for 1 minute 
in 0.1% (v/v) Mayer’s haematoxylin solution. A further running water wash was followed by 
30 seconds in warm tap water to blue. Sections were then passed through 2 ethanol baths and 2 
xylene baths for 5 minutes each and were mounted with cover-slips using Shandon Consul-
Mount. Sections were left (flat) overnight in the fume cupboard to dry fully before scoring.  
2.2.2.2 Immunohistochemistry Using Citric Acid 
Sections were passed through 2 xylene baths to de-wax then dehydrated in 2 ethanol baths (5 
minutes each). There followed a 20 minute immersion in 10% (v/v) hydrogen peroxide in 
methanol to eliminate endogenous peroxidase activity. For antigen retrieval the sections were 
then immersed in 0.01M tri-sodium citrate buffer at pH 6.0 and microwaved for 5 minutes 3 
times, topping up the buffer in between. After 5 minutes cooling, sections were washed in 
TBS and the process continued with the Dako system as described above. 
2.2.2.3 Evaluation of Immunostaining 
Sections prepared as described above were examined using a Nikon Eclipse E600 microscope. 
Images were taken with a Nikon DXM1200F digital camera and Nikon ACT-1 (version 2.62) 
software. Cellular localisation of antigen was documented (nuclear, cytoplasmic or cell 
surface) and staining intensity (indicating antigen expression) graded from 0 (absent), through 
1 (weak) and 2 (moderate), to 3 (strong). Evaluation of immunostaining was performed by the 
author and validated by an independent consultant histopathologist. Positive (tissue known to 
express the relevant antigen) and negative (primary antibody not included) controls were 
included with each series of processed slides. Each series consisted of 5 normal breast 
specimens, 5 DCIS and 20 breast cancer. 
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2.2.3 Cell Culture 
2.2.3.1 Routine Cell Culture 
Appropriate growth media for the cell lines investigated are listed in table 2-4. The additives 
present in the basic media are described in section 2.2.3.2. Unless specified in individual 
protocols, all media and trypsin were pre-warmed to 37ºC in a water bath before being used on 
cells. A laminar flow tissue culture cabinet and full aseptic technique were employed for all 
cell culture procedures. Cells were passaged through 25cm3 and 75cm
3 tissue culture flasks 
and bulked/maintained in 150cm3 flasks. Once 90-95% confluence was reached, medium was 
removed by aspiration. Cells were washed in (calcium- and magnesium-free) phosphate-
buffered saline (PBS) and lysed by incubating at 37ºC in a solution containing 0.05% trypsin 
and 0.53mM EDTAx4Na. Once detached, an equal volume of culture medium was added to 
neutralise the trypsin. The suspension was aspirated into an appropriately sized centrifuge tube 
and centrifuged for 5 minutes at 1500rpm. The supernatant was aspirated and the pellet re-
suspended in either normal medium, for splitting into further culture flasks, or a freezing 
solution made with 9 parts FCS to 1 part DMSO. Once cells were suspended in an appropriate 
volume of freezing solution, 1ml aliquots were pipetted into cryovials. These were placed in a 
Mr Frosty® freezing container (Nalgene) in the -80ºC freezer for 5 days then transferred to 
liquid nitrogen for long term storage. The Mr Frosty® slows the rate of freezing to a 
maximum of 1ºC/min, allowing effective cryopreservation.  
To resurrect the cells, the cryovials were rapidly warmed to 37ºC and the cells re-suspended in 
culture medium in a 25cm2 culture flask. The medium was changed the following day whether 
or not the cells required further splitting. 
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2.2.3.2 Cell Line Stimulation 
Standard formulations for iron- and haem-containing media are shown below in table 2-5. A 
range of concentrations were used during initial proliferation and viability assays to determine 
optimal stimulation conditions for each cell line. FCS has been shown to have an iron content 
of approximately 30µmol/L432. Therefore, although control media will have contained a very 
small amount of iron, concentration in the experimental media was supra-physiological by a 
factor of several thousand. Valid comparisons could thus be made and appropriate conclusions 
drawn. 
Medium Basic Medium 
(DMEM, 10%FCS) 
Ferrous Sulphate 
(100mM) 
Sodium Ascorbate 
(100mM) 
Hemin 
(1mM) 
Control 50ml - 5µl - 
IL 
(100µM) 
50ml 50µl 5µl - 
HL 
(40µM) 
50ml - - 2ml 
 
Table 2-5: Basic Cell Stimulation Media  
IL – Iron Loaded; HL – Haem Loaded 
Ferrous Sulphate: Filter sterilised distilled water was used to prepare stock solutions of 
100mM ferrous sulphate and 100mM sodium ascorbate (which aids iron absorption388). These 
solutions were refrigerated at 4ºC in the dark until needed.  
Haem Iron: A 2mM haem solution was prepared with filter sterilised distilled water and 
solubilised with an equal volume of 0.1mM sodium hydroxide (giving a final concentration of 
1mM). Hydrochloric acid was added drop-wise to neutralise pH to 7.4. The solution was kept 
refrigerated in the dark until needed. 
63 
 
2.2.4 Determination of Intracellular Iron Content 
2.2.4.1 Ferrozine Assay 
The ferrozine assay quantifies intracellular iron levels389. Cells were cultured in triplicate in 6 
well plates with appropriate media. After incubation they were washed 3 times with 1ml sterile 
PBS (to remove excess iron-containing medium) and trypsinized. They were then moved into 
a microcentrifuge tube and spun for 5 minutes at 12000rpm. The trypsin was aspirated and the 
pellet re-suspended in 100µl HEPES saline (10mM HEPES in 0.9% (w/v) NaCl at pH 7.4). 
90µl of this suspension was removed and added to 200µl 20% (w/v) TCA in 4% (w/v) sodium 
pyrophosphate (5µl of the remainder was added to 95µl RIPA solution and used for protein 
quantification – see section 2.2.4.2). This was boiled for 5 minutes then re-centrifuged for a 
further 5 minutes at 12000rpm. 200µl of the supernatant was aspirated and added to 100µl 
0.23M sodium ascorbate, 80µl 10mM ferrozine and 420µl 2M sodium acetate. This was 
thoroughly mixed and 200µl aliquots placed in triplicate in a flat-bottomed 96-well plate. A 
blank (HEPES + TCA + reaction mix) and a standard (the same mixture with 1µl 10mM FeCl3 
added to make a 12.5µM FeCl3 solution) were included. The colorimetric change in each 
sample was measured using a Bio-Tek ELx800 plate reader at 550nm. The absorbance in the 
blank was used to correct each sample before determining iron concentration through 
comparison with the FeCl3 control. Experiments were repeated 3 times. 
2.2.4.2 Protein Assay 
A BCA assay was used to determine sample protein concentrations. Standard bovine serum 
albumin solutions were made up at concentrations ranging from 0-2mg/ml. 20µl of each 
experimental sample and each standard were placed in triplicate in a flat-bottomed 96-well 
plate. 200µl BCA working solution (reagent A 50:1 reagent B) was added to each well and the 
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absorbance measured at 562nm using a Bio-Tek ELx800 plate reader. The protein standards 
were used to plot optical density against protein concentration using Microsoft Excel software. 
A best-fit line was used to generate a y=mx+c equation. If necessary the absorbance of each 
experimental sample was corrected for dilution, then the equation was used to calculate 
protein concentration in mg/ml. 
2.2.5 Cell Phenotype Assays  
2.2.5.1 MTT Viability Assay 
MTT contains tetrazolium rings which are cleaved by mitochondrial dehydrogenase. This 
leads to the formation of purple formazan crystals within cells. MTT can thus be used to 
quantify viable cell numbers, as only healthy, metabolically active cells express the enzyme390. 
A 5mg/ml stock solution of MTT was made in sterile PBS. Cells were seeded into 96-well 
plates and cultured for appropriate lengths of time in 100µl experimental growth medium. 8 
wells were allocated to each growth medium. Following stimulation, 10µl of MTT solution 
was added to each well and the plates re-incubated for 3 hours. The medium was then removed 
by gentle aspiration and replaced with 50µl DMSO. Plates were left for 30 minutes at room 
temperature then the absorbance of the resulting purple solution at 490nm was measured using 
a Bio-Tek ELx800 microplate reader. Percentage viability with respect to control was 
calculated from these optical densities. Experiments were repeated 3 times. 
2.2.5.2 BrdU Proliferation Assay 
When introduced to cell culture medium, BrdU is incorporated into cellular DNA in place of 
thymidine during replication. This allows a colorimetric ELISA to quantify cellular 
proliferation391. 
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Cells were seeded into 96-well plates and cultured for appropriate lengths of time in 100µl 
experimental growth medium. 8 wells were allocated to each growth medium. A stock solution 
of 10mM BrdU labelling reagent diluted 1:100 in culture medium was made and 10µl added to 
each well after stimulation. Included in each assay were a blank to correct for binding to the 
well itself (culture medium and BrdU, but no cells), and a background control to correct for 
immunoreactivity between anti-BrdU-peroxidase and unlabelled cells (10µl of blank medium 
added to the wells). The plates were re-incubated for 4 hours to allow BrdU incorporation then 
the labelling mixture was removed by gentle aspiration. 100µl FixDenat solution was added to 
each well and left at room temperature for 30 minutes. FixDenat fixes the cells and denatures 
DNA to expose incorporated BrdU. It was replaced with 50µl/well 1:100 anti-BrdU-
peroxidase antibody solution (diluent supplied with the kit) and left at room temperature for 90 
minutes. Following removal of the antibody solution, wells were washed 3 times with 200µl of 
assay wash solution then left for 5-30 minutes with 50µl/well of TMB substrate solution. TMB 
is a chromogenic substrate which forms a blue substance when allowed to react with 
peroxidase enzymes. The density of the blue colouration corresponds to the number of 
immune complexes formed between incorporated BrdU and anti-BrdU-POD, allowing 
quantification of cell proliferation. Absorbance of each well at 370nm was measured using a 
Bio-Tek ELx800 microplate reader. Following correction for the blanks and background 
controls, optical density of test wells was used to express percentage proliferation relative to 
those left untreated. Experiments were repeated 3 times. 
2.2.5.3 Anchorage Independent Growth Assay (Colony Forming Assay) 
This assay uses a two gel system to study the ability of cells suspended in agar or 
methylcellulose to form colonies392, which can be extrapolated as a measure of malignant 
potential in vivo.  
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For the base gel, 1% (w/v) agar was microwaved and left in a water bath to cool to 37ºc. An 
equal volume of solution containing 2x DMEM with 20% FCS was warmed to the same 
temperature. The solutions were mixed to give final concentrations of 0.5% (w/v) agar, 1x 
growth medium and 10% FCS. Appropriate amounts of supplemental reagents (eg iron and/or 
chelators) were added to achieve optimal stimulation concentrations (100mM FeSO4 and 
20mM haem), as determined by viability and proliferation assays (sections 4.2.2 and 4.2.3). 
2ml of base agar per well was pipetted into 6 well plates, using 3 wells per experimental line. 
Care was taken to avoid air bubbles permeating the solution. Plates were allowed to cool and 
refrigerated at 4ºc until adding the superficial agar (base agar can be kept refrigerated for up to 
1 week). 
The superficial gel solution was prepared as described above (substituting 0.7% (w/v) for 1% 
(w/v) agar, giving a final concentration of 0.35% (w/v)) and kept in a water bath at 37ºC. 
Supplemental reagents were added as for the base gel. 
Trypsinised cells were passed through a 50µm cell sieve (to prevent clumping) and counted, 
then sufficient added to the superficial gel solution to plate out at 1x104/ml. Care was taken 
not to add the cells until the solution had cooled to 37ºc. 0.5ml of superficial gel was gently 
placed onto the base gel. 
Each well was photographed at 5 marked points at T=0 hours using a Zeiss Axiovert 40 CFL 
microscope and a camera with Axiovision Rel 4.6 imaging software. Plates were then 
incubated at 37ºc for 2 weeks. Repeat photographs were then taken at the same points, 
colonies counted and their surface areas measured. Experiments were repeated 3 times. 
2.2.5.4 Cell Migration (Wound-Healing) Assay 
Cells were seeded into 6 well plates in 3ml/well of appropriate growth medium and allowed to 
form a confluent monolayer. At this point the medium was removed and a longitudinal wound 
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made in the monolayer using a white (0.1-10µl) pipette tip. The undersides of the wells were 
marked with a fine permanent marker to allow sequential photographs of the same point in the 
monolayer wound. 3 wells each were stimulated with 3ml of iron- or haem-loaded medium at 
concentrations dictated by previous proliferation and viability assays. A control was included. 
When necessary the media were changed every 24 hours until wound closure. 
Photographs were taken at T=0 hours (immediately following wound formation and addition 
of stimulant media) with a Zeiss Axiovert 40 CFL microscope and a camera with Axiovision 
Rel 4.6 imaging software. Subsequent images were captured at time points determined by 
speed of migration of cells across the wound.  
For each image the width of the wound was measured at 3 distinct points on the scale provided 
by the imaging software (N=9 points per experiment per test medium). The same 3 points 
were used for every image for robust comparison of migration rates under different conditions. 
2.2.5.5 Matrigel Invasion Assay 
Matrigel is a reconstituted extract generated from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma used as an analogue of true basement membrane in many cell phenotype assays393;394. 
It contains the constituents of basement membrane (collagens, laminin, proteoglycans) as well 
as growth factors and matrix-degrading enzymes (and their inhibitors)395;396. 
Cells were incubated overnight in culture medium containing only 0.5% FCS (to eliminate any 
extrinsic enzymatic activity). Overnight incubation included iron- and haem-loaded media (at 
concentrations dictated by previous proliferation and viability assays), and a control. 
Commercial stock matrigel was thawed at 4ºC and diluted 1:3 in cold serum-free cell culture 
medium. When handling the matrigel, pre-cooled pipette tips were used and plates kept on ice 
to prevent premature gel formation. Transwell inserts with 8.0µm pores were used, in keeping 
with previous invasion experiments performed on the same cell lines397-400.   
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The underside of the polycarbonate membrane in a transwell insert was covered with 15µl of 
diluted matrigel. This was allowed to set at 37ºC for at least 40 minutes. Both sides of the 
membrane were then washed with PBS. Serum-starved cells were released into solution using 
cell dissociation buffer. They were centrifuged at 12 000rpm for 5 minutes to allow aspiration 
of the buffer then re-suspended in serum-free medium and counted using a Neubauer 
haemocytometer. The cell suspension was then diluted as necessary to give a concentration of 
0.5x106/ml. 400µl of cell suspension was added to the insert, along with an appropriate 
amount of iron or haem. To the outside of the insert was added 400µl serum-free medium 
containing 5µg/ml fibronectin (to promote adhesion). Alamar Blue was added to the medium 
on both sides of the insert to a concentration of 10%. Alamar Blue is reduced by the products 
of cell metabolism to a form which can be made to fluoresce and can thus be used to quantify 
cell numbers401. The samples were left to invade at 37ºC for 24-48 hours. Following invasion, 
200µl of medium from outside the transwell was transferred to a 96-well plate. To quantify the 
total number of cells added, fluorescence in this sample was measured at wavelengths of 
560nm for excitation and 590nm for emission using a Fluoroskan plate reader with Ascent 
software. Because liquid equilibrates between the two sides of the membrane, fluorescence 
inside and outside the transwell is the same and represents dye reduction due to the total 
number of cells present initially. Following migration, the transwell was moved to a fresh well 
containing PBS. A sterile cotton bud was used to wipe non-invaded cells from the inner 
surface of the membrane, which was then washed again in PBS. The transwell was placed in a 
well containing 800µl medium with 10% alamar blue. This medium contained 10% serum to 
ensure cells remained viable. The sample was left for a further 5 hours (or overnight) at 37ºC 
before fluorescence was measured again to estimate the number of invaded cells. Relative 
fluorescence between total and invaded cells allowed calculation of percentage invasion. 
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2.2.6 Real-time PCR Analysis of mRNA Expression 
2.2.6.1 RNA Extraction from Tissue Specimens and Cultured Cell Lines 
Tissue specimens: were thawed and homogenized on ice with lml Trizol reagent using an 
UltraTurrax homogenizer.  
Cultured cells: were grown in 6-well plates. After incubation culture media was aspirated and 
the cells washed 3 times with PBS. 500µl Trizol reagent was added and a cell scraper used to 
harvest the cells, which were thoroughly mixed with the Trizol and transferred into 1.5ml 
micro-centrifuge tubes.  
Following addition of Trizol, fresh tissue specimens and cultured material were processed in 
the same way.  
After 5 minutes’ incubation, 200µl chloroform per 1ml Trizol was added and samples left at 
room temperature for a further 3 minutes. They were then centrifuged at 12000rpm for 15 
minutes at 4ºC and the colourless upper phase (containing total RNA) transferred to a fresh 
tube. The interphase (containing DNA) and lower red organic phase (containing protein) were 
transiently stored at 4ºC for subsequent isolation of protein for Western blotting. 500µl 
isopropanol per 1 ml Trizol was added to the aqueous phase and the mixture left at room 
temperature for 10 minutes to precipitate RNA. The sample was centrifuged at 12000rpm for a 
further 10 minutes at 4ºC and the supernatant discarded. The RNA pellet was washed in 1ml 
75% (v/v) ethanol per 1ml Trizol and re-centrifuged at 7500rpm for 5 minutes at 4ºC. The 
supernatant was again discarded and the pellet dried for 5 minutes at room temperature. The 
pellet was dissolved in an appropriate volume of nuclease-free water (depending on pellet 
size) and a Nanodrop ND1000 spectrophotometer was used to measure total RNA 
concentration and purity. 
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2.2.6.2 cDNA Synthesis by Reverse Transcription 
cDNA was synthesised using a Eurogentec reverse transcription kit according to 
manufacturer’s instructions. An amount of solution containing 0.4µg total RNA was added to 
sufficient nuclease-free water to give a total volume of 8.1µl. This was added to 2µl reverse 
transcription buffer (10x), 4µl 25mM MgCl, 4µl 2.5mM dNTP mix, 1µl random nonamer, 
0.4µl RNAse inhibitor and 0.5µl reverse transcriptase. Samples were loaded into a BioRad 
MyCycler thermocycling machine and cycled for 10 minutes at 25ºC, 30 minutes at 48ºC and 
5 minutes at 95ºC. 16µl nuclease-free water was added to the mixture, making a total of 36µl 
cDNA solution which was stored at -20ºC until needed. 
2.2.6.3 TaqMan real-time qRT-PCR 
TaqMan probes were available for all the genes of interest, using FAM (6-carboxyfluorescein) 
as a fluorophore and TAMRA (tetramethylrhodamine) as a quencher. See table 2-2 for probe 
and primer sequences. 
A mastermix was prepared comprising 750µl sensimix (TaqMan DNA polymerase, dNTPs, 
MgCl2), varying volumes of probe (dictated by optimization reactions), 150µl each of forward 
and reverse primers, 7.5µl 18S probe, 15µl 18S forward/reverse primer mix and sufficient 
nuclease-free water to give a total volume of 1.4ml. Probes were supplied in 1.25pM solutions. 
Optimised volumes of probes are given in table 2-5, along with the corresponding quantity of 
water required for each mastermix. 
1µl of each cDNA was pipetted in triplicate into an optical 96-well plate along with 14µl PCR 
mastermix. Plates were sealed with adhesive optical sealant film and centrifuged for a few 
seconds at 1200rpm to remove any bubbles from the bases of the wells. Plates were 
refrigerated or frozen if there was a delay in processing, but were re-centrifuged prior to 
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analysis. They were then taken to an Applied Biosystems 7500 FAST real-time PCR detection 
system and subjected to 40 cycles of PCR. 
Following PCR, SDS software was used to generate Ct values for the gene of interest (Cttarget) 
and 18S (Ctcontrol) in each well. Relative quantification was then achieved as follows
402: 
A δCt value was first obtained for every sample: 
δCt = Cttarget - Ctcontrol 
To compare two samples (for example matched samples of normal and cancerous tissue), a 
δδCt value was calculated: 
δδCt = δCtsample 1 – δCtsample 2 
Note: the triplicate values for sample 1 in any given calculation were averaged to generate 3 
values for δδCt.  
 As these values are generated from exponentially increasing quantities of DNA, relative 
amounts of original DNA (and hence sample mRNA) can thus be calculated: 
Relative mRNA expression = 2-δδCt. 
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Gene Probe Volume (µl) Volume H2O (µl) 
Dcytb 1.5 1.775 
DMT1 1.2 2.075 
Ferritin 1.5 1.775 
Ferroportin 1.5 1.775 
HCP1 1.5 1.775 
Hepcidin 1.8 1.475 
Hephaestin 1.2 2.075 
IRP1 0.9 2.375 
IRP2 0.9 2.375 
LRP1 1.5 1.775 
TfR1 1.2 2.075 
 
BCRP 1.0 5.275 
FLVCR 1.0 5.275 
 
Table 2-6 Optimized gene-specific probe volumes used in TaqMan PCR reactions 
All probes supplied as 1.25pM solutions. Required volumes of nuclease-free water also shown 
(to generate individual reaction volumes of 15µl). BCRP and FLVCR came as combined kits 
containing probe and forward/reverse primers and thus required larger volumes of diluent.  
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2.2.7 SDS-Polyacrylamide Gel Electrophoresis and Western Blotting 
2.2.7.1 Sample Preparation 
After extraction of the RNA-containing phase from homogenized samples, 300µl 100% 
ethanol per 1ml Trizol was added, mixed and left at room temperature for 3 minutes. After 5 
minutes centrifugation at 2000rpm at 4ºC the supernatant was moved to a fresh tube, leaving 
behind a DNA-containing pellet, which was discarded. 1.5ml isopropanol per 1ml Trizol was 
added to the supernatant, mixed and left for 10 minutes at room temperature. After 
centrifuging at 12000rpm for 10 minutes at 4ºC, the supernatant was again discarded leaving a 
protein pellet. This was washed 3 times in 1ml 0.3M guanidine hydrochloride (made with 95% 
ethanol). The pellet was left for 20 minutes at room temperature in each wash, and re-
centrifuged at 7500rpm for 5 minutes at 4ºC before changing the wash solution. After the final 
wash the pellet was re-suspended in 100% ethanol, at which point it was frozen if not required 
for immediate use. 
For analysis, the pellet was thawed and centrifuged at 7500rpm for 5 minutes at 4ºC. The 
ethanol was removed by aspiration and the pellet dried under a vacuum for 5 minutes. It was 
then dissolved in 1% (w/v) sodium dodecyl sulphate and the solution centrifuged at 10000rpm 
for 10 minutes at 4ºC to allow removal of an entirely liquid supernatant for Western blotting. 
This was subjected to a BCA protein assay (section 1.4.4.2) to standardise loading of protein 
samples. Before electrophoresis, samples were boiled for 5 minutes with 3x Laemmli sample 
buffer (0.0625M Tris HCl, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 
0.001% (w/v) bromophenol blue) at a ratio of 2:1 to denature the proteins.    
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2.2.7.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
A Bio-Rad mini-PROTEAN tetra electrophoresis system was used. Resolving and stacking 
gels were prepared with compositions varying according to the molecular weight of the protein 
of interest (table 2-4). The resolving gel was poured into a 1.5mm casting tray and allowed to 
set. A layer of ethanol was poured onto the resolving gel to ensure a perfectly flat surface for 
receipt of the stacking gel. Once set, the ethanol was poured off and the stacking gel 
introduced along with a 10-well comb. Gels were submerged in running buffer (0.192M 
Glycine, 25mM Tris HCl, 0.01% (w/v) SDS, adjusted to pH 8.3) and 5µl of Amersham 
rainbow marker loaded into the first well of each. The remaining 9 wells were loaded with an 
amount of protein sample/laemmli buffer containing 10µg protein. Electrophoresis was 
commenced at 160V and continued until the dye front had reached the bottom of the gel.  
2.2.7.3 Western Blotting: Protein Transfer and Detection 
Following electrophoresis, gels were placed in a bath of transfer buffer (48mM Tris HCl, 20% 
(w/v) methanol, 39mM glycine, 0.0375% (w/v) SDS). Blotting pads and pre-cut filter paper 
were soaked in transfer buffer. Pre-cut PVDF membrane was labelled to identify and orientate 
the resulting protein transfers before being submerged in methanol for 30 seconds. It was 
passed through distilled and de-ionised water then immersed in transfer buffer. Transfer 
sandwiches were prepared with components kept soaked in transfer buffer at all times, and the 
sandwich was rolled before clamping to expel any air bubbles which would prevent transfer 
onto the membrane. Clamps were placed in the transfer apparatus and submerged in transfer 
buffer. Transfer was commenced at 100V for 60 minutes with ice packs in the tank to provide 
cooling. 
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Following transfer, membranes were blocked for 30 minutes with 5% (w/v) bovine serum 
albumin in Tris-buffered saline (made by adding 2.423g Trizma base and 8.006g NaCl to 80ml 
ultra-pure water, adjusting to pH 7.6 with HCl and topping up to 100ml with ultra-pure water) 
with Tween (TBST – 100ml x10 TBS, 900ml ultra-pure water and 1ml Tween). After 
blocking, membranes were incubated with optimised primary antibody solutions (in TBST) for 
one hour at room temperature, or overnight at 4˚C. They were then washed 3 times in TBST 
for 10 minutes each before incubation with an appropriate secondary horseradish-conjugated 
antibody for 30 minutes at room temperature. A further 3 10 minute washes in TBST preceded 
2 minutes bathing of the membrane in a 1:1 solution of ECL detection reagents 1 and 2. The 
membrane was then exposed to Amersham hyperfilm and developed using an X-OGRAPH X2 
developer.  
Densitometry was performed on the resulting immunoreactive bands using a BioRad GS800 
densitometer and Quantity One software. Each sample was also processed for β-actin as a 
control, to ensure that initial protein quantification via the BCA assay had adequately 
normalised amounts of total protein. If necessary the entire process was repeated with adjusted 
volumes of protein in laemmli buffer being used for SDS-PAGE. 
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Gel Constituent 5% Stacking 
Gel 
Separating Gel 
8% 10% 12% 
H2O (ml) 5.5 18.5 15.9 13.2 
30% Acrylamide 
(ml) 
1.3 10.7 13.3 16 
1.5M Tris 
(pH8.8) (ml) 
1 10 10 10 
10% SDS (µl) 80 400 400 400 
10% Ammonium 
Persulfate (µl) 
80 400 400 400 
TEMED (µl) 8 24 16 16 
 
Table 2-7 Composition of SDS-Polyacrylamide Gels 
Volumes of components given above are those required to make 40ml resolving gel and 8ml 
stacking gel; enough to make 4 SDS-polyacrylamide gels for electrophoresis. 
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2.2.8 Statistical Analysis 
Immunohistochemical analysis on archived material was performed on sections cut from 5 
distinct blocks of normal breast tissue, 5 blocks of DCIS and 20 blocks of breast carcinoma. 
As the data generated were non-parametric, statistical analysis of differences in protein 
expression between the tissue types was performed using the Mann-Whitney U-test. 
Protein and mRNA extracted from prospectively collected tissue was analysed in triplicate for 
every sample of each protein of interest on 3 separate occasions. Frequency histograms 
confirmed normal distribution of data generated from these experiments. Statistical 
significance was then tested using a 2-tailed Student’s t-test. 
All tissue culture experiments were performed using at least n=3 samples in each experimental 
condition. Each experiment was repeated on 3 separate occasions to ensure reliability and 
reproducibility of results. Frequency histograms confirmed normal distribution of data 
generated from these experiments. Statistical significance was then tested using a 2-tailed 
Student’s t-test. 
Regardless of the statistical methods used, significance was accepted when the resulting p-
value was 0.05 or less. 
Microsoft Excel and SPSS v16 (IBM) software were used for statistical analysis. 
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CHAPTER 3: DYSREGULATION OF IRON AND HAEM 
TRANSPORT PROTEINS IN BREAST CANCER 
3.1 Introduction 
Iron was first implicated as a carcinogen when intra-muscular injections induced sarcomata in 
rats276, rabbits277 and humans278. Epidemiological studies have related iron exposure to 
carcinogenesis in general279;280 and to the development of specific epithelial tumours, 
including those of the colon311;403, kidney404;405 and breast354;406. Many carcinomas exhibit 
over-expression of iron import proteins including TfR1, DMT1 and Dcytb and reduced 
expression of the export proteins ferroportin and hephaestin319;407;408.    
Delineation of the iron transport apparatus in breast cancer specifically has so far revealed a 
number of important changes in expression of the proteins involved in transporting non-haem 
iron into and out of mammary epithelial cells. Ferritin levels are demonstrably up-regulated in 
breast cancer cells cultured in vitro relative to normal breast cell lines, implying higher levels 
of intra-cellular iron. Tissue culture and human tissue studies correlate a more aggressive 
phenotype and correspondingly poorer prognosis with higher expression of ferritin360;361;409.  
The non-haem iron importers TfR1 and DMT1 are over-expressed in breast cancer relative to 
normal cells in tissue culture370;373, and this is coupled with a down-regulation of ferroportin 
expression, owing to over-expression of hepcidin366. The use of antisense oligonucleotides to 
suppress TfR1 mRNA expression has been shown to reduce intra-cellular iron concentration, 
and simultaneously inhibits both in vitro proliferation of cultured 4T1, MCF-7 and MDA-MB-
231 breast cancer cells, and tumour growth and metastasis in the 4T1 murine mammary 
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adenocarcinoma model373;410. Similar results are seen with antisense oligonucleotides to 
suppress ferritin expression; these induce apoptosis in MCF-7 cells411.  
The decrease in ferroportin expression in malignant breast cells seen in tissue culture is 
mirrored in vivo, where it has also been demonstrated to have value as a prognostic indicator 
(high levels of ferroportin, along with low hepcidin levels, place breast cancer patients in a 
favourable cohort)366. Transfecting breast cancer cells with ferroportin has been shown to 
significantly inhibit their growth when orthotopically implanted into the mouse mammary fat 
pad366. 
The above evidence is gleaned from a combination of tissue culture experiments and analyses 
of tissue specimens. However, none of the papers quoted compared expression of the iron 
transport proteins in breast carcinoma samples with normal breast tissue harvested from the 
same patients. Observed changes could therefore reflect differences in basal expression of iron 
transport proteins between individuals rather than a modulation in expression in cancer 
compared to normal tissue. 
Furthermore, there has been very little exploration of the role of haem importers (HCP1, 
LRP1) and exporters (BCRP, FLVCR) in breast cancer. LRP1 is thought to be involved in the 
development and invasion of metastases412-416, including those associated with breast 
cancer415;417. LRP1 gene polymorphism has been linked to increased susceptibility to breast 
carcinoma418, though to date the mechanism by which LRP1 functions in breast carcinogenesis 
and whether it is acting as a haem import protein are not known.  
BCRP, a putative haem exporter, has been implicated in cancer, specifically those of the colon 
and cervix, where it has been shown to be down-regulated419.  However, expression of BCRP 
in breast cancer and whether it functions as a haem exporter in this context has not yet been 
investigated. What evidence has been published demonstrates that BCRP can function as an 
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export protein and that this enables it to confer chemo-resistance on breast cancer cell lines265. 
However, it is also capable of extruding multiple other compounds from mammary cells420-423, 
including porphyrins272;275;424. No evidence has yet been published linking changes in 
expression of either HCP1 or FLVCR with any form of cancer. 
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Chapter Aims 
1. Determine the mRNA/protein expression profile of iron and haem import, export and 
storage proteins in prospectively collected matched specimens of normal breast tissue 
and cancer. 
2. Determine the cellular location of these proteins in archived specimens of normal 
breast tissue (NB), ductal carcinoma in situ (DCIS) and breast cancer (BC). 
3. Determine levels of intracellular iron in archived specimens of normal breast tissue, 
DCIS and cancer. 
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3.2 Expression Data 
3.2.1 Immunolocalisation of Iron and Haem Transport Proteins 
Paraffin-embedded sections of normal breast tissue, DCIS and breast carcinoma were 
subjected to immunohistochemistry.  
Samples were obtained from 5 individual blocks of normal breast tissue, 5 blocks of DCIS and 
20 blocks of breast carcinoma. 1 section from each block was evaluated for expression of 
every protein of interest. All 30 sections for each protein were processed concurrently using 
the same antibody solutions to ensure identical conditions 
Optimised antibody concentrations are listed in table 2-1.  
Localisation of immuno-staining within cells was compared between the three groups.  
Semi-quantitative analysis allocated a score of 0 (no staining), 1 (weak), 2 (moderate) or 3 
(strong) to each specimen.  
Formal blinding was not undertaken as the samples arrived pre-labelled and the architectural 
differences between the 3 tissue types are profound and obvious even on cursory examination.  
Staining intensity was quantified by the author and validated by a consultant histopathologist. 
P values were calculated using the Mann-Whitney U-test.  
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3.2.1.1 Immunolocalisation of Iron Import Proteins 
Dcytb 
Expression of Dcytb was both cytoplasmic and membranous, with stronger staining observed 
on the cell membranes in all three tissue types (figure 3.1). Semi-quantitative analysis 
suggested that expression of Dcytb was significantly increased in breast cancer relative to 
normal tissue with a positive mean fold change of 2.69 (p=0.004). There was no difference 
between DCIS and normal tissue (table 3-1). 
DMT1 
Expression of DMT1 in normal breast tissue was largely cytoplasmic. Both DCIS and cancer 
specimens exhibited stronger staining on cell membranes than in the cytoplasm, although the 
avidity of staining in the cancer specimens made this difference negligible (figure 3.1). Cancer 
specimens also exhibited significant stromal staining, not seen in normal tissue. Semi-
quantitative analysis showed DMT1 expression to be significantly increased relative to normal 
breast in the cancer sections with a mean fold change of 2.19 (p=0.015). No other results were 
significant. 
TfR1 
There was little staining observed in the normal specimens. TfR1 was expressed in the 
cytoplasm of DCIS and carcinoma specimens. The cancer specimens also exhibited marked 
TfR1 expression on the cell membranes, as well as in the stroma, as for DMT1 (figure 3.1). 
Semi-quantitative analysis demonstrated significantly increased TfR1 expression in cancer 
specimens relative to normal tissue with a mean fold change of 2.16 (p=0.004). Other 
differences were not significant. 
  
84 
 
Protein Staining Intensity Fold Change Relative to NB 
NB DCIS BC DCIS BC 
Dcytb 0.8+/-0.837 1.4+/-0.548 2.15+/-0.745 1.75 2.688* 
DMT1 0.8+/-0.447 1.2+/-0.837 1.75+/-0.716 1.5 2.188* 
TfR1 1.25+/-0.5 2.0+/-0.707 2.7+/-0.483 1.6 2.16* 
 
Table 3-1 Semi-quantitative analysis of expression of the iron import proteins 
Intensity of immunohistochemical staining for the iron import proteins was compared between 
normal breast tissue (NB, n=5), DCIS (n=5) and breast carcinoma (BC, n=20). Results are 
expressed as a semi-quantitative score +/-2SEM (standard error of mean), and as a fold change 
relative to normal tissue.  
* denotes statistical significance relative to normal breast (p<0.05). 
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Figure 3.1 Immunolocalisation of the iron import proteins 
Immunohistochemistry was performed on paraffin-embedded sections to localise expression of 
Dcytb, DMT1 and TfR1 in normal breast (NB), DCIS and breast cancer (BC). Antibody 
concentrations for each are given in table 2-2. A negative control (NEG) was included by 
omitting primary antibody then processing the section in the usual manner with the relevant 
secondary antibody. Positive controls were mouse duodenum for Dcytb and DMT1 and mouse 
liver for TfR1. Images displayed are at x20 and x40 magnification. 
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3.2.1.2 Immunolocalisation of Haem Import Proteins 
HCP1 
Staining for HCP1 was cytoplasmic in all three specimen types. There was no significant 
difference in staining intensity between any of the three tissues. 
LRP1 
LRP1 expression was also cytoplasmic in normal breast, DCIS and carcinoma. There were no 
significant differences in staining intensity. 
 
Protein Staining Intensity Fold Change Relative to NB 
NB DCIS BC DCIS BC 
HCP1 1.4+/-0.548 2.25+/-0.96 1.5+/-0.855 1.607 1.071 
LRP1 0.8+/-0.837 1.4+/-0.548 1.3+/-0.675 1.75 1.625 
 
Table 3-2 Semi-quantitative analysis of expression of the haem import proteins 
Intensity of immunohistochemical staining for the haem import proteins was compared 
between normal breast tissue (NB, n=5), DCIS (n=5) and breast carcinoma (BC, n=5). Results 
are expressed as a semi-quantitative score +/-2SEM (standard error of mean), and as a fold 
change relative to normal tissue.  
* denotes statistical significance relative to normal breast (p<0.05). 
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Figure 3.2 Immunolocalisation of haem import proteins 
Immunohistochemistry was performed on paraffin-embedded sections to localise expression of 
HCP1 and LRP1 in normal breast (NB), DCIS and breast cancer (BC). Antibody 
concentrations are given in table 2-2. A negative control (NEG) was included by omitting 
primary antibody then processing the section in the usual manner with the relevant secondary 
antibody. Positive controls were mouse stomach (HCP1) and liver (LRP1) Images displayed 
are at x20 and x40 magnification.  
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3.2.1.3 Immunolocalisation of Iron Export Proteins 
Ferroportin 
All three tissue types demonstrated cytoplasmic and membranous staining for ferroportin, with 
membranous expression being more avid throughout. Semi-quantitative analysis did not reveal 
significant differences in expression between normal, DCIS or cancer specimens. 
Hephaestin 
Hephaestin expression was confined to the cytoplasm in all specimens. Expression levels 
analysed by semi-quantitative analysis were unchanged across the 3 tissue subtypes.  
Hepcidin 
Staining for hepcidin was cytoplasmic in all tissue types. No significant differences in 
expression were demonstrated by semi-quantitative analysis. 
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Protein Staining Intensity Fold Change Relative to NB 
NB DCIS BC DCIS BC 
Ferroportin 1.6+/-0.548 2.0+/-0 2.4+/-0.681 1.25 1.5 
Hephaestin 1.8+/-0.837 2.4+/-0.548 2.45+/-0.609 1.33 1.36 
Hepcidin 0.6+/-0.548 0.4+/-0.548 1.2+/-0.632 0.667 2.0 
 
Table 3-3 Semi-quantitative analysis of expression of the iron export proteins 
Intensity of immunohistochemical staining for the iron export proteins was compared between 
normal breast tissue (NB, n=5), DCIS (n=5) and breast carcinoma (BC, n=20). Results are 
expressed as a semi-quantitative score +/-2SEM (standard error of mean), and as a fold change 
relative to normal tissue.  
* denotes statistical significance relative to normal breast (p<0.05). 
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Figure 3.3 Immunolocalisation of the iron export proteins 
Immunohistochemistry was performed on paraffin-embedded sections to localise expression of 
ferroportin, hephaestin and hepcidin in normal breast (NB), DCIS and breast cancer (BC). 
Antibody concentrations are given in table 2-2. A negative control (NEG) was included by 
omitting primary antibody then processing the section in the usual manner with the relevant 
secondary antibody. Positive controls were mouse liver (ferroportin and hepcidin) and colon 
(hephaestin). Images displayed are at x20 and x40 magnification. 
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3.2.1.4 Immunolocalisation of the Haem Export Proteins 
FLVCR 
Staining for FLVCR was localised to the nuclei in all three tissue types. Semi-quantitative 
analysis did not reveal significant differences in expression. 
BCRP  
BCRP expression was cytoplasmic in normal breast tissue. However, in DCIS and breast 
cancer BRCP is localised at the cell border. Semi-quantitative analysis reported a statistically 
significant increase in expression of BCRP in breast cancer relative to normal tissue, with a 
mean fold change of 1.7 (p=0.026). There were no other significant differences. 
 
Protein Staining Intensity Fold Change Relative to NB 
NB DCIS BC DCIS BC 
FLVCR 2.0+/-0.816 2.2+/-0.447 2.3+/-1.054 1.1 1.15 
BCRP 1.5+/-0.577 2.0+/-0 2.54+/-0.519 1.333 1.693* 
 
Table 3-4  Semi-quantitative analysis of expression of the haem export proteins 
Intensity of immunohistochemical staining for the haem export proteins was compared 
between normal breast tissue (NB, n=5), DCIS (n=5) and breast carcinoma (BC, n=5). Results 
are expressed as a semi-quantitative score +/-2SEM (standard error of mean), and as a fold 
change relative to normal tissue.  
* denotes statistical significance relative to normal breast (p<0.05). 
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Figure 3.4 Immunolocalisation of haem export proteins 
Immunohistochemistry was performed on paraffin-embedded sections to localise expression of 
FLVCR and BCRP in normal breast (NB), DCIS and breast cancer (BC). Antibody 
concentrations are given in table 2-2. A negative control (NEG) was included by omitting 
primary antibody then processing the section in the usual manner with the relevant secondary 
antibody. Positive control for both was mouse kidney. Images displayed are at x20 and x40 
magnification. 
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3.2.1.5 Immunolocalisation of Ferritin 
Staining for ferritin in all three tissue types was cytoplasmic. No significant differences in 
expression between tissue types were revealed by semi-quantitative analysis. 
 
Protein Staining Intensity Fold Change Relative to NB 
NB DCIS BC DCIS BC 
Ferritin 2.25+/-0.96 1.2+/-0.447 1.7+/-0.801 0.533 0.756 
 
Table 3-5 Semi-quantitative analysis of expression of ferritin 
Intensity of immunohistochemical staining for ferritin was compared between normal breast 
tissue (NB, n=5), DCIS (n=5) and breast carcinoma (BC, n=20). Results are expressed as a 
semi-quantitative score +/-2SEM (standard error of mean), and as a fold change relative to 
normal tissue. * denotes statistical significance relative to normal breast (p<0.05). 
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Figure 3.5 Immunolocalisation of ferritin 
Immunohistochemistry was performed on paraffin-embedded sections to localise expression of 
ferritin in normal breast (NB), DCIS and breast cancer (BC). Antibody concentrations are 
given in table 2-2. A negative control (NEG) was included by omitting primary antibody then 
processing the section in the usual manner with the relevant secondary antibody. Positive 
control was mouse liver. Images displayed are at x20 and x40 magnification. 
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3.2.2 Intracellular Iron Content 
Perl’s staining was utilised to compare the intracellular iron content of normal breast tissue, 
DCIS and breast cancer. Normal liver was used as a positive control. 
No staining for iron was observed in the normal breast sections. Although there were isolated 
deposits in the DCIS and cancer specimens, they were sparse, and of insufficient number to 
perform meaningful statistical analysis. This was the case throughout all the specimens 
analysed and was therefore unlikely to be due to tumour heterogeneity. 
 
Figure 3.6 Perl’s staining for intracellular iron 
Perl’s staining was performed to analyse the iron content of paraffin-embedded sections of 
normal breast (NB, n=5), DCIS (n=5) and breast cancer (BC, n=20). The arrows highlight 
areas of each section where iron has been liberated from ferritin and stained. Normal liver was 
used as a positive control (POS CONT) and demonstrates large amounts of intracellular iron. 
There are small pockets in the DCIS and cancer specimens, but no staining in normal breast. 
Images displayed are at x20 and x40 magnification. 
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3.2.3 Iron and Haem Transport Protein Expression in Matched Tissue Pairs 
SDS-PAGE and Western blotting were utilised to examine expression levels of the iron and 
haem import, export and storage proteins in breast carcinoma samples and matched normal 
tissue (see pages 58 and 73). 
Owing to the finite amounts of protein generated from each collected tissue specimen, a 
number of the experiments did not utilise the entire library of samples.  
All results are reported as mean expression in cancer relative to normal tissue (normal tissue 
results were standardised to 1 throughout).  
β-actin was used as a loading control.  
Values are expressed as average relative expression +/- 2SEM (Standard Error of Mean). P 
values were obtained using the student t-test.  
3.2.3.1 Iron Import Proteins 
All three of the iron import proteins studied demonstrated significant over-expression in breast 
cancer compared to matched normal tissue (standardised to 1). 
Dcytb expression in breast cancer specimens exhibited an increase of 1.57+/-0.52 (p=0.05) 
relative to matched normal tissue. 
There was a fold increase of 2.67+/-1.06 (p=0.008) in expression of DMT1 in breast cancer 
compared to matched normal tissue. 
TfR1 expression was also higher in cancer specimens relative to matched normal tissue with a 
mean fold change of 3.51+/-2.12 (p=0.036). 
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A             
B              
C              
Figure 3.7 Expression of iron import proteins in breast cancer relative to matched 
normal tissue 
Expression of Dcytb (A), DMT1 (B) and TfR1 (C) was significantly increased in breast cancer 
relative to matched normal breast tissue (n=13 matched samples). β-actin was utilised for 
normalisation purposes. * denotes statistical significance (p<0.05, student t-test). 
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3.2.3.2 Haem Import Proteins 
Expression of HCP1 was down-regulated in cancer specimens with a 45% reduction relative to 
normal breast tissue (standardised to 1). Average relative expression was 0.55+/-0.24 
(p=0.004). 
Despite multiple attempts on multiple sets of tissue lysates using antibodies from a number of 
sources, no adequate Western blots could be produced to investigate the relative expression of 
LRP1. 
 
 
Figure 3.8 Expression of HCP1 in breast cancer relative to matched normal tissue 
Expression of the haem import protein HCP1 is significantly down-regulated in breast cancer 
relative to matched normal tissue (n=10 matched pairs). β-actin was utilised for normalisation 
purposes.   
* denotes statistical significance (p<0.05, student t-test). 
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3.2.3.3 Iron Export Proteins 
Expression of the iron export protein ferroportin was reduced by 58% in breast cancer 
compared to matched normal breast tissue (standardised to 1). Average relative expression was 
0.42+/-0.14 (p<0.005). 
Expression of the ferroportin co-factor hephaestin was similarly inhibited, with an average 
relative expression of 0.47+/-0.20 (p=0.006), corresponding to a 53% reduction. 
Conversely, expression of hepcidin was significantly increased in breast cancer relative to 
matched normal tissue. The average fold increase was 20.33+/-15.43 (p=0.033) compared to 
standardised normal tissue as throughout. 
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A                      
B                       
C                       
Figure 3.9 Expression of iron export proteins in breast cancer relative to matched 
normal tissue 
Expression levels of ferroportin (A, n=13 matched pairs) and hephaestin (B, n=5 matched 
pairs) were significantly repressed in breast cancer relative to matched normal tissue. Levels 
of hepcidin (C, n=10 matched pairs) were significantly increased. β-actin was utilised for 
normalisation purposes.  
* denotes statistical significance (p<0.05, student t-test). 
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3.2.3.4 Haem Export Proteins 
BCRP levels were significantly reduced (by 33%) in breast cancer compared to normal breast 
tissue. Average relative expression was 0.67+/-0.35 (p=0.005) compared to normal breast 
standardised to 1. 
Expression of FLVCR was also significantly down-regulated, with an average relative 
expression in breast cancer of 0.52+/-0.15 (a 48% reduction) compared with standardised, 
matched normal tissue (p<0.005). 
A                     
B                     
Figure 3.10 Expression of haem export proteins in breast cancer relative to matched 
normal tissue 
Expression of BCRP (A, n=12 matched pairs) and FLVCR (B, n=11 matched pairs) was 
significantly down-regulated in breast cancer compared to matched normal breast tissue. β-
actin was utilised for normalisation purposes. * denotes statistical significance (p<0.05, 
student t-test). 
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3.2.3.5 Iron Storage   
Ferritin-H was significantly over-expressed in breast cancer relative to matched normal tissue. 
There was a fold increase of 4.55+/-2.07 (p=0.012) compared to normal samples standardised 
to 1.  
 
Figure 3.11 Expression of ferritin-H in breast cancer relative to matched normal tissue 
Ferritin-H is significantly over-expressed in breast cancer specimens relative to matched 
normal tissue (n=10 matched pairs). β-actin was utilised for normalisation purposes.* denotes 
statistical significance (p<0.05, student t-test). 
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3.2.4 Relative Expression of mRNA of Iron and Haem Transport Proteins  
Quantitative real-time polymerase chain reactions (qRT-PCR) were employed to elucidate 
changes in expression levels of mRNA coding for the various iron and haem transport proteins 
in the breast carcinoma samples and matched normal tissue (see pages 58 and 69). 
Owing to the finite amounts of mRNA generated from each collected tissue specimen, a 
number of the experiments did not utilise the entire library of samples.  
Results are expressed graphically as histograms demonstrating relative expression of mRNA 
in each matched pair, with summary histograms depicting the overall change in expression of 
mRNA for each protein.  
Results are automatically normalised by the relative quantification PCR protocol such that 
expression in cancer specimens is always expressed relative to a value of 1 in normal breast 
tissue.  
Fold changes are expressed as mean fold change+/-2SEM. P values were obtained using the 
student’s t-test. 
3.2.4.1 Expression of mRNA for the Iron Import Proteins 
Dcytb mRNA expression was increased in 16 of 19 cancer specimens when compared to 
matched normal breast tissue (84%). The overall fold increase was 7.45+/-3.75 (p=0.003).  
DMT1 mRNA was up-regulated in 8 of 12 (67%) breast cancer samples relative to matched 
normal tissue, equating to an average fold increase of 5.25+/-3.42 (p=0.037). 
TfR1 mRNA demonstrated a fold increase of 2.23+/-0.63 (p=0.002) in expression, being over-
expressed in 12 of 13 (92%) cancers relative to matched normal tissue. 
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A             
B  
C       
Figure 3.12 Changes in expression of mRNA coding for the iron import proteins across 
matched tissue pairs 
Expression of mRNA coding for the iron import proteins Dcytb (A), DMT1 (B) and TfR1 (C) 
was significantly increased in breast cancer tissue relative to matched normal tissue. 
Histograms show relative expression +/- 2SEM. * denotes statistical significance (p<0.05, 
student’s t-test). 
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3.2.4.2 Expression of mRNA for the Haem Import Proteins  
Expression of mRNA coding for HCP1 was up-regulated in 12 of 16 (75%) breast cancers 
relative to matched normal tissue, with an average fold increase of 14.11+/-5.52 (p=0.0003). 
There was increased expression of mRNA for LRP1 in 10 of 12 (83%) breast cancers 
compared to matched benign tissue; an average fold increase of 23.60+/-15.46 (p=0.014). 
A               
B             
Figure 3.13 Changes in expression of mRNA coding for the haem import proteins across 
matched tissue pairs 
Expression of mRNA coding for HCP1 (A) and LRP1 (B) was significantly up-regulated in 
breast cancer specimens compared to matched normal tissue. Histograms show relative 
expression +/- 2SEM. * denotes statistical significance (p<0.05, student’s t-test). 
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3.2.4.3 Expression of mRNA for the Iron Export Proteins 
There was no significant change in expression of ferroportin mRNA in breast cancer relative 
to matched normal tissue.  
Levels of mRNA coding for hephaestin were increased in the malignant samples in 14 of 19 
(74%) matched tissue pairs. There was a statistically significant average fold increase of 
8.16+/-3.53 (p=0.0007).   
mRNA coding for the regulatory protein hepcidin was over-expressed in 8 of 11 (73%) 
malignant samples compared to matched normal tissue. There was a statistically significant 
average fold increase of 14.48+/-8.74 (p=0.012). 
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A                
B                
C               
Figure 3.14 Changes in expression of mRNA coding for the iron export proteins across 
matched tissue pairs 
Expression of mRNA coding for ferroportin (A) was not significantly changed in breast cancer 
relative to matched normal tissue. Expression of mRNA coding for hephaestin (B) and 
hepcidin (C) was significantly up-regulated in the malignant samples. Histograms show 
relative expression +/- 2SEM. * denotes statistical significance (p<0.05, student’s t-test). 
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3.2.4.4 Expression of mRNA for the Haem Export Proteins 
Expression of BCRP mRNA was elevated in 9 of 11 (82%) breast cancer specimens relative to 
their  normal counterparts, with a statistically significant average fold increase of 4.0+/-1.92 
(p=0.011). 
FLVCR mRNA was over-expressed in every one of 12 breast cancers relative to matched 
normal tissue, with a significant average fold increase of 11.63+/-6.45 (p=0.007). 
A               
B               
Figure 3.15 Changes in expression of mRNA coding for the haem export proteins across 
matched tissue pairs 
Expression of mRNA for both BCRP (A) and FLVCR (B) was significantly up-regulated in 
breast cancer relative to matched normal tissue. Histograms show relative expression +/- 
2SEM. * denotes statistical significance (p<0.05, student’s t-test). 
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3.2.4.5 Expression of mRNA Coding for Ferritin 
Levels of mRNA coding for ferritin were elevated in 16 of 18 (89%) breast cancers compared 
to matched benign tissue. There was a significant average fold increase in cancer of 4.43+/-
1.85 (p=0.002). 
 
Figure 3.16 Changes in expression of mRNA coding for H+L ferritin across matched 
tissue pairs 
There was a significant positive fold change in expression of the mRNA coding for ferritin in 
breast cancer compared to matched normal tissue. Results are displayed to show expression in 
the malignant specimen of each matched pair tested relative to its normal counterpart, and as 
an overall summary histogram. Histograms show average relative expression +/- 2SEM. * 
denotes statistical significance (p<0.05, student’s t-test). 
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3.2.4.6 Expression of mRNA Coding for Iron Regulatory Proteins 
Expression of IRP1 mRNA was unchanged across 19 matched tissue pairs with an expression 
in cancer relative to matched normal tissue of 1.19+/-1.46 (p=0.8).  
mRNA for IRP2 was elevated in 14 of 16 (88%) breast cancer samples relative to their 
matched normal tissue. There was a significant mean fold increase of 4.89+/-1.77 (p=0.0007). 
A                   
B                   
 
Figure 3.17 Changes in expression of mRNA coding for the iron regulatory proteins 
across matched tissue pairs 
Expression of mRNA coding for IRP1 (A) was unchanged across matched tissue pairs. mRNA 
for IRP2 (B) was significantly over-expressed in breast cancer relative to normal tissue. 
Histograms show average relative expression +/- 2SEM. * denotes statistical significance 
(p<0.05, student’s t-test). 
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 Expression of protein relative to 
matched normal tissue 
Expression of mRNA relative to 
matched normal tissue 
Dcytb 1.57 +/- 0.52 (p=0.05) * 7.45 +/- 3.75 (p=0.003) * 
DMT1 2.67+/- 1.06 (p=0.008) * 5.25 +/- 3.42 (p=0.037) * 
TfR1 3.51 +/- 2.12 (p=0.036) * 2.23 +/- 0.63 (p=0.02) * 
HCP1 0.55 +/- 0.26 (p=0.004) * 14.11 +/- 5.52 (p=0.0003) * 
LRP1 N/A 23.6 +/- 15.46 (p=0.014) * 
Ferroportin 0.42 +/- 0.14 (p<0.005) * 1.63 +/- 0.67 (p=0.078) 
Hephaestin 0.47 +/- 0.2 (p=0.06) * 8.16 +/- 3.53 (p=0.0007) * 
Hepcidin 20.33 +/- 15.43 (p=0.033) * 14.48 +/- 8.74 (p=0.012) * 
BCRP 0.67 +/- 0.35 (p=0.005) * 4.0 +/- 1.92 (p=0.011) * 
FLVCR 0.52 +/- 0.15 (p<0.005) * 11.63 +/- 6.45 (p=0.007) * 
Ferritin 4.55 +/- 2.07 (p=0.012) * 4.43 +/- 1.85 (p=0.002) * 
IRP1 N/A 1.19+/-1.46 (p=0.8) 
IRP2 N/A 4.89+/-1.77 (p=0.0007) * 
 
Table 3-6 A summary of the changes in expression of the iron and haem import, export, 
storage and regulatory proteins and mRNA in breast cancer specimens relative to 
matched normal tissue 
Results are displayed as expression in cancer specimens relative to matched normal breast 
tissue (normalised to 1 in all cases) +/- 2SEM. * denotes statistical significance (p<0.05, 
student t-test). 
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Figure 3.18 Changes in expression of the iron and haem import, export, storage and 
regulatory proteins and mRNA in breast cancer relative to matched normal tissue 
Relative expression in cancer specimens is expressed as fold change relative to expression in 
normal breast tissue. * denotes statistical significance (p<0.05, student t-test). 
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 Relative Protein Expression Relative mRNA Expression 
Dcytb ↑ ↑ 
DMT1 ↑ ↑ 
TfR ↑ ↑ 
HCP1 ↓ ↑ 
LRP1 - ↑ 
Ferroportin ↓ → 
Hephaestin ↓ ↑ 
Hepcidin ↑ ↑ 
FLVCR ↓ ↑ 
BCRP ↓ ↑ 
Ferritin ↑ ↑ 
IRP1 - → 
IRP2 - ↑ 
 
Table 3-7 Changes in expression of the iron and haem import, export, storage and 
regulatory proteins and mRNA in breast cancer relative to matched normal tissue 
The table summarises the significant changes in expression of the iron and haem transport 
proteins expressed numerically in table 3-6 and graphically in figure 3.18. The overall changes 
in protein expression would act to increase intracellular iron content. Some of these changes 
must be achieved by post-translational regulation given the differences in expression profile at 
the mRNA level.  
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3.3 Summary and Discussion 
Mounting evidence suggests that dysregulation in the iron transport machinery is crucial to 
epithelial carcinogenesis. A number of studies demonstrate such a link in gastrointestinal 
carcinogenesis319;407 and recent work has begun to demonstrate similar changes in breast 
cancer360;361;364;366;373;409-411.  
Expression levels of Dcytb, DMT1 and TfR1 were significantly increased in breast cancer 
relative to normal breast tissue in our prospectively collected library of matched samples. 
These significant increases were also observed at the mRNA level. These results correlate with 
previous studies demonstrating increased expression of DMT1 and TfR1 in breast cancer, 
allowing increased transferrin receptor-mediated endocytosis of iron370;373. However, this is 
the first time expression levels have been compared in benign and malignant tissue obtained 
from the same individuals. Dcytb has not previously been studied in breast cancer and these 
results therefore represent a novel finding. Oesophageal and colorectal cancers have been 
shown to over-express Dcytb relative to normal tissue319;407, although as Dcytb is localised to 
the luminal cell membrane in both, this could be perceived as an upregulation of normal 
epithelial iron import machinery to cope with increased demand.  
Immunohistochemistry on archived samples localised all 3 import proteins to the cell 
membranes in cancer, although both DMT1 and TfR1 also demonstrated marked immuno-
reactivity in the cytoplasm, likely reflecting accelerated turnover due to increased TfR-
mediated endocytosis. Expression of Dcytb was also localised to the cell membrane in normal 
breast, although semi-quantitative analysis confirmed the significant increase in expression in 
cancer specimens revealed by Western blotting. DMT1 expression in normal breast tissue was 
largely cytoplasmic, indicating a translocation to the cell membrane in cancer. TfR1 
expression in normal breast was negligible. 
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The observed changes reinforce the hypothesis that breast carcinoma cells have evolved a 
phenotype able to sequester increased amounts of iron from the circulation. In such a model, 
increased membranous TfR1 would allow increased influx of transferrin-bound iron through 
endocytosis. Increased cytoplasmic DMT1 would be required to process the excess endosomal 
iron resulting from increased import.  
The increased expression of both Dcytb and DMT1 on the cell membranes in carcinoma may 
reflect a further step in evolution of normal mammary cells towards a phenotype geared to 
maximal iron uptake, attempting to mimic the gut luminal iron import mechanism to sequester 
unbound circulating iron. 
A further interesting observation was the presence of significant staining for Dcytb, DMT1 
and TfR1 in the stroma surrounding glandular tissue in breast cancer specimens particularly, 
although also to an extent in DCIS. This is not a feature that has previously been reported in 
the literature in relation to breast or any other cancer. It is conceivable that there is a peri-
tumoural reaction in the connective tissue that induces such changes and this may be an area 
worthy of further study. 
Immunolocalisation showed ferroportin to be located on the cell membrane in normal breast 
tissue as well as in cancer. Although there was no significant difference in levels of mRNA 
coding for ferroportin in cancer relative to matched normal tissue, Western blotting 
demonstrated a clear down-regulation in expression of the protein product, in keeping with 
results from previous studies366, and fitting the model of hepcidin-dependent internalisation 
and destruction of the protein product.  
Similarly, Western blotting showed hephaestin expression to be significantly decreased in 
breast cancer tissue relative to matched normal samples, although paradoxically there 
appeared to be a significant increase in hephaestin mRNA. Given that the cells have adopted a 
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phenotype geared to increasing iron import, the mRNA up-regulation represents an 
appropriate response via the CDX2-regulated mechanism described on page 19. The decrease 
in protein levels therefore represents a post-translational moderation in hephaestin expression 
although the process is unclear. Immunohistochemistry revealed most of the staining to be 
cytoplasmic, in cancer specimens as well as normal tissue, which does not fit with its usual 
localisation to the cell membrane. This may well be a technical issue as previous groups have 
all demonstrated membranous expression in normal tissue, although expression in breast 
cancer has never been examined.  
Immunohistochemistry revealed hepcidin expression to be localised to the cytoplasm in 
normal and malignant tissue. Previous studies have demonstrated cytoplasmic expression of 
hepcidin in the duodenum, although at a much reduced intensity than in hepatocytes, where 
synthesis occurs433. This duodenal staining is likely due to internalisation of the ferroportin-
hepcidin complex which results in ferroportin degradation. A similar process must occur in 
both benign and malignant breast cells. Hepcidin expression was significantly increased in 
prospectively collected cancer specimens relative to matched normal tissue at both the protein 
and mRNA level, again reinforcing previously published data on breast cancer366, as well as 
replicating the situation previously described in colorectal carcinoma320. 
The overall effect of the observed changes in expression of iron export proteins would be to 
decrease iron efflux from cells. Increased local expression of hepcidin would act to promote 
degradation of ferroportin. Thus, in the face of unchanged mRNA levels, amounts of the iron 
export protein will fall. Whether the discrepancies between expression of hephaestin and its 
mRNA are due to translational defects or increased degradation of the protein product, the 
consequence is a down-regulated iron export mechanism in the face of increased expression of 
iron import proteins.  
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Expression of the iron storage protein ferritin was significantly increased in breast cancer 
tissue relative to matched normal samples, replicating previously published results360;361;409. 
Immunohistochemistry demonstrated ferritin to be localised to the cytoplasm in all tissue 
types. There was a significant increase in mRNA expression. These changes are likely to be an 
appropriate response, regulated by the IRE/IRP interaction, to prevent increased intracellular 
iron levels (secondary to increased importer expression and decreased exporter function) 
causing damage via induction of ROS. 
Immunohistochemistry showed both HCP1 and LRP1 to be localised to the cytoplasm of 
benign and cancerous breast tissue.  
Western blotting on matched tissue pairs revealed HCP1 levels to be significantly reduced in 
cancer relative to normal tissue, although expression of HCP1 mRNA was significantly 
increased. Although HCP1 is recognised as a haem importer230, it is also known to transport a 
number of other compounds, including folate244, and it may be the case that the inhibition of 
HCP1 expression is a compensatory mechanism deployed in response to increased 
intracellular iron levels. 
LRP1 mRNA levels were also significantly higher in breast cancer than matched normal 
tissue. Although LRP1 is known to have multiple functions, up-regulation in mRNA 
expression would permit breast cancer cells to import increased amounts of haem, thus 
contributing to the toxic intracellular milieu driving carcinogenesis. Unfortunately Western 
blotting with a number of antibodies raised against LRP1 failed to yield any results. 
Immunohistochemistry showed expression of FLVCR to be nuclear in normal breast tissue, 
DCIS and breast cancer. Western blotting revealed a significant decrease in FLVCR 
expression in cancer relative to matched normal tissue, although levels of FLVCR mRNA 
were significantly up-regulated in malignant specimens compared to normal.  
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BCRP expression was shown to be largely membranous in breast cancer (and DCIS), whereas 
it was mainly cytoplasmic in normal tissue samples. Western blotting demonstrated significant 
down-regulation of BCRP expression in cancer relative to matched normal specimens, there 
was significant up-regulation in expression of BCRP mRNA.  
Decreased expression of known haem exporter proteins would likely increase intracellular 
haem levels. Translocation of BCRP expression to the cell membrane in cancer specimens 
may suggest an attempt to export greater amounts of haem, although the decrease in overall 
quantity of the protein would be counter-productive and the varied role of BCRP in effluxing 
multiple compounds makes identification of its exact role in any context extremely 
challenging. The decreased expression of FLVCR in cancer combined with its nuclear location 
renders it ineffective as an exporter of haem from breast cancer cells. Nuclear localisation of 
FLVCR has not previously been reported and represents a novel finding, although the 
significance of this is uncertain. What can be stated is that confinement of FLVCR to the 
nucleus prevents it exporting haem from the cell and may contribute to an increase in 
intracellular haem. Although mRNA coding for both haem exporters is increased, post-
translational regulation leading to decreased expression of the protein product would explain 
the observed results.  
In this context, irrespective of the observed changes in expression of the putative haem import 
proteins, repression of the haem export proteins will lead to increasing intracellular haem 
which can be catabolised by HO-1 to liberate free iron. However, care must be taken in 
speculating on the degree to which these changes relate purely to haem metabolism given the 
varied functions carried out by these proteins264-266;270-272.  
No antibody was available which yielded any positive immunohistochemistry or Western 
blotting results for the iron response proteins. However, an increase in IRP2 mRNA was 
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demonstrated in breast cancer samples relative to matched normal tissue. IRP1 mRNA 
expression was unchanged. Induction of IRP2 protein expression would cause cells to adopt an 
iron-deficient phenotype with up-regulation of TfR1 and DMT1, and inhibition of ferroportin 
expression, as seen in breast cancer366;367;369;370;373. The increase in expression of IRP2 mRNA 
suggests that the trigger for up-regulation of the protein product is inappropriate stimulation 
rather than failed degradation.  
 
In summary, the changes observed in expression of iron and haem transport proteins combine 
to produce trafficking mechanisms for iron and haem which would act to increase intracellular 
concentrations of both. High levels of ferritin (disclosing an iron-replete intracellular 
environment) indicate that the increased expression of iron importers and down-regulation of 
exporters is inappropriate. This dysregulated expression profile appears to be multi-factorial 
with increased hepcidin down-regulating ferroportin on one hand and IRP2 stabilising TfR1 
and DMT1 expression on the other.  
Our data concerning non-haem iron transporters largely reinforce the results of previously 
published studies. As our comparisons of protein and mRNA expression between cancer and 
normal breast tissue are based on matched specimens taken from the same patient, all other 
variables are excluded and the differences observed must be due solely to altered expression 
profiles in malignant cells. 
Haem transporters have not previously been studied in this context. However, down-regulation 
of haem exporter protein expression in the face of increased LRP1 expression would act to 
increase intracellular haem stores in a similar manner, although this may be partly offset by a 
down-regulation in HCP1 protein levels. 
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The likely consequence of these changes would be to increase the intracellular labile iron pool, 
driving carcinogenesis through the generation of reactive oxygen species, induction of 
oncogenic Wnt signalling and dysregulation of the cell cycle.  
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CHAPTER 4: CHANGES IN CELL PHENOTYPE INDUCED 
BY IRON AND HAEM LOADING IN VITRO 
4.1 Introduction 
The results reported in chapter 3 describe a modulation in expression of the iron and haem 
import and export proteins which could feasibly allow breast cancer cells to accumulate excess 
intracellular iron. These results support previously published studies in which breast cancer 
cell lines have been shown to up-regulate TfR1 and DMT1 relative to normal cells while 
down-regulating ferroportin373. It has been demonstrated that increased ability to sequester 
iron drives malignant mammary cells to behave more aggressively, reflected by the fact that 
higher levels of hepcidin, and subsequent down-regulation of ferroportin expression, bestow a 
poorer prognosis on breast cancer patients366. High levels of ferritin are also a poor prognostic 
marker361;409.  
The observed modulation in expression of iron transport proteins would act to increase 
intracellular iron stores. A larger intracellular labile iron pool has the potential to mediate 
carcinogenesis through lipid peroxidation of membranes and DNA damage. In addition, 
increased intracellular iron levels are permissive for increased activity of ribonucleotide 
reductase, allowing higher rates of DNA synthesis and therefore cell cycling. De-regulation of 
ribonucleotide reductase expression has been shown to be an independent oncogenic stimulant 
in rodent studies425. The crucial role of iron in cell cycling has been described; in particular the 
incubation of malignant cells derived from a number of cancer subtypes (including breast) 
with an iron chelator reduced cellular expression of cyclins causing cell cycling to arrest296-298.  
Iron has also been shown to be a regulator of Wnt signalling; a major oncogenic signalling 
pathway implicated in a number of cancers including those of the breast323,359. 
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To date, very little work has been done to explore the changes induced in breast cell phenotype 
by increasing intracellular iron levels, or to investigate whether haem may play a part in 
modulating cell behaviour. The assumption has been that malignant cells manifest altered 
transport protein profiles due to their increased demand for iron. It has not been considered 
that iron and haem may drive a malignant cell phenotype, and that the altered expression 
profile of their transport proteins could be a causative factor in the development of 
malignancy. This could be mediated via direct toxicity, a permissive effect on ribonucleotide 
reductase function and cell cycling, or the induction of Wnt or some other signalling pathway. 
It has been shown that a proportion of breast cancer cells will arrest during cell cycling when 
incubated with chelators297. Iron chelators have also demonstrated an anti-proliferative action 
on cultured MCF-7 cells426 and can potentiate the effects of traditional chemotherapy agents 
against breast cancer cell lines in vitro379. However, the effect of iron chelation on many of the 
phenotypic traits associated with cancer cells has yet to be investigated. The behaviour of 
breast cancer cells in terms of their proteomic response to increasing iron levels also remains 
to be formally reported. 
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Chapter Aims 
1. Determine whether benign and malignant mammary cell lines can import iron and 
haem and whether the efficacy of iron import differs between the two. 
2. Investigate the effects of increased intracellular iron on the following aspects of cell 
phenotype (in benign and malignant lines): 
a. Viability 
b. Proliferation 
c. Anchorage independent growth  
d. Migration 
e. Invasion 
3. Determine whether any observed changes in cell phenotype are affected by iron 
chelation with deferasirox (ICL670A). 
4. Examine the effects of iron, haem and iron chelators on cellular expression of the iron 
and haem transport proteins. 
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4.2 The Effect of Iron, Haem and Iron Chelation on Cell 
Phenotype 
4.2.1 The Effects of Iron and Haem Loading on Intracellular Iron Concentration 
To determine whether mammary cells can take up extracellular iron, cells were incubated with 
iron and haem at varying concentrations and time intervals.  
We utilised HB2, MCF-7 and MDA-MB-231 cells in this and all other tissue culture 
experiments. Benign HB2 cells are derived from normal breast epithelium. MCF-7 cells are of 
intermediate malignant phenotype and are derived from invasive ductal carcinoma. MDA-MB-
231 cells are also derived from invasive ductal carcinoma but exhibit a more malignant 
phenotype. 
Each line was incubated with haem at 20, 40 and 80µM and FeSO4 at 50, 100, 150 and 200µM 
for 24, 48 and 72 hours. 6 well plates were used, 3 wells for each experimental condition. 
Experiments were repeated 3 times.  
Ferrozine and BCA protein assays were performed on recovered cell pellets (see sections 
2.2.4.1 and 2.2.4.2), allowing iron content to be expressed as nmol Fe per unit protein and 
compared to control conditions. 
  
127 
 
HB2  
Incubation with FeSO4 increased intracellular iron content at all concentrations and time 
periods (p<0.005). There were no differences in iron content following incubation with haem 
at any of the concentrations or time periods studied. 
MCF7 
Incubation with FeSO4 at all concentrations and time periods increased intra-cellular iron 
content (p<0.05). Culturing with 80µM haem increased intra-cellular iron at all time points 
(p<0.05). 40µM haem increased cellular iron levels at 24 (p=0.01) and 48 (p=0.004) hours 
while 20µM haem was only effective at 48 hours (p=0.036). 
MDA-MB-231 
Incubation with FeSO4 increased cellular iron content over all concentrations and time periods 
except in cells incubated with 50µM FeSO4 for 72 hours (p<0.05). 40-80µM haem increased 
cellular iron levels at all time points (p<0.05). 20µM haem only increased cellular iron levels 
at 24 hours. 
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Figure 4.1 Changes in intracellular iron content of benign breast cells induced by iron 
and haem loading 
Benign HB2 cells showed no increase in intra-cellular iron content in response to incubation 
with any concentration of haem for any period of time. Incubation with FeSO4 significantly 
increased cellular iron levels in every experimental arm. Statistical significance (p<0.05) is 
denoted by * (student t-test). Results are expressed graphically as mean intra-cellular iron 
content +/- 2SEM. 
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Figure 4.2 Changes in intracellular iron content of malignant breast cells induced by iron 
and haem loading 
MCF7 and MDA-MB-231 cells were capable of importing both iron and haem to increase 
their intracellular iron content at a variety of concentrations and time intervals. Statistical 
significance (p<0.05) is denoted by * (student t-test). Results are expressed graphically as 
mean intra-cellular iron content +/- 2SEM.  
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4.2.2 The Effects of Iron and Haem Loading on Cell Viability 
An MTT assay was utilised to explore the effects of iron and haem loading on the viability of 
benign and malignant cells as described in section 2.2.5.1. Benign HB2 and malignant MCF7 
and MDA-MB-231 cells were incubated with haem at 20, 40 and 80µM and FeSO4 at 50, 100, 
150 and 200µM for 24, 48 and 72 hours. Percentage viability in each arm was calculated 
relative to control cells normalised to 100%. Results are summarised in figure 4.2. 
HB2 
Incubation with FeSO4 increased cell viability across all concentrations and time points 
(p<0.05). Haem loading had no effect at low concentrations but decreased cell viability at 
40µM after 48 hours (p<0.005) and at 80µM after 48 (p=0.0002) and 72 (p=0.004) hours. 
MCF7 
150-200µM FeSO4 induced increased viability across all 3 time intervals (p<0.05). 50-100µM 
FeSO4 was only effective at 48 hours (p<0.001). 20µM haem increased viability from 24 to 72 
hours (p<0.02). Higher haem concentrations were harmful to cells. Cells incubated in 40µM 
haem exhibited reduced cell viability at 72 hours (p<0.001); 80µM haem had a negative effect 
at both 48 and 72 hours (p<0.002). 
MDA-MB-231 
Viability was significantly increased at all concentrations and time points with both FeSO4 and 
haem loading (p<0.05). At higher haem concentrations the increase in viability relative to 
control was less profound, but remained statistically significant. FeSO4 induced an increase in 
viability that became more marked as duration of incubation was prolonged. 
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Figure 4.3 Changes in viability of benign and malignant mammary cells induced by iron 
and haem loading 
HB2 cells exhibit significantly up-regulated viability in response to FeSO4 loading at all 
concentrations and time points. Haem loading was largely ineffective but significantly 
deleterious at high concentrations.  Viability of MCF7 cells was significantly increased 
following incubation with 20µM haem, but a significant inhibition of viability was seen at 
higher concentrations. Incubation with FeSO4 significantly stimulated viability of MCF7 cells 
at higher concentrations. MDA-MB-231 cells display universally up-regulated viability when 
incubated with FeSO4 or haem across all concentrations and time points. Statistical 
significance (p<0.05) is denoted by * (student t-test). Results are expressed graphically as 
mean percentage viability (relative to control) +/- 2SEM. 
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4.2.3 The Effects of Iron and Haem Loading on Cell Proliferation 
Changes in cellular proliferation induced by culturing cells with FeSO4 and haem were 
measured using a BrdU assay as described in section 2.2.5.2. Concentrations and time points 
matched those used for the viability assays detailed in section 4.2.2. Percentage proliferation 
in each arm was calculated relative to control cells (unadulterated culture medium) normalised 
to 100%. Results are summarised in figure 4.3. 
HB2 
Incubating with haem for 24 hours at 20-80µM led to significantly increased cellular 
proliferation (p<0.02). A significant increase was also observed at 48 hours at 80µM 
(p=0.004). Incubation with FeSO4 at 100-200µM led to significantly increased proliferation at 
24 and 72 hours (p<0.05). 
MCF7 
MCF7 cells displayed significantly up-regulated proliferation at all haem concentrations 
across all time points, although at 72 hours the effects were less pronounced (all p<0.05). 
FeSO4 loading produced a significant increase in proliferation under all experimental 
conditions (p<0.04) except following 72 hours incubation at 150 or 200µM where no changes 
were observed. 
MDA-MB-231 
After 24 hours, incubation with 20 and 40µM haem led to significantly increased proliferation 
as did 48 hours incubation at 20µM. 50-150µM FeSO4 significantly up-regulated proliferation 
at all time points, as did 200µM at 24 and 72 hours (all p<0.05). 
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Figure 4.4 Changes in proliferation of benign and malignant mammary cells induced by 
iron and haem loading 
Proliferation of benign HB2 cells and malignant MCF7 and MDA-MB-231 cells was 
significantly increased after incubation with both haem and FeSO4 after varying amounts of 
time at varying concentrations. There were no inhibitory effects. Statistical significance is 
denoted by * (student t-test). Results are expressed graphically as mean percentage 
proliferation (relative to control) +/- 2SEM. 
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4.2.4 The Effects of Iron Chelation on Cell Viability 
The experiments described in sections 4.2.2 and 4.2.3 indicated the concentrations of FeSO4 
and haem likely to induce the most profound changes in cell behaviour. Subsequent assays 
utilised these concentrations. ICL670A (deferasirox) was used to assess the effect of iron 
chelation on cell viability. HB2, MCF7 and MDA-MB-231 cells were incubated for 24 hours 
with 100µM FeSO4 or 20µM haem, with and without 20µM ICL670A. Percentage viability 
was calculated relative to control cells normalised to 100%. Results are displayed in figure 4.4 
and table 4-1. 
HB2 
FeSO4 alone significantly increased HB2 cell viability with respect to control (p=0.038). This 
effect was reversed in the presence of ICL670A. No significant changes were observed in 
response to incubation with haem, with or without ICL670A. ICL670A alone also failed to 
provoke any significant change. 
MCF7 
100µM FeSO4 and 20µM haem significantly increased MCF7 viability over 24 hours 
(p<0.03). Introduction of ICL670A in addition to iron/haem abrogated this response and 
returned cellular viability to control levels. However p values did not indicate a significant 
difference between iron/haem alone and with ICL670A, implying incomplete resolution of the 
up-regulation in viability conferred by these reagents. ICL670A alone did not affect MCF7 
viability. 
MDA-MB-231 
The increases in viability conferred by FeSO4 and haem were maintained (p<0.04). 
Subsequent ICL670A-mediated restoration of viability to levels approximate to control 
represented a statistically significant change relative to FeSO4/haem alone (p<0.03), implying 
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complete resolution of this up-regulation in viability. In isolation ICL670A did not alter 
viability significantly. 
 
 
Figure 4.5 The effects of iron chelation on benign and malignant mammary cell viability 
Cells were incubated with 100µM FeSO4 and 20µM haem alone and in the presence of 20µM 
ICL670A, as well as 20µM ICL670A alone, for 24 hours. ICL670A proved capable of 
reversing the changes seen previously in response to FeSO4/haem, either wholly or partially, 
but had no significant effects on cell viability in isolation. * denotes statistical significance 
relative to control and # that relative to chelator-free medium with other additives still present 
(p<0.05, student t-test). Results are expressed graphically as mean percentage viability 
(relative to control) +/- 2SEM. 
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Cell Type 
HB2 MCF7 MDA-MB-231 
Control 100+/-2.8 100+/-1.5 100+/-2.7 
100µM Fe 120+/-5.1 109+/-2.7 119+/-2.6 
100µM Fe + 20µM ICL670A 108+/-3.0 102+/-3.4 100+/-1.8 
20µM Haem  99+/-2.5 108+/-1.7 116+/-1.6 
20µM Haem + 20µM ICL670A 98+/-5.0 87+/-9.0 101+/-1.2 
20µM ICL670A 98+/-1.4 100+/-5.1 91+/-2.4 
 
Table 4-1 The effects of iron chelation on benign and malignant mammary cell viability 
This table summarises the data in figure 4.4. Values displayed are mean percentage viability of 
cells following 24 hours incubation with the reagents shown relative to control. Results are 
expressed as mean percentage viability +/- 2SEM. Significant values (p<0.05) relative to 
control are highlighted in bold print. 
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4.2.5 The Effects of Iron Chelation on Cell Proliferation 
To assess the effect of iron chelation on cell proliferation, HB2, MCF7 and MDA-MB-231 
cells were incubated for 24 hours in the presence of experimental media and a BrdU assay 
performed. Cells were exposed to control medium and media containing either 100µM FeSO4 
or 20µM haem, both with and without 20µM ICL670A. Percentage proliferation in each arm 
was calculated relative to control cells normalised to 100%. Results are displayed in figure 4.5 
and table 4-2. 
HB2 
Incubation with FeSO4 and haem induced statistically significant increases in cell proliferation 
(p<0.04). Co-culture with ICL670A reversed these effects, with a significant fall in 
proliferation relative to media containing iron/haem alone (p<0.002). ICL670A in isolation 
also had a significantly inhibitory effect on HB2 proliferation relative to control (p=0.003). 
MCF7 
Adding ICL670A to FeSO4- and haem-loaded media reversed the previously documented up-
regulation in cell proliferation, although there was no statistically significant difference 
between the FeSO4/ICL670A population and cells incubated with FeSO4 alone (implying 
incomplete abrogation). ICL670A induced a significant fall in proliferation when added to 
haem-containing media as compared to haem alone, and to control (both p=0.003). ICL670A 
alone significantly inhibited proliferation of MCF7 cells (p<0.0005). 
MDA-MB-231 
FeSO4 and haem again led to significantly up-regulated proliferation (p<0.05). Adding 
ICL670A to these media induced significant falls in proliferation rates relative to both the 
stimulant-containing media and to control (p<0.03). ICL670A alone had no significant effect 
on proliferation relative to control media. 
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Figure 4.6 The effects of iron chelation on benign and malignant mammary cell 
proliferation 
HB2, MCF7 and MDA-MB-231 cells were incubated for 24 hours with either 100µM FeSO4 
or 20µM haem, with and without 20µM ICL670A. A further population was incubated with 
20µM ICL670A alone. The positive effects of FeSO4 and haem on cell proliferation were once 
again observed. ICL670A was capable of wholly or partially abrogating these effects in both 
benign and malignant cells and also had a significant inhibitory effect on un-stimulated HB2 
and MCF7 cells. * denotes statistical significance relative to control and # that relative to 
chelator-free medium with other additives still present (p<0.05, student t-test). Results are 
expressed graphically as mean percentage proliferation (relative to control) +/- 2SEM. 
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Cell Type 
HB2 MCF7 MDA-MB-231 
Control 100+/-8.8 100+/-3.5 100+/-1.1 
100µM Fe 116+/-7.2 120+/-4.6 121+/-5.0 
100µM Fe + 20µM ICL670A 87+/-7.3 107+/-6.1 103+/-6.1 
20µM Haem 118+/-7.0 120+/-8.8 120+/-8.3 
20µM Haem + 20µM ICL670A 68+/-12.3 76+/-9.6 94+/-8.0 
20µM ICL670A 70+/-9.7 47+/-6.8 107+/-8.5 
 
Table 4-2 The effects of iron chelation on benign and malignant mammary cell 
proliferation 
This table summarises the data in figure 4.5. Values displayed are mean percentage 
proliferation of cells following 24 hours incubation with the reagents shown relative to 
control. Results are expressed as mean percentage proliferation +/- 2SEM. Significant values 
(p<0.05) relative to control are highlighted in bold print. 
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4.2.6 The Effects of Iron and Haem Loading on Anchorage-Independent Growth 
The effects of 100µM FeSO4, 20µM haem and 20µM ICL670A on anchorage-independent 
growth were measured in MCF7 and MDA-MB-231 cells as described in section 2.2.5.3. HB2 
cells are incapable of forming colonies and were not subjected to this assay.  
MCF7 
FeSO4 did not induce a significant change in mean size or number of colonies formed relative 
to control agar. Haem had no effect on mean colony size but significantly increased numbers 
of colonies formed (p=0.032). 20µM ICL670A had profound effects on colony formation, 
reversing the haem-induced increase in colony numbers (p=0.002) and significantly inhibiting 
the size and number of colonies formed whether or not iron or haem were also present (all 
p<0.03). Results are shown in figure 4.6 and table 4-3. 
MDA-MB-231 
FeSO4 significantly up-regulated the mean number (p=0.013) and size (p=0.044) of colonies 
formed. These changes were reversed by ICL670A with a significant down-regulation of both 
size and number (both p=0.009) relative to control and to FeSO4 alone (both p<0.002). Haem 
significantly up-regulated mean colony size (p=0.0015); this effect was reversed by ICL670A 
(p=0.0008). In isolation ICL670A significantly down-regulated colony numbers relative to 
control (p=0.024) but had no significant effect on colony size. Results are displayed in figure 
4.6 and table 4-3. 
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Figure 4.7 The effects of FeSO4, haem and iron chelation on anchorage-independent 
growth of malignant mammary cells 
MCF7 and MDA-MB-231 cells were seeded in agar gels containing either 100µM FeSO4 or 
20µM haem, with and without 20µM ICL670A, and 20µM ICL670A alone. Colonies were 
counted and measured at 2 weeks. * denotes significance relative to control and # that relative 
to chelator-free medium with other additives still present (p<0.05, student t-test). Results are 
expressed as mean fold change in colony size/number relative to control +/- 2SEM.  
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Cell Type Agar Additives Mean Fold 
Change in Colony 
Number 
Mean Fold 
Change in Colony 
Size 
MCF7 100µM FeSO4 1.28+/-0.28 1.1+/-0.32 
100µM FeSO4 + 20µM 
ICL670A 
0.44+/-0.33 0.27+/-0.11 
20µM Haem 1.39+/-0.25 1.04+/-0.25 
20µM Haem + 20µM 
ICL670A 
0.67+/-0.14 0.4+/-0.07 
20µM ICL670A 0.39+/-0.14 0.29+/-0.13 
MDA-MB-231 100µM FeSO4 1.81+/-0.41 1.23+/-0.2 
100µM FeSO4 + 20µM 
ICL670A 
0.5+/-0.15 0.66+/-0.19 
20µM Haem 1.38+/-0.25 2.31+/-0.72 
20µM Haem + 20µM 
ICL670A 
0.38+/-0.31 0.82+/-0.34 
20µM ICL670A 0.38+/-0.36 0.75+/-0.22 
 
Table 4-3 Changes in colony formation after treatment with FeSO4, haem and ICL670A 
The table summarizes mean fold changes in colony size and number following incubation of 
cells in agar gels containing 100µM FeSO4 or 20µM haem, with and without 20µM ICL670A, 
and 20µM ICL670A alone. Results are expressed as mean fold change in size/number of 
colonies relative to control medium +/- 2SEM. Significant values (p<0.05) relative to control 
are highlighted in bold print. 
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4.2.7 The Effects of Iron on Cell Migration 
Scratch assays were used to evaluate the effects of FeSO4, haem and the chelator ICL670A on 
the ability of benign and malignant mammary cells to migrate across a wound created in a 
confluent cell monolayer. Each cell line was exposed to control medium and media containing 
either 100µM FeSO4 or 20µM haem, both with and without 20µM ICL670A.  
HB2 
There was no increase in migratory capacity following incubation with iron or haem. 
Incubating cells with ICL670A alone and in conjunction with FeSO4 led to a significant fall in 
rate of migration (both p<0.01). Results are displayed in figures 4.7 and 4.8 and table 4-2. 
MCF7 
FeSO4 (p=0.037) and haem (p=0.019) significantly up-regulated migration of MCF7 cells. 
This was reversed following addition of ICL670A to stimulant media, although this reversal 
was only significant relative to the stimulant medium alone in the case of FeSO4 (p=0.024). In 
isolation ICL670A had no significant effect on cell migration relative to control. Results are 
displayed in figures 4.7 and 4.8 and table 4-2. 
MDA-MB-231 
FeSO4 and haem demonstrated a significantly positive effect on cell migration (both p=0.049), 
although the subsequent down-regulation following addition of ICL670A failed to reach 
significance in either the FeSO4- or haem-loaded cells. ICL670A alone had no effect relative 
to control. Results are displayed in figures 4.7 and 4.8 and table 4-2. 
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Figure 4.8 The effects FeSO4, haem and iron chelation on migration of benign and 
malignant mammary cells 
Scratched monolayers of HB2, MCF7 and MDA-MB-231 cells were incubated for 20 hours 
with media containing 100µM FeSO4 or 20µM haem, with and without 20µM ICL670A. A 
further population was incubated with 20µM ICL670A alone. Results are expressed as mean 
distance migrated +/- 2SEM. * denotes statistical significance relative to control and # that 
relative to chelator-free medium with other additives still present (p<0.05, student t-test). 
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Figure 4.9 Rates of mammary cell migration in the presence of iron, haem and ICL670A 
HB2, MCF7 and MDA-MB-231 cells were incubated with 100µM FeSO4 or 20µM haem, with 
and without 20µM ICL670A. A further population was incubated with 20µM ICL670A alone. 
Photomicrographs were taken of wounds made in the cell monolayers as time progressed and 
distance travelled by cells across the wound measured for comparison with cells in control 
medium. Results are presented in table 4-2 and figure 4.7. 
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Cell Type Composition of Culture 
Medium  
Mean Distance Migrated (pixels) 
over 20 Hours 
HB2 Control 333.8+/-39.3 
100µM FeSO4 262.8+/-79.8 
100µM FeSO4 + 20µM ICL670A 237.5+/-21.8 
20µM Haem 316.8+/-59.6 
20µM Haem + 20µM ICL670A 367.2+/-22 
20µM ICL670A 200.8+/-32.6 
MCF7 Control 242.5+/-56.7 
100µM FeSO4 409.8+/-15.5 
100µM FeSO4 + 20µM ICL670A 269.5+/-68.9
 
20µM Haem 358.5+/-41.3 
20µM Haem + 20µM ICL670A 300.5+/-44.9 
20µM ICL670A 203.3+/-34.1 
MDA-MB-231 
 
 
 
Control 116.8+/-46.7 
100µM FeSO4 226.8+/-72.4 
100µM FeSO4 + 20µM ICL670A 184+/-13.9
 
20µM Haem 189+/-12.7 
20µM Haem + 20µM ICL670A 143.8+/-62.2 
20µM ICL670A 115.3+/-34 
 
Table 4-4 Changes in cell migration following treatment with FeSO4, haem and ICL670A 
Wound-healing assays were performed over a 20 hour period in the presence of combinations 
of FeSO4, haem and ICL670A as shown. Results are expressed as mean distance migrated +/- 
2SEM. Significant values (p<0.05) relative to control are highlighted in bold print. 
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4.2.8 The Effects of FeSO4, Haem and Iron Chelation on the Invasive Capacity of 
Breast Cells 
The effects of iron, haem and iron chelation on cellular invasion were assessed using a 
matrigel invasion assay. Each cell line was exposed to control medium and media containing 
either 100µM FeSO4 or 20µM haem, both with and without 20µM ICL670A.  
HB2  
No effect on invasive capacity of benign HB2 cells was seen with either FeSO4 or haem. 
Adding ICL670A to control and stimulant media had no significant effect. Results are 
displayed in figure 4.9 and table 4-5. 
MCF7 
FeSO4 (p=0.018) and haem (p=0.001) significantly increased the invasive capacity of MCF7 
cells. Co-culture with ICL670A reversed this change, causing a significant drop in invasive 
capability relative to cells incubated with FeSO4 (p=0.01) or haem (p<0.001) alone, although 
there was no significant difference relative to control cells. ICL670A alone had a significant 
negative effect on invasiveness of MCF7 cells relative to control (p=0.012). Results are 
displayed in figure 4.9 and table 4-5. 
MDA-MB-231 
Invasive capacity of MDA-MB-231 cells was significantly increased by adding FeSO4 
(p=0.004) or haem (p<0.001) to incubation medium. Adding ICL670A to stimulant media 
nullified this change, causing a significant fold decrease in percentage invasion of FeSO4 and 
haem loaded cells relative to both stimulated and control cells (all p<0.02). ICL670A alone 
significantly inhibited invasion relative to control (p=0.012). Results are displayed in figure 
4.9 and table 4-5. 
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Figure 4.10 The effects of FeSO4, haem and iron chelation on invasive capacity of benign 
and malignant mammary cells 
Cells were left in transwell plates for 24 hours in the presence of combinations of FeSO4, 
haem and ICL670A as shown. Percentage invasion through a matrigel layer was measured and 
results expressed as mean fold change relative to control +/- 2SEM. *denotes statistical 
significance relative to control and # that relative to chelator-free medium with other additives 
still present (p<0.05, student t-test). Results are summarized in table 4-5. 
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Cell Type Composition of Culture 
Medium  
Mean Fold Change in Percentage 
Invasion 
HB2 Control 1+/-0.33 
100µM FeSO4 0.89+/-0.28 
100µM FeSO4 + 20µM ICL670A 0.92+/-0.29
 
20µM Haem 1.04+/-0.35 
20µM Haem + 20µM ICL670A 0.81+/-0.17 
20µM ICL670A 0.69+/-0.2 
MCF7 Control 1+/-0.11 
100µM FeSO4 1.69+/-0.17 
100µM FeSO4 + 20µM ICL670A 1.24+/-0.06
 
20µM Haem 1.67+/-0.07 
20µM Haem + 20µM ICL670A 1.29+/-0.08 
20µM ICL670A 0.8+/-0.06 
MDA-MB-231 
 
 
 
Control 1+/-0.09 
100µM FeSO4 1.38+/-0.24 
100µM FeSO4 + 20µM ICL670A 0.9+/-0.1 
20µM Haem 1.47+/-0.09 
20µM Haem + 20µM ICL670A 0.8+/-0.09 
20µM ICL670A 0.71+/-0.09 
 
Table 4-5 Changes in cell invasion following treatment with iron, haem and ICL670A 
Invasion assays were performed over 24 hours in the presence of stimulant and chelating 
reagents as shown. Results are expressed as mean fold change relative to control +/- 2SEM. 
Significant values (p<0.05) relative to control are highlighted in bold print. 
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 100µM 
FeSO4 
100µM FeSO4 
+ 20µM 
ICL670A 
20µM 
Haem 
20µM Haem + 
20µM 
ICL670A 
20µM 
ICL670A 
HB2 Viability ↑ → → → → 
Proliferation ↑ → ↑ ↓ ↓ 
Colony Formation - - - - - 
Migration → ↓ → → ↓ 
Invasion → → → → → 
MCF7 Viability ↑ → ↑ → → 
Proliferation ↑ → ↑ ↓ ↓ 
Colony 
Formation 
Size → ↓ → ↓ ↓ 
No. → ↓ ↑ ↓ ↓ 
Migration ↑ → ↑ → → 
Invasion ↑ → ↑ → ↓ 
MDA-
MB-231 
Viability ↑ → ↑ → → 
Proliferation ↑ ↑ ↑ ↓ → 
Colony 
Formation 
Size ↑ ↓ ↑ → → 
No. ↑ ↓ → ↓ ↓ 
Migration ↑ → ↑ → → 
Invasion ↑ ↓ ↑ ↓ ↓ 
 
Table 4-6 A summary of the effects of iron, haem and ICL670A on cell phenotype 
This table provides an overview of the overall impact of iron, haem and ICL670A, alone and 
in combination, on various aspects of cellular phenotype. Benign HB2 and malignant MCF7 
and MDA-MB-231 cells were studied. The arrows denote significant up- (↑) or down-
regulation (↓), or no effect (→). HB2 cells were not subjected to a colony-forming assay.  
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4.3 The Effects of Exogenous Iron, Haem and Iron Chelators on 
the Iron Transport Mechanism in Vitro 
To determine the effects of modulating exogenous iron levels on benign and malignant 
mammary cell expression of the iron and haem transport proteins and their mRNA, HB2 cells 
were compared to the malignant MDA-MB-231 cell line.  
Cells were incubated for 24 hours in the presence of control medium or media containing 
100µM FeSO4 or 20µM hemin, both with and without 20µM ICL670A. Levels of the iron and 
haem transporters and their mRNA were evaluated following exposure. Results are reported 
throughout as expression of protein or mRNA under experimental conditions relative to that in 
control media which has been normalised to a level of 1. 
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4.3.1 Changes in Expression of Iron and Haem Transport Proteins in Response to Iron 
and Chelators 
4.3.1.1 Iron Import Proteins 
Expression of Dcytb was significantly reduced across all experimental media relative to 
control in HB2 cells (p<0.02 throughout). Although the introduction of ICL670A partially 
ameliorated this effect, levels did not return to normal. There was no significant change in 
expression of Dcytb in MDA-MB-231 cells upon introduction of either iron or haem. The 
presence of a chelator had a negative effect on Dcytb expression in the malignant line, both 
with and without iron or haem in the culture medium (p<0.0002 throughout). 
 
DMT1 expression levels were unchanged in both HB2 and MDA-MB-231 cells in the 
presence of either iron or haem. The mixture of iron and ICL670A induced a significant up-
regulation in DMT1 in both cell lines (both p<0.002). DMT1 was also up-regulated to a 
significant extent in the malignant line following culture with haem and ICL670A, and with 
ICL670A alone (both p<0.002).  
 
TfR1 levels were significantly up-regulated in the MDA-MB-231 cells following culture with 
ICL670A in the presence and absence of iron and haem (all p<0.009), but were unchanged by 
culturing with iron or haem alone. HB2 cells exhibited an appropriate down-regulation of 
TfR1 expression after culture with iron or haem (both p<0.004), which was eliminated by the 
addition of ICL670A.  
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Figure 4.11 Relative expression of the iron import proteins in benign and malignant 
breast cells following exposure to iron and chelators 
Protein expression of Dcytb (A), DMT1 (B) and TfR1 (C) was investigated following 
exposure of benign HB2 and malignant MDA-MB-231 mammary cells to culture media 
containing iron or haem with or without ICL670A, and ICL670A alone. Results are expressed 
as mean relative protein expression +/-2SEM. * denotes statistical significance relative to 
control (p<0.05, student t-test). 
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Cell Type Experimental 
Medium 
Relative Dcytb 
Expression  
Relative DMT1 
Expression  
Relative TfR1 
Expression  
HB2 Control 1+/-0.01 1+/-0.03 1+/-0.01 
100µM FeSO4 0.56+/-0.04 1.12+/-0.1 0.81+/-0.03 
100µM FeSO4 + 
20µM ICL670A 
0.69+/-0.09 1.42+/-0.04 1.02+/-0.03 
20µM Haem 0.35+/-0.02 1.05+/-0.04 0.75+/-0.02 
20µM Haem + 
20µM ICL670A 
0.56+/-0.06 0.83+/-0.2 1.02+/-0.05 
20µM ICL670A 0.4+/-0.03 0.88+/-0.08 1.14+/-0.03 
MDA-MB-231 Control 1+/-0.02 1+/-0.04 1+/-0.04 
100µM FeSO4 0.99+/-0.01 0.92+/-0.06 0.99+/-0.07 
100µM FeSO4 + 
20µM ICL670A 
0.67+/-0.02 1.28+/-0.05 1.12+/-0.03 
20µM Haem 0.95+/-0.03 1.05+/-0.02 0.96+/-0.05 
20µM Haem + 
20µM ICL670A 
0.61+/-0.03 1.52+/-0.08 1.24+/-0.04 
20µM ICL670A 0.56+/-0.03 1.24+/-0.02 1.18+/-0.05 
 
Table 4-7 Relative expression of the iron import proteins in benign and malignant breast 
cells following exposure to iron and chelators 
Protein expression of Dcytb, DMT1 and TfR1 was investigated following exposure of benign 
HB2 and malignant MDA-MB-231 mammary cells to culture media containing iron or haem 
with or without ICL670A, and ICL670A alone. Results are expressed as mean relative protein 
expression +/-2SEM. Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.1.2 Iron Export Proteins 
Expression of ferroportin was significantly increased in both benign HB2 and malignant 
MDA-MB-231 cells following culture with iron or haem, with and without ICL670A (all 
p<0.006). Neither cell type displayed any change in expression after culture with ICL670A 
alone.  
 
 
 
 
B  
 
Figure 4.12 Relative ferroportin expression in benign and malignant breast cells 
following exposure to iron and chelators 
Expression of ferroportin was investigated following exposure of benign HB2 and malignant 
MDA-MB-231 mammary cells to culture media containing iron or haem with or without 
ICL670A, and ICL670A alone. Results are expressed as mean relative protein expression +/-
2SEM. * denotes statistical significance relative to control (p<0.05, student t-test). 
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Cell Type Culture Medium Relative Ferroportin 
Expression 
HB2 Control 1+/-0.02 
100µM FeSO4 2.28+/-0.07 
100µM FeSO4 + 20µM 
ICL670A 
1.5+/-0.04 
20µM Haem 1.72+/-0.02 
20µM Haem + 20µM ICL670A 1.62+/-0.02 
20µM ICL670A 1.13+/-0.03 
MDA-MB-231 Control 1+/-0.02 
100µM FeSO4 1.52+/-0.04 
100µM FeSO4 + 20µM 
ICL670A 
1.31+/-0.03 
20µM Haem 1.49+/-0.02 
20µM Haem + 20µM ICL670A 1.32+/-0.01 
20µM ICL670A 0.92+/-0.04 
 
Table 4-8 Relative ferroportin expression in benign and malignant breast cells following 
exposure to iron and chelators 
Ferroportin expression was investigated following exposure of benign HB2 and malignant 
MDA-MB-231 mammary cells to culture media containing iron or haem with or without 
ICL670A, and ICL670A alone. Results are expressed as mean relative protein expression +/-
2SEM. Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.1.3 Hepcidin 
Hepcidin expression was significantly reduced in both cell populations following culture with 
iron or haem alone (all p<0.008). This down-regulation was eliminated by adding ICL670A to 
the culture medium in the case of iron-loading for both cell lines, and haem-loading for HB2. 
Reduced expression persisted in MDA-MB-231 cells cultured with haem, despite adding 
ICL670A. ICL670A alone stimulated up-regulation of hepcidin expression in the HB2 cells 
(p=0.0005) but had no significant effect on MDA-MB-231. See figure 4.9. 
 
Figure 4.13 Relative hepcidin expression in benign and malignant breast cells following 
exposure to iron and chelators 
Expression of hepcidin was investigated following exposure of benign HB2 and malignant 
MDA-MB-231 mammary cells to culture media containing iron or haem with or without 
ICL670A, and ICL670A alone. Results are expressed as mean relative protein expression +/-
2SEM. * denotes statistical significance relative to control (p<0.05, student t-test). 
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Cell Type Culture Medium Relative Hepcidin Expression 
HB2 Control 1+/-0.05 
100µM FeSO4 0.62+/-0.03 
100µM FeSO4 + 20µM ICL670A 1+/-0.02 
20µM Haem 0.74+/-0.01 
20µM Haem + 20µM ICL670A 1.08+/-0.04 
20µM ICL670A 1.35+/-0.05 
MDA-MB-231 Control 1+/-0.03 
100µM FeSO4 0.53+/-0.01 
100µM FeSO4 + 20µM ICL670A 0.96+/-0.02 
20µM Haem 0.49+/-0.02 
20µM Haem + 20µM ICL670A 0.94+/-0.02 
20µM ICL670A 1+/-0.04 
 
Table 4-9 Relative hepcidin expression in benign and malignant breast cells following 
exposure to iron and chelators 
Hepcidin expression was investigated following exposure of benign HB2 and malignant 
MDA-MB-231 mammary cells to culture media containing iron or haem with or without 
ICL670A, and ICL670A alone. Results are expressed as mean relative protein expression +/-
2SEM. Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.1.4 Iron Storage 
Ferritin expression was significantly elevated in MDA-MB-231 cells following incubation 
with iron or haem in isolation, and with iron even in the presence of ICL670A (all p<0.009). 
Expression was significantly lower after incubation with haem in the presence of ICL670A 
and with ICL670A alone (both p<0.03).  
Incubation with iron or haem alone stimulated up-regulation in ferritin expression in HB2 cells 
(both p<0.0003), although in both cases this was abrogated by the introduction of ICL670A. 
ICL670A alone again elicited a significant reduction in expressed ferritin levels (p=0.002). 
 
Figure 4.14 Relative expression of ferritin in benign and malignant cells following 
exposure to iron and chelators 
Protein expression of ferritin was investigated following exposure of benign HB2 and 
malignant MDA-MB-231 mammary cells to culture media containing iron or haem with or 
without ICL670A, and ICL670A alone. Results are expressed as mean relative protein 
expression +/-2SEM. * denotes statistical significance relative to control (p<0.05, student t-
test). 
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Cell Type Culture Medium Relative Ferritin Expression 
HB2 Control 1+/-0.02 
100µM FeSO4 1.58+/-0.05 
100µM FeSO4 + 20µM ICL670A 1.03+/-0.06 
20µM Haem 1.26+/-0.04 
20µM Haem + 20µM ICL670A 0.97+/-0.01 
20µM ICL670A 0.88+/-0.02 
MDA-MB-231 Control 1+/-0.07 
100µM FeSO4 13.51+/-2.29 
100µM FeSO4 + 20µM ICL670A 2+/-0.15 
20µM Haem 2.93+/-0.13 
20µM Haem + 20µM ICL670A 0.58+/-0.17 
20µM ICL670A 0.47+/-0.08 
 
Table 4-10 Relative ferritin expression in benign and malignant breast cells following 
exposure to iron and chelators 
Ferritin expression was investigated following exposure of benign HB2 and malignant MDA-
MB-231 mammary cells to culture media containing iron or haem with or without ICL670A, 
and ICL670A alone. Results are expressed as mean relative protein expression +/-2SEM. 
Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.1.5 Haem Import Proteins 
Expression of HCP1 was unchanged in both the benign and malignant lines following 
incubation with iron or haem alone. Malignant MDA-MB-231 cells significantly increased 
expression of HCP1 when the chelating agent was introduced alongside iron/haem (both 
p<0.02), although there was no response in the presence of a chelator in isolation. Conversely, 
HB2 cells showed no change in HCP1 expression when ICL670A was added to the iron/haem 
containing media, although levels increased significantly when ICL670A was introduced as a 
solitary reagent (p=0.01). 
 
Figure 4.15 Relative expression of HCP1 in benign and malignant cells following 
exposure to iron and chelators 
Protein expression of HCP1 was investigated after exposure of benign HB2 and malignant 
MDA-MB-231 mammary cells to culture media containing iron or haem with or without 
ICL670A, and ICL670A alone. Results are expressed as mean relative protein expression +/-
2SEM. * denotes statistical significance relative to control (p<0.05, student t-test). 
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Cell Type Culture Medium Relative HCP1 Expression 
HB2 Control 1+/-0.03 
100µM FeSO4 1.02+/-0.06 
100µM FeSO4 + 20µM ICL670A 1.03+/-0.04 
20µM Haem 0.91+/-0.06 
20µM Haem + 20µM ICL670A 0.97+/-0.03 
20µM ICL670A 1.41+/-0.11 
MDA-MB-231 Control 1+/-0.03 
100µM FeSO4 0.98+/-0.02 
100µM FeSO4 + 20µM ICL670A 1.36+/-0.11 
20µM Haem 0.91+/-0.06 
20µM Haem + 20µM ICL670A 1.38+/-0.08 
20µM ICL670A 0.93+/-0.08 
 
Table 4-11 Relative HCP1 expression in benign and malignant breast cells following 
exposure to iron and chelators 
HCP1 expression was investigated following exposure of benign HB2 and malignant MDA-
MB-231 mammary cells to culture media containing iron or haem with or without ICL670A, 
and ICL670A alone. Results are expressed as mean relative protein expression +/-2SEM. 
Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.1.6 Haem Export Proteins 
Iron and haem both induced benign HB2 cells to up-regulate expression of FLVCR when 
added to standard culture medium (both p<0.002). Expression returned to normal when 
ICL670A was also introduced. ICL670A alone had no effect. 
Malignant MDA-MB-231 cells demonstrated increased FLVCR expression in response to the 
addition of haem (p=0.0004), but no other significant changes. 
 
 
Figure 4.16 Relative expression of FLVCR in benign and malignant cells following 
exposure to iron and chelators 
Protein expression of FLVCR was investigated after exposure of benign HB2 and malignant 
MDA-MB-231 mammary cells to culture media containing iron or haem with or without 
ICL670A, and ICL670A alone. Results are expressed as mean relative protein expression +/-
2SEM. * denotes statistical significance relative to control (p<0.05, student t-test). 
169 
 
Cell Type Culture Medium Relative FLVCR Expression 
HB2 Control 1+/-0.07 
100µM FeSO4 2.17+/-0.16 
100µM FeSO4 + 20µM ICL670A 1.09+/-0.04 
20µM Haem 2.53+/-0.16 
20µM Haem + 20µM ICL670A 0.89+/-0.17 
20µM ICL670A 1.08+/-0.05 
MDA-MB-231 Control 1+/-0.03 
100µM FeSO4 1.04+/-0.03 
100µM FeSO4 + 20µM ICL670A 1.03+/-0.02 
20µM Haem 1.23+/-0.03 
20µM Haem + 20µM ICL670A 0.98+/-0.03 
20µM ICL670A 1.01+/-0.05 
 
Table 4-12 Relative FLVCR expression in benign and malignant breast cells following 
exposure to iron and chelators 
FLVCR expression was investigated following exposure of benign HB2 and malignant MDA-
MB-231 mammary cells to culture media containing iron or haem with or without ICL670A, 
and ICL670A alone. Results are expressed as mean relative protein expression +/-2SEM. 
Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.2 Changes in Expression of Iron and Haem Transport Protein mRNA in Response 
to Iron and Chelators 
4.3.2.1 Iron Import Proteins 
HB2 cells demonstrated a significant down-regulation of Dcytb mRNA in response to excess 
extracellular iron or haem (both p<0.03). The addition of ICL670A reversed the observed 
changes. ICL670A alone appeared to result in reduced expression (p=0.003). MDA-MB-231 
cells exhibited no significant change when iron was added to culture medium. Inclusion of 
haem prompted significantly increased expression of Dcytb mRNA (p=0.045). ICL670A had 
no significant effect on Dcytb mRNA expression, whether alone or in combination with iron 
or haem. 
 
Neither HB2 nor MDA-MB-231 cells demonstrated a change in DMT1 mRNA levels after 
incubation with iron or haem in isolation, although both displayed significantly up-regulated 
expression when ICL670A was also present (all p<0.04). The malignant cells demonstrated 
similar behaviour following incubation with ICL670A alone (p=0.0004), although this pattern 
was not observed for HB2 cells. 
 
TfR1 mRNA expression was significantly down-regulated by HB2 cells incubated with haem 
(p=0.001), but appeared unchanged with iron. Adding ICL670A returned expression to 
normal. ICL670A resulted in significantly up-regulated expression of TfR1 in the benign cells 
(p=0.035). MDA-MB-231 cells did not modify expression of TfR1 mRNA in response to 
either iron or haem, but significantly up-regulated expression in response to the presence of 
the chelator, whether in isolation or in conjunction with iron/haem (all p<0.05). 
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Figure 4.17 Relative expression of iron import protein mRNA in benign and malignant 
breast cells following exposure to iron and chelators 
Expression of mRNA coding for Dcytb (A), DMT1 (B) and TfR1 (C) was investigated 
following exposure of benign HB2 and malignant MDA-MB-231 mammary cells to culture 
media containing iron or haem with or without ICL670A, and ICL670A alone. Results are 
expressed as mean relative mRNA expression +/-2SEM. * denotes statistical significance 
relative to control (p<0.05, student t-test). 
  
173 
 
Cell Type Experimental 
Medium 
Relative Dcytb 
mRNA 
Expression  
Relative DMT1 
mRNA 
Expression  
Relative TfR1 
mRNA 
Expression  
HB2 Control 1+/-0.12 1+/-0.28 1+/-0.1 
100µM FeSO4 0.34+/-0.28 0.76+/-0.08 0.59+/-0.25 
100µM FeSO4 + 
20µM ICL670A 
0.89+/-0.37 1.99+/-0.71 1.02+/-0.43 
20µM Haem 0.41+/-0.25 0.85+/-0.27 0.45+/-0.09 
20µM Haem + 
20µM ICL670A 
0.67+/-0.4 1.38+/-0.17 1.27+/-0.37 
20µM ICL670A 0.4+/-0.14 1.95+/-0.91 2.52+/-0.61 
MDA-MB-231 Control 1+/-0.45 1+/-0.61 1+/-0.14 
100µM FeSO4 1.42+/-0.21 1.26+/-0.09 1.25+/-0.26 
100µM FeSO4 + 
20µM ICL670A 
3.21+/-1.27 5.01+/-1.92 1.93+/-0.42 
20µM Haem 1.95+/-0.43 1.73+/-0.3 1.19+/-0.03 
20µM Haem + 
20µM ICL670A 
3.33+/-1.74 3.16+/-1.17 2.33+/-0.65 
20µM ICL670A 2.87+/-1.42 5.15+/-0.81 2.32+/-0.47 
 
Table 4-13 Relative expression of iron import protein mRNA in benign and malignant 
breast cells following exposure to iron and chelators 
Expression of mRNA coding for Dcytb, DMT1 and TfR1 was investigated following exposure 
of benign HB2 and malignant MDA-MB-231 mammary cells to culture media containing iron 
or haem with or without ICL670A, and ICL670A alone. Results are expressed as mean 
relative mRNA expression +/-2SEM. Statistically significant results (p<0.05) are highlighted 
in bold. 
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4.3.2.2 Iron Export Proteins 
Expression of ferroportin mRNA was significantly up-regulated in MDA-MB-231 cells 
incubated with iron alone, and in the same cells following incubation with haem and ICL670A 
simultaneously (both p<0.02). Neither cell line demonstrated a significant response to any of 
the other experimental media. 
 
Hephaestin mRNA was significantly over-expressed in benign HB2 cells incubated with either 
iron or haem alone (both p<0.04). Addition of a chelator abrogated this response, returning 
levels to normal. MDA-MB-231 cells did not modulate expression of hephaestin mRNA 
following incubation with any of the experimental media. 
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Figure 4.18 Relative expression of iron export protein mRNA in benign and malignant 
breast cells following exposure to iron and chelators 
Expression of mRNA coding for ferroportin (A) and hephaestin (B) was investigated 
following exposure of benign HB2 and malignant MDA-MB-231 mammary cells to culture 
media containing iron or haem with or without ICL670A, and ICL670A alone. Results are 
expressed as mean relative mRNA expression +/-2SEM. * denotes statistical significance 
relative to control (p<0.05, student t-test).  
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Cell Type Experimental Medium Relative ferroportin 
mRNA Expression 
Relative hephaestin 
mRNA Expression 
HB2 Control 1+/-0.43 1+/-0.25 
100µM FeSO4 1.43+/-0.09 3.95+/-0.45 
100µM FeSO4 + 20µM 
ICL670A 
1.11+/-0.33 1.44+/-0.25 
20µM Haem 1.34+/-0.34 3.21+/-0.94 
20µM Haem + 20µM 
ICL670A 
1.1+/-0.31 1.68+/-1.09 
20µM ICL670A 1.27+/-0.53 1.01+/-0.24 
MDA-MB-231 Control 1+/-0.34 1+/-0.53 
100µM FeSO4 2.6+/-0.59 0.95+/-0.52 
100µM FeSO4 + 20µM 
ICL670A 
1.6+/-0.31 0.43+/-0.17 
20µM Haem 2.3+/-0.77 0.71+/-0.31 
20µM Haem + 20µM 
ICL670A 
1.96+/-0.19 0.54+/-0.45 
20µM ICL670A 1.13+/-0.07 0.2+/-0.91 
 
Table 4-14 Relative expression of iron export protein mRNA in benign and malignant 
breast cells following exposure to iron and chelators  
Expression of mRNA coding for ferroportin and hephaestin was investigated following 
exposure of benign HB2 and malignant MDA-MB-231 mammary cells to culture media 
containing iron or haem with or without ICL670A, and ICL670A alone. Results are expressed 
as mean relative mRNA expression +/-2SEM. Statistically significant results (p<0.05) are 
highlighted in bold.  
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4.3.2.3 Hepcidin 
Both HB2 and MDA-MB-231 cells exhibited reduced expression of hepcidin mRNA after 
incubation with either iron or haem alone (all p<0.03). Addition of ICL670A reversed the 
change in both cases. HB2 cells also displayed over-expression of hepcidin mRNA following 
incubation with ICL670A alone (p=0.008). 
 
 
Figure 4.19 Relative expression of hepcidin mRNA in benign and malignant breast cells 
following exposure to iron and chelators 
Expression of mRNA coding for hepcidin was investigated following exposure of benign HB2 
and malignant MDA-MB-231 mammary cells to culture media containing iron or haem with 
or without ICL670A, and ICL670A alone. Results are expressed as mean relative mRNA 
expression +/-2SEM. * denotes statistical significance relative to control (p<0.05, student t-
test). 
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Cell Type Culture Medium Relative Hepcidin mRNA 
Expression 
HB2 Control 1+/-0.16 
100µM FeSO4 0.35+/-0.07 
100µM FeSO4 + 20µM ICL670A 1+/-0.16 
20µM Haem 0.65+/-0.13 
20µM Haem + 20µM ICL670A 0.95+/-0.29 
20µM ICL670A 1.81+/-0.24 
MDA-MB-231 Control 1+/-0.18 
100µM FeSO4 0.62+/-0.1 
100µM FeSO4 + 20µM ICL670A 0.84+/-0.25 
20µM Haem 0.37+/-0.12 
20µM Haem + 20µM ICL670A 0.71+/-0.27 
20µM ICL670A 1.05+/-0.12 
 
Table 4-15 Relative expression of hepcidin mRNA in benign and malignant breast cells 
following exposure to iron and chelators 
Expression of mRNA coding for hepcidin was investigated following exposure of benign HB2 
and malignant MDA-MB-231 mammary cells to culture media containing iron or haem with 
or without ICL670A, and ICL670A alone. Results are expressed as mean relative mRNA 
expression +/-2SEM. Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.2.4 Iron Storage 
Ferritin mRNA levels were significantly increased in MDA-MB-231 cells exposed to iron or 
haem in isolation and in conjunction with ICL670A (all p<0.02). ICL670A alone had no 
effect. HB2 cells exhibited significantly increased ferritin mRNA expression after incubation 
with haem and ICL670A in combination (p=0.018), but were unaffected by any other 
combination of reagents. 
 
Figure 4.20 Relative expression of ferritin mRNA in benign and malignant breast cells 
following exposure to iron and chelators 
Expression of mRNA coding for ferritin was investigated following exposure of benign HB2 
and malignant MDA-MB-231 mammary cells to culture media containing iron or haem with 
or without ICL670A, and ICL670A alone. Results are expressed as mean relative mRNA 
expression +/-2SEM. * denotes statistical significance relative to control (p<0.05, student t-
test). 
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Cell Type Culture Medium Relative Ferritin mRNA 
Expression 
HB2 Control 1+/-0.66 
100µM FeSO4 3.22+/-1.47 
100µM FeSO4 + 20µM ICL670A 2.3+/-0.56 
20µM Haem 2.68+/-1.58 
20µM Haem + 20µM ICL670A 2.89+/-0.66 
20µM ICL670A 0.92+/-0.59 
MDA-MB-231 Control 1+/-0.13 
100µM FeSO4 11.43+/-2.78 
100µM FeSO4 + 20µM ICL670A 9.02+/-1.25 
20µM Haem 9+/-1.27 
20µM Haem + 20µM ICL670A 8.03+/-1.27 
20µM ICL670A 1.19+/-0.13 
 
Table 4-16 Relative expression of ferritin mRNA in benign and malignant breast cells 
following exposure to iron and chelators 
Expression of mRNA coding for ferritin was investigated following exposure of benign HB2 
and malignant MDA-MB-231 mammary cells to culture media containing iron or haem with 
or without ICL670A, and ICL670A alone. Results are expressed as mean relative mRNA 
expression +/-2SEM. Statistically significant results (p<0.05) are highlighted in bold. 
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4.3.2.5 Haem Import Proteins 
Neither HB2 cells nor MDA-MB-231 moderated expression of HCP1 mRNA in response to 
incubation with either iron or haem. Adding a chelator to iron/haem in the culture medium 
induced significant up-regulation in MDA-MB-231 cells (both p<0.02); expression was once 
again unaltered in HB2 cells. ICL670A in isolation induced significantly higher levels of 
HCP1 mRNA in HB2 cells (p=0.005) but not in the MDA-MB-231 line.  
 
Incubation with iron alone did not affect LRP1 mRNA expression in either cell line. Adding 
ICL670A to the iron resulted in significantly higher levels of LRP1 mRNA in MDA-MB-231 
cells (p=0.0002) but did not influence the HB2 line. Haem in isolation caused LRP1 mRNA 
expression to be significantly inhibited in both cell lines (both p<0.02); addition of ICL670A 
restored levels to normal in both cases. ICL670A alone stimulated significant up-regulation of 
LRP1 mRNA expression in both cell lines (both p<0.05). 
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Figure 4.21 Relative expression of haem import protein mRNA in benign and malignant 
breast cells following exposure to iron and chelators 
Expression of mRNA coding for HCP1 (A) and LRP1 (B) was investigated following 
exposure of benign HB2 and malignant MDA-MB-231 mammary cells to culture media 
containing iron or haem with or without ICL670A, and ICL670A alone. Results are expressed 
as mean relative mRNA expression +/-2SEM. * denotes statistical significance relative to 
control (p<0.05, student t-test). 
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Cell Type Experimental Medium Relative HCP1 mRNA 
Expression 
Relative LRP 
mRNA Expression 
HB2 Control 1+/-0.38 1+/-0.17 
100µM FeSO4 1.19+/-0.13 0.78+/-0.28 
100µM FeSO4 + 20µM 
ICL670A 
2.14+/-0.65 1.71+/-0.63 
20µM Haem 0.9+/-0.12 0.5+/-0.18 
20µM Haem + 20µM 
ICL670A 
1.64+/-0.27 1.13+/-0.4 
20µM ICL670A 3.05+/-0.52 1.78+/-0.4 
MDA-MB-231 Control 1+/-0.07 1+/-0.2 
100µM FeSO4 1.2+/-0.13 1.05+/-0.09 
100µM FeSO4 + 20µM 
ICL670A 
4.38+/-0.79 3.28+/-0.12 
20µM Haem 1.97+/-0.89 0.36+/-0.16 
20µM Haem + 20µM 
ICL670A 
3.62+/-0.66 3.37+/-1.5 
20µM ICL670A 2.66+/-1.04 5.24+/-0.85 
 
Table 4-17 Relative expression of HCP1 and LRP mRNA in benign and malignant breast 
cells following exposure to iron and chelators  
Expression of mRNA coding for HCP1 and LRP was investigated following exposure of 
benign HB2 and malignant MDA-MB-231 mammary cells to culture media containing iron or 
haem with or without ICL670A, and ICL670A alone. Results are expressed as mean relative 
mRNA expression +/-2SEM. Statistically significant results (p<0.05) are highlighted in bold.  
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4.3.2.6 Haem Export Proteins 
Expression of FLVCR mRNA was significantly inhibited in HB2 cells following incubation 
with either iron or haem (both p<0.02). Adding ICL670A to these culture media restored 
expression to normal levels. ICL670A alone had no effect on FLVCR mRNA expression in 
HB2 cells. MDA-MB-231 cells did not modulate their expression of FLVCR mRNA when 
exposed to either iron or haem, although adding ICL670A to the haem did induce significant 
down-regulation, as did ICL670A alone (both p<0.02).  
 
BCRP mRNA expression was significantly increased in HB2 cells following incubation with 
iron (p=0.016), but not haem. Adding ICL670A to the iron led to significant down-regulation 
in expression (p=0.008). Incubation with ICL670A alone also appeared to significantly 
increase BCRP mRNA levels in the benign cells (p=.021). MDA-MB-231 cells demonstrated 
a significant inhibition of BCRP mRNA levels after exposure to iron and ICL670A in 
combination (p=0.034). No other experimental media stimulated any change in expression. 
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Figure 4.22 Relative expression of haem export protein mRNA in benign and malignant 
breast cells following exposure to iron and chelators 
Expression of mRNA coding for FLVCR (A) and BCRP (B) was investigated following 
exposure of benign HB2 and malignant MDA-MB-231 mammary cells to culture media 
containing iron or haem with or without ICL670A, and ICL670A alone. Results are expressed 
as mean relative mRNA expression +/-2SEM. * denotes statistical significance relative to 
control (p<0.05, student t-test). 
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Cell Type Experimental 
Medium 
Relative FLVCR 
mRNA Expression 
Relative BCRP 
mRNA Expression 
HB2 Control 1+/-0.19 1+/-0.0 
100µM FeSO4 1.76+/-0.32 1.49+/-0.13 
100µM FeSO4 + 
20µM ICL670A 
0.76+/-0.13 0.73+/-0.05 
20µM Haem 1.89+/-0.26 2.34+/-0.67 
20µM Haem + 20µM 
ICL670A 
0.84+/-0.12 1.62+/-0.39 
20µM ICL670A 1.2+/-0.15 2.03+/-0.31 
MDA-MB-231 Control 1+/-0.16 1+/-0.38 
100µM FeSO4 0.93+/-0.21 1.08+/-0.35 
100µM FeSO4 + 
20µM ICL670A 
1.24+/-0.17 0.05+/-0.01 
20µM Haem 2.18+/-0.94 1.01+/-0.08 
20µM Haem + 20µM 
ICL670A 
0.62+/-0.16 1.19+/-0.09 
20µM ICL670A 0.26+/-0.11 0.76+/-0.33 
 
Table 4-18 Relative expression of FLVCR and BCRP mRNA in benign and malignant 
breast cells following exposure to iron and chelators  
Expression of mRNA coding for FLVCR and BCRP was investigated following exposure of 
benign HB2 and malignant MDA-MB-231 mammary cells to culture media containing iron or 
haem with or without ICL670A, and ICL670A alone. Results are expressed as mean relative 
mRNA expression +/-2SEM. Statistically significant results (p<0.05) are highlighted in bold.  
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4.3.2.7 Iron Regulatory Proteins 
Both iron and haem significantly inhibited expression of IRP1 mRNA in HB2 cells (both 
p<0.03). ICL670A significantly increased IRP1 mRNA expression in HB2 cells with and 
without haem (both p<0.02). ICL670A in isolation led to significant up-regulation of IRP1 
mRNA in MDA-MB-231 cells (p=0.005). 
 
IRP2 expression was also significantly repressed in HB2 cells incubated with either iron or 
haem (both p<0.04). Haem and ICL670A in co-culture significantly increased IRP2 mRNA 
expression in MDA-MB-231 cells (p=0.0008). ICL670A alone significantly increased IRP2 
mRNA expression in both HB2 and MDA-MB-231 cells (both p<0.03). 
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Figure 4.23 Relative expression of iron regulatory protein mRNA in benign and 
malignant breast cells following exposure to iron and chelators 
Expression of mRNA coding for IRP1 (A) and IRP2 (B) was investigated following exposure 
of benign HB2 and malignant MDA-MB-231 mammary cells to culture media containing iron 
or haem with or without ICL670A, and ICL670A alone. Results are expressed as mean 
relative mRNA expression +/-2SEM. * denotes statistical significance relative to control 
(p<0.05, student t-test). 
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Cell Type Experimental Medium Relative IRP1 
mRNA 
Expression 
Relative IRP2 
mRNA Expression 
HB2 Control 1+/-0.32 1+/-0.3 
100µM FeSO4 0.19+/-0.09 0.31+/-0.05 
100µM FeSO4 + 20µM 
ICL670A 
1.41+/-0.27 0.53+/-0.1 
20µM Haem 0.19+/-0.1 0.34+/-0.11 
20µM Haem + 20µM 
ICL670A 
1.84+/-0.27 1.51+/-0.27 
20µM ICL670A 3.07+/-0.68 2.11+/-0.14 
MDA-MB-231 Control 1+/-0.12 1+/-0.24 
100µM FeSO4 1.23+/-0.24 0.94+/-0.03 
100µM FeSO4 + 20µM 
ICL670A 
1.73+/-0.41 3.37+/-1.69 
20µM Haem 1.36+/-0.57 1.24+/-0.49 
20µM Haem + 20µM 
ICL670A 
1.79+/-0.51 3.05+/-0.33 
20µM ICL670A 2.88+/-0.35 2.94+/-0.76 
 
Table 4-19 Relative expression of IRP1 and IRP2 mRNA in benign and malignant breast 
cells following exposure to iron and chelators  
Expression of mRNA coding for IRP1 and IRP2 was investigated following exposure of 
benign HB2 and malignant MDA-MB-231 mammary cells to culture media containing iron or 
haem with or without ICL670A, and ICL670A alone. Results are expressed as mean relative 
mRNA expression +/-2SEM. Statistically significant results (p<0.05) are highlighted in bold. 
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 100µM 
FeSO4 
100µM FeSO4 + 
20µM ICL670A 
20µM 
Haem 
20µM Haem + 
20µM ICL670A 
20µM 
ICL670A 
HB2 Dcytb Protein ↓ ↓ ↓ ↓ ↓ 
mRNA ↓ → ↓ → ↓ 
DMT1 Protein → ↑ → → → 
mRNA → ↑ → ↑ → 
TfR1 Protein ↓ → ↓ → ↑ 
mRNA → → ↓ → ↑ 
MDA-
MB-231 
Dcytb Protein → ↓ → ↓ ↓ 
mRNA → → ↑ → → 
DMT1 Protein → ↑ → ↑ ↑ 
mRNA → ↑ → ↑ ↑ 
TfR1 Protein → ↑ → ↑ ↑ 
mRNA → ↑ → ↑ ↑ 
 
Table 4-20 Summary of changes in expression of the iron import proteins and their 
mRNA in response to iron, haem and ICL670A 
Benign HB2 and malignant MDA-MB-231 cells were incubated with iron, haem and ICL670A 
alone and in combination. Levels of the Dcytb, DMT1 and TfR1 and their mRNA were then 
assessed. The arrows denote significant up- (↑) or down-regulation (↓), or no effect (→). 
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 100µM 
FeSO4 
100µM FeSO4 + 
20µM ICL670A 
20µM 
Haem 
20µM Haem + 
20µM ICL670A 
20µM 
ICL670A 
HB2 FPN Protein ↑ ↑ ↑ ↑ → 
mRNA → → → → → 
Heph Protein - - - - - 
mRNA ↑ → ↑ → → 
Hepcidin Protein ↓ → ↓ → ↑ 
mRNA ↓ → ↓ → ↑ 
MDA-
MB-231 
FPN Protein ↑ ↑ ↑ ↑ → 
mRNA ↑ → → ↑ → 
Heph Protein - - - - - 
mRNA → → → → → 
Hepcidin Protein ↓ → ↓ ↓ → 
mRNA ↓ → ↓ → → 
 
Table 4-21 Summary of changes in expression of hepcidin and the iron export proteins 
and their mRNA in response to iron, haem and ICL670A  
Benign HB2 and malignant MDA-MB-231 cells were incubated with iron, haem and ICL670A 
alone and in combination. Levels of ferroportin and hepcidin were then assessed. Levels of 
hephaestin were undetectable on Western blotting with the available antibodies. mRNA for all 
3 proteins was assayed. The arrows denote significant up- (↑) or down-regulation (↓), or no 
effect (→). 
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 100µM 
FeSO4 
100µM FeSO4 + 
20µM ICL670A 
20µM 
Haem 
20µM Haem + 
20µM ICL670A 
20µM 
ICL670A 
HB2 
 
Protein ↑ → ↑ → ↓ 
mRNA → → → ↑ → 
MDA-MB-231 Protein ↑ ↑ ↑ ↓ ↓ 
mRNA ↑ ↑ ↑ ↑ → 
 
Table 4-22 Summary of changes in expression of ferritin and its mRNA in response to 
iron, haem and ICL670A  
Benign HB2 and malignant MDA-MB-231 cells were incubated with iron, haem and ICL670A 
alone and in combination. Levels of ferritin and its mRNA were then assessed. The arrows 
denote significant up- (↑) or down-regulation (↓), or no effect (→). 
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 100µM 
FeSO4 
100µM FeSO4 + 
20µM ICL670A 
20µM 
Haem 
20µM Haem + 
20µM ICL670A 
20µM 
ICL670A 
HB2 HCP1 Protein → → → → ↑ 
mRNA → → → → ↑ 
LRP1 Protein - - - - - 
mRNA → → ↓ → ↑ 
MDA-
MB-231 
HCP1 Protein → ↑ → ↑ → 
mRNA → ↑ → ↑ → 
LRP1 Protein - - - - - 
mRNA → ↑ ↓ → ↑ 
 
Table 4-23 Summary of changes in expression of the haem import proteins and their 
mRNA in response to iron, haem and ICL670A  
Benign HB2 and malignant MDA-MB-231 cells were incubated with iron, haem and ICL670A 
alone and in combination. Levels of HCP1 were then assessed. LRP1 levels were undetectable 
on Western blotting with the antibodies available to us. mRNA for both proteins was assayed. 
The arrows denote significant up- (↑) or down-regulation (↓), or no effect (→). 
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 100µM 
FeSO4 
100µM FeSO4 + 
20µM ICL670A 
20µM 
Haem 
20µM Haem + 
20µM ICL670A 
20µM 
ICL670A 
HB2 FLVCR Protein ↑ → ↑ → → 
mRNA ↑ → ↑ → → 
BCRP Protein - - - - - 
mRNA ↑ ↓ → → ↑ 
MDA-
MB-231 
FLVCR Protein → → ↑ → → 
mRNA → → → ↓ ↓ 
BCRP Protein - - - - - 
mRNA → ↓ → → → 
 
Figure 4.24 Summary of changes in expression of the haem export proteins and their 
mRNA in response to iron, haem and ICL670A  
Benign HB2 and malignant MDA-MB-231 cells were incubated with iron, haem and ICL670A 
alone and in combination. Levels of FLVCR were then assessed. BCRP levels were 
undetectable on Western blotting with the antibodies available to us. mRNA for both proteins 
was assayed. The arrows denote significant up- (↑) or down-regulation (↓), or no effect (→). 
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 100µM 
FeSO4 
100µM FeSO4 + 
20µM ICL670A 
20µM 
Haem 
20µM Haem + 
20µM ICL670A 
20µM 
ICL670A 
HB2 IRP1 mRNA ↓ → ↓ ↑ ↑ 
IRP2 mRNA ↓ → ↓ → ↑ 
MDA-
MB-231 
IRP1 mRNA → → → → ↑ 
IRP2 mRNA → → → ↑ ↑ 
 
Figure 4.25 Summary of changes in expression of the iron regulatory protein mRNA in 
response to iron, haem and ICL670A  
Benign HB2 and malignant MDA-MB-231 cells were incubated with iron, haem and ICL670A 
alone and in combination. Western blotting did not reveal any detectable IRP1 or IRP2 using 
the antibodies available to us. mRNA for both proteins was assayed. The arrows denote 
significant up- (↑) or down-regulation (↓), or no effect (→).  
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4.4 Summary and Discussion 
Iron and haem have been implicated as potential carcinogens in the development of a number 
of epithelial cancers, including breast.  
Utilising one benign and two malignant mammary cell lines, it was possible to explore 
differences in their respective ability to sequester iron and haem, and to investigate whether 
differential absorption produced quantifiable changes in cell phenotype resulting in more 
aggressive patterns of behaviour.  
Initial incubation with FeSO4 and haem at various concentrations demonstrated that both 
benign and malignant cells were able to import non-haem iron from extracellular solution. 
However, only the malignant cell lines MCF7 and MDA-MB-231 exhibited increased 
concentrations of iron following incubation with haem. Further, the more avid importer of 
haem iron was the more aggressive MDA-MB-231 line. These results validate the hypothesis 
that more aggressive breast cancer phenotypes display greater capability to import iron, 
including haem. This is a novel finding. 
Measuring cell viability demonstrated positive effects due to FeSO4 on both benign HB2 cells 
and the two malignant lines. This is not surprising, given that iron is a vital component of 
many cellular processes. Haem had no positive influence on HB2 viability and was in fact 
detrimental at higher concentrations. The more indolent of the malignant lines, MCF7, 
responded positively to low concentrations of haem, but also suffered a loss of viability as 
concentration increased. The aggressive MDA-MB-231 cells displayed increased viability 
across the range of haem concentrations with which they were incubated. This may be because 
their higher turnover allows malignant cells to utilise excess iron more quickly than benign 
cells, generating less of a labile iron pool and therefore fewer of the harmful free radicals and 
reactive oxygen species which are detrimental to cell health.  
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Although these data are suggestive that increased intracellular iron could be responsible for 
conferring a malignant phenotype, the trends observed could still conceivably be explained 
through increased iron utilisation by aggressive cells undergoing frequent cycling.  
Similarly, all 3 cell lines exhibited augmented proliferation when incubated with FeSO4, as 
expected given that proliferation is essentially ubiquitous to all cells and is dependent on 
ample supplies of iron to allow proper functioning of ribonucleotide reductase and the cyclins. 
Again, haem significantly up-regulated proliferation in the malignant cell lines, although 
interestingly it was the less aggressive MCF7 line that seemed to benefit the most. It is harder 
to explain why haem appeared to have a positive effect on proliferation of benign HB2 cells. 
Given that HB2 cells were earlier shown to be incapable of importing haem iron, it is difficult 
to see how this can be rationalised unless HB2 cells are in fact able to take up haem from 
solution, but lack the ability to liberate iron from haem molecules such that it can be detected 
by a ferrozine assay. 
The ability of cells seeded individually to form colonies in agar gel can be extrapolated to 
estimate their potential to metastasize in vivo. Unlike proliferation, the ability to generate 
colonies from single cells is not a feature of normal cell behaviour, so it is therefore 
unsurprising that iron and haem had no effect on HB2 cells. Conversely, MCF7 and MDA-
MB-231 cells were both stimulated to up-regulate colony formation in response to the 
presence of iron or haem in the agar. MCF7 cells exhibited a significant rise in number of 
colonies formed with the introduction of either additive, although in neither case did average 
colony size increase. MDA-MB-231 cells were driven to increase both the size and number of 
colonies forming when iron was present and produced larger colonies in the presence of haem. 
Studying anchorage-independent growth provided the first evidence of truly divergent 
responses to supplemental iron between benign and malignant mammary cells and produced 
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the first compelling proof that iron can augment malignant behaviour. It was again instructive 
to note that the more aggressive cancer cells were the most responsive to increasing iron 
levels. Investigating the mechanism behind the positive effects of iron and haem on the 
anchorage-independent growth of breast cancer cells fell outside the scope of this study. It is 
possible that this effect is mediated via the cytoplasmic protein NDRG1. This protein is 
involved in stress responses and cell differentiation and is a known suppressor of tumour 
metastasis434,435. NDRG1 expression is amplified when cellular iron levels fall427. It may be 
that increased intra-cellular iron up-regulates anchorage-independent growth via an inhibitory 
effect on NDRG1 and that the elevated iron levels induced in these experiments had an anti-
NDRG1 effect allowing increased colony formation.  
Migratory capacity is a further phenotypic trait that is more pronounced in malignant cells. 
Although there was a degree of closure of wounds formed in HB2 monolayers, this was 
inhibited by iron and haem. Migration of MCF7 and MDA-MB-231 cells was significantly up-
regulated by both iron and haem, reinforcing the concept of iron-driven augmentation of 
aggressive behaviour in malignant cells.  
Further evidence emerged from invasion assays demonstrating HB2 cells to be minimally 
invasive, and displaying no up-regulation in invasive capacity following introduction of iron 
or haem to transwell inserts. MCF7 and MDA-MB-231 cells incubated with iron or haem 
exhibited significantly greater invasion through a matrigel membrane than control cells. 
Previous studies have suggested that a major factor permitting increased motility and 
invasiveness of malignant cells in epithelial neoplasms is repression of E-cadherin, an 
adherens junction protein. Lack of function of E-cadherin reduces the integrity of intercellular 
junctions allowing malignant cells to break free and disperse428. It has been shown that iron 
has an inhibitory effect on E-cadherin function in both hepatocellular and colorectal 
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carcinoma319. Loss of E-cadherin is also strongly implicated in the progression of breast 
cancer429 and although the role of iron in this context has never been investigated it is possible 
that increased iron levels may play a similar inhibitory role to that observed in other epithelial 
malignancies.   
In summary, iron-loading studies proved that malignant mammary cells are capable of 
importing and utilising iron in both its ferrous and haem forms. Subsequently, iron and haem 
were shown to be capable of up-regulating an array of malignant traits in breast cancer cells. 
Although HB2 cells can utilise a degree of supplemental iron to increase viability and 
proliferation, this is easily explained by the presence of a more plentiful supply of an essential 
cell nutrient. HB2 cells did not exhibit any increase in aggressive behavioural traits in 
response to iron or haem. These findings support the hypothesis that the dysregulation in iron 
and haem transport proteins demonstrated previously in breast cancer specimens could be 
acting to mediate a carcinogenic process.  
The use of iron chelators as a potential adjunct in management of breast cancer is a novel idea 
which is gaining traction in the breast cancer community. If the concepts outlined above are 
accurate, it would be logical to assume that depriving breast cancer cells of iron would 
suppress their aggressive behaviour. Whether the alterations in iron trafficking and cell 
phenotype in malignant lines conferred by increased availability of iron betray a previously 
unsuspected carcinogenic pathway, or merely reflect increased demand for iron due to 
behavioural changes in cancer, malignant cells still depend on increased iron levels for 
survival. It was therefore instructive to observe the effect of ICL670A on cell phenotype. Iron 
chelation inhibited the previously observed up-regulation in viability and proliferation induced 
in MCF7 and MDA-MB-231 cells by iron and haem. There were also negative effects on these 
phenotypic traits when ICL670A was added to growth medium in the absence of stimulant 
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additives, implying a detrimental effect on the normal functioning of malignant breast cells. 
Iron chelation was shown to inhibit proliferation in benign HB2 cells relative to control, 
indicating that some of the negative effects on cell health and functioning are not confined to 
malignant populations, and are therefore likely due to insufficient iron being available to 
support normal cell metabolism.  
Adding ICL670A to agar gels abrogated the positive effects of iron and haem on anchorage-
independent growth of MCF7 and MDA-MB-231 cells, and significantly inhibited colony 
formation in un-stimulated cells relative to control. The consequences of adding ICL670A to 
wound-healing assays were less definitive. Although rates of migration in malignant lines 
treated with the chelator fell relative to control or the relevant stimulant medium, these 
changes were not overt and did not achieve statistical significance. In contrast, ICL670A had a 
marked inhibitory effect on the invasive capacity of malignant breast cells, both reversing the 
positive influence of iron and haem on invasion and significantly inhibiting invasion in 
untreated cells relative to control. 
Iron chelating agents have already been demonstrated to have anti-tumour effects against 
oesophageal carcinoma430 and melanoma426, among others. A recent study demonstrated 
induction of apoptosis in MCF-7 and MDA-MB-231 cells in response to administration of the 
chelator desferrioxamine, as well as an increased susceptibility to chemotherapeutic agents431. 
Our results, using a wider range of phenotype assays than previous groups have reported, 
would appear to confirm the anti-tumour effect of iron chelators on breast cancer cells.  
 
Studying the effects of iron and haem loading on benign and malignant mammary cells in 
tissue culture provided further evidence that expression of the iron and haem transport proteins 
and their mRNA is inappropriately controlled in breast cancer.  
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Expression of Dcytb and TfR1 and their mRNA decreased appropriately when HB2 cells were 
incubated with iron and haem, whereas malignant MDA-MB-231 cells maintained baseline 
expression. Adding ICL670A led to increased production of TfR1 protein and mRNA in 
MDA-MB-231 control cells, and those incubated with iron or haem, whereas only control 
HB2 cells demonstrated the same response. Expression of DMT1 protein and mRNA was 
unchanged with iron or haem loading in either population although addition of a chelator 
appeared to stimulate production to a far greater extent in malignant cells. Ferroportin 
expression increased in both cells lines in response to iron or haem loading, as would be 
expected. This was accompanied by a reduction in hepcidin expression, which would act to 
preserve ferroportin levels. Thus, although both cell lines up-regulated their iron export 
machinery in response to excess extra-cellular iron or haem, only benign cells exhibited a 
synergistic down-regulation of iron import. Intra-cellular iron levels in benign cells would 
therefore be expected to remain close to normal, whereas those in the malignant line would be 
likely to climb. This was demonstrated when ferritin levels were seen to rise to a far greater 
extent in malignant cells in response to loading with iron or haem. At the mRNA level, iron 
and haem loading had no effect on HB2 cells, whereas MDA-MB-231 cells increased ferritin 
mRNA production markedly to sequester as much of the available iron as possible, rather than 
exporting it. Interestingly, the addition of ICL670A to control medium led to a greater 
reduction in ferritin expression in MDA-MB-231 than in HB2 cells, potentially demonstrating 
increased susceptibility to iron chelation in malignant populations. 
Although there was no significant change in expression of haem import proteins in either cell 
line in response to iron or haem loading alone, the addition of a chelator to malignant cells 
already exposed to excess iron or haem significantly up-regulated HCP1 protein and mRNA 
production. This effect was not duplicated in the HB2 cells, although these did express both 
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HCP1 protein and mRNA in response to ICL670A alone, which MDA-MB-231 cells did not. 
LRP1 mRNA production was appropriately down-regulated in both populations following 
incubation with haem and significantly up-regulated in both in the presence of the chelator.  
Expression of the haem export protein FLVCR was significantly elveated in HB2 cells 
following incubation with either reagent, and in MDA-MB-231 cells in response to excess 
haem only. BCRP mRNA levels increased significantly in HB2 cells after iron or haem 
loading, but were unchanged in MDA-MB-231 cells. The effects of the observed changes in 
haem transport protein expression in response to increased extra-cellular iron or haem are 
therefore similar to the iron transport chain: haem importer expression is apparently 
unchanged in either population, but haem export is up-regulated to a greater extent in benign 
cells. The shift in balance between import and export would allow benign cells to expel excess 
iron, whereas the malignant cells retained more of their normal haem transporter profile in an 
iron-rich environment, which could be permissive for the accumulation of intra-cellular iron.  
The observed down-regulation of IRP1 and IRP2 mRNA expression in HB2 cells in response 
to iron and haem loading reflects an appropriate response aimed at minimising import of 
further iron. There was no such reaction in the malignant cells, with normal expression of 
IRP1 and IRP2 mRNA maintained in the face of increasing levels of FeSO4 and haem. This 
matches the unchanged expression of DMT1 and TfR1 in iron-rich conditions and implicates 
dysregulation of iron regulatory protein expression as a potential underlying factor in the 
development of an iron-hungry phenotype leading to a carcinogenic environment.  
Although multiple studies have previously demonstrated a clear relationship between 
dysregulation of non-haem iron transporters and breast cancer, most have been limited to 
reporting an up-regulation in iron import along with inhibition of export leading to an increase 
in intra-cellular iron levels. Our results report the responses of cultured cells to dynamic 
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changes in the availability of iron and demonstrate that breast cancer cells will attempt to 
sequester iron even when there is a huge surplus and intra-cellular reserves are plentiful. 
Although this could perhaps have been assumed from historic studies, it has not been formally 
reported until now. 
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CHAPTER 5: CONCLUSION 
There is mounting evidence that dysregulation in the way iron is handled by tissues may play a 
part in carcinogenesis. The majority of earlier research was performed on gastro-intestinal 
cancer but more recent work has demonstrated that breast carcinogenesis may also be due at 
least in part to similar changes in iron processing. 
Most of the available evidence focusses on the proteins responsible for transport of ferric and 
ferrous iron, with no investigation into haem metabolism.  
It has previously been demonstrated that levels of the iron import proteins TfR and DMT1, 
and the iron storage protein ferritin, are elevated in breast cancer relative to normal tissue. This 
is accompanied by down-regulation of the exporter ferroportin. This would clearly lead to 
increased intra-cellular iron and it has also been shown that higher levels of iron correspond to 
a more malignant phenotype in breast cancer. 
Iron chelation has been investigated as a possible therapeutic modality in a number of different 
cancers, and recent preliminary research has indicated a potential role in breast cancer 
treatment.  
This thesis aimed to confirm previously reported changes in the expression of non-haem iron 
transport proteins in breast cancer, as well as to examine the expression profiles of other 
transporters of haem and non-haem iron. We also set out to examine the effects of increasing 
intra-cellular iron levels on the behaviour of both benign and malignant breast cell lines in 
tissue culture, and how their expression of iron and haem transporters was altered in response 
to the availability of iron. Finally, we sought to further clarify the utility of iron chelators in 
breast cancer treatment through investigation of how the behaviour of both benign and 
malignant cells changed in response to chelation of extra-cellular iron. 
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We began by demonstrating that there is a clear difference in the expression profiles of both 
iron and haem transporters in breast carcinoma relative to matched normal tissue. We 
confirmed the up-regulation of the importers DMT1 and TfR1, increased ferritin expression 
and decreased expression of ferroportin that has previously been described (albeit in non-
matched samples), as well as replicating previous results demonstrating increased hepcidin 
expression. However we also report the novel finding that Dcytb appears to be over-expressed 
in breast cancer, and that haem export is down-graded with significantly lower levels of 
expression of FLVCR and BCRP. We also demonstrated the previously un-reported finding of 
stromal staining for the iron import proteins Dcytb, DMT1 and TfR1 around deposits of breast 
cancer which may represent some form of peri-tumoural field change in the same way that 
certain cancers generate marked inflammation in the surrounding tissues. 
Tissue culture experiments revealed that although benign and malignant cell lines are both 
capable of importing non-haem iron (as would be expected given its crucial role in 
metabolism), only malignant cells could import haem. Iron was shown to have positive effects 
on viability and proliferation in all cell populations, which was also anticipated, but only had a 
positive effect on what could be deemed “aggressive” phenotypic traits (colony forming, 
migration, invasion etc) in malignant cell lines.  
Iron chelation was found to have significant anti-cancer effects when added to incubation 
media for a range of phenotypic assays, which tallies with previous results in other cancer 
populations. This also supports published data on the effect of iron chelation on breast cancer 
cells in vitro, although previous in vitro studies on breast cancer have tended to focus solely on 
the anti-proliferative effects of chelation. Our results showing anti-migratory and anti-invasive 
effects, as well as inhibition of colony formation, demonstrate the multi-factorial efficacy of 
iron chelation against cancer cell behaviour. 
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Investigation of iron and haem transporter expression in response to increasing exogenous iron 
and haem demonstrated that benign cells change their expression profiles to maintain normal 
levels of intra-cellular iron (via up-regulation of export and inhibiting import), whereas 
malignant cells will continue to behave in an “iron-hungry” manner, with normal expression 
of the import proteins, regardless of the availability of iron or intra-cellular iron concentration.  
Although malignant cells do require slightly more iron due to higher turnover and cell cycling, 
it is unlikely that this explains the significant differences in protein expression. It is more 
likely that protein expression is inappropriately dysregulated, and that the resulting increase in 
labile iron levels drives carcinogenesis. The mechanisms by which this could happen are 
beyond the scope of this work, although we have already described the damaging effects of 
reactive oxygen species on membranes and DNA. This environment of oxidative stress is a 
consequence of high iron levels via Fenton reaction chemistry. The oncogenic Wnt signalling 
pathway has already been implicated in gastro-intestinal and breast carcinoma, and has been 
demonstrated to be responsive to increasing iron levels. Induction of Wnt signalling may 
therefore represent a further carcinogenic consequence of the iron overload precipitated by the 
observed changes in expression of the iron and haem transporters in breast cancer. 
Future work should focus on clarifying which intra-cellular signalling pathways are induced in 
breast cancer in response to iron, and whether blocking these pathways has an anti-cancer 
effect. Knockout studies may help determine the significance of dysregulated haem transport 
in breast cancer. There is sufficient evidence for an anti-cancer action of iron chelators to 
suggest that further work in this area would be worthwhile. Chelators have been shown to 
down-regulate progression of other cancers in murine models and it would be instructive to 
repeat such experiments using implanted breast cancer tissue. Positive findings could inform 
human trials with a view to developing novel adjuncts in breast cancer treatment.   
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